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Abstract
Title: The association between polycystic ovary syndrome and endometrial carcinoma.
Hypothesis: Women suffering from polycystic ovary syndrome have an increased risk of
developing endometrial carcinoma.
Aim: To determine whether people with polycystic ovary syndrome have an increased
risk of developing endometrial carcinoma.
Background:
Endometrial cancer is one of the commonest cancers to occur in women in the Western
World and unopposed oestrogen stimulation of the uterus is amongst one of the
aetiologies postulated for this condition. It is generally assumed that women with
polycystic ovary syndrome are more likely to develop endometrial hyperplasia and
carcinoma for the reason mentioned above. The validity of this association has however
never been tested. This relationship is investigated within this thesis.
Methods:
1. A case- control study comparing the ovarian morphology of women diagnosed
with endometrial carcinoma and those with benign gynaecological conditions.
2. An immunohistochemical study to assess expression of cell cycle and apoptotic
proteins (surrogate markers of prognosis) in cases of endometrial carcinoma from
women with PCO or from women with normal ovaries.11
3. A microarray study of gene expression in the endometrium of cycling and non-
cycling women with polycystic ovary syndrome.
Results:
We found no significant difference in the prevalence of PCO (using this as a marker of
PCOS in the absence of information on biochemistry) in the ovaries of patients diagnosed
with endometrial cancer compared to women with benign gynaecology disease. Cyclin
D1 expression was significantly increased in the endometrial cancers associated with
PCO whilst the expression of ki67, Bcl2 and p53 was not significantly different.
A total of 101 genes were differentially expressed in the endometrium of women with
PCOS with regular cycles, long cycles and simple endometrial hyperplasia.
Conclusion:
Although our numbers were small, these results challenge the assumption that PCOS is a
risk factor for endometrial cancer. The raised expression of Cyclin D1 in endometrial
cancers associated with PCO suggests that the prognosis for women with PCO is not
necessarily better than those without PCO. There were alterations in the expression of
genes which affect endometrial function in women with PCOS including those with
regular menstrual cycle women. This suggests that the altered hormonal environment has
an effect on gene expression at a very early stage which may have an implication on
endometrial carcinogenesis.12
Chapter 1
INTRODUCTION13
1.1 Outline
This thesis investigates the hypothesis that polycystic ovary syndrome (PCOS) is a risk
factor for endometrial carcinoma (EC).
This is, in general, the currently accepted view
1 however many clinicians accept it is
based on scanty evidence, while seeming eminently logical. Specifically, menstrual
periods are absent in many women with PCOS thus endometrial tissue remains exposed
to proliferative estrogenic stimulation for abnormally long periods, without the
differentiation stimulating effects of Progesterone
2. Endometrial re-differentiation and
over proliferation in women with PCOS would be expected to increase the incidence of
EC.
The introduction to this thesis includes a description of the anatomy, physiology and
histology of the ovary and endometrium, in addition to the changes in these organs in the
normal menstrual cycle. The nature of PCOS and EAC are then discussed, and evidence
relevant to assumed association between the two conditions is reviewed. Finally the
studies used to test the proposed hypothesis are outlined.
1.2 The ovary
1.2.1 Ovarian development.
The ovaries appear in the 5
th week of foetal development in the human female, as
swellings on the right and left medial and caudal aspects of the urogenital ridge
3. These14
gonadal ridges are produced by proliferation of the mesothelial coelomic epithelium and
condensation of the underlying mesenchyme. Germ cells appear within the gonadal
ridges in the 6
th week, and in the 7
th, the surface epithelium gives rise to the cortical
cords, which penetrate the underlying mesenchyme
3. In the 4
th month of development,
the cords split into isolated cell clusters surrounding one or more germ cells, which
subsequently differentiate into oogonia while the cord epithelial cells form follicular
cells
3. The oogonia undergo a number of mitotic divisions and differentiate to produce
primary oocytes, which replicate their DNA then stall at prophase I of meiosis. By the 5
th
month, there are ca. 7 million germ cells per ovary, but a wave of apoptotic cell death
occurs and many oogonia and primary oocytes become atretic
3. In the 7
th month,
primordial follicles form consisting of primary oocytes surrounded by flattened follicular
epithelial cells
3.
Ovarian development then remains static until puberty, when 5 - 15 primordial follicles
begin to mature with each ovarian cycle. The primary oocytes enlarge and the
surrounding follicular cells proliferate and differentiate into a one-cell thick layer of
granulosa epithelial cells, forming primary follicles. Granulosa cells secrete a layer of
glycoprotein onto the oocyte - the zona pellucida. As the follicle continues to grow
through granulosa cell proliferation, it acquires a fluid-filled cavity - the antrum - and is
referred to as an antral secondary follicle. Generally only one follicle reaches maturity in
each ovarian cycle, the Graafian follicle. The primary oocyte it contains resumes its first
meiotic division to produce the secondary oocyte and the 1
st polar body. The second
meiotic division then starts, ovulation generally occurring when the oocyte has15
progressed to prophase II. Oocyte meiosis arrests at metaphase II and further maturation
occurs only if the oocyte is fertilized.
1.2.2 Ovarian anatomy
Normally two ovaries are found in the human female. Each is ovoid, measuring
approximately 3 x 1.5 x 1 cm, and composed of dense fibrous tissue, in which primary
and developing follicles are embedded. They are attached by the mesovarium to the
posterior leaf of the broad ligament and lie on the peritoneum of the side wall of the
pelvis, in the ovarian fossa between the angle of the internal and external iliac vessels and
the ureter, just superior to the obturator nerve. The ovaries can sometimes be palpated
through the vagina on digital examination, and are in close proximity to the sigmoid
colon and the ileum within the rectouterine pouch (Pouch of Douglas). Each ovary
usually lies with its long axis oblique and its tubal extremity uppermost and medial,
attached to the upper angle of the uterus by the ovarian ligament, a mass of fibrous tissue
and smooth muscle which is continuous with the round ligament and lies between the two
sheets of the broad ligament
416
Figure 1.1- The pelvic anatomy with a cross-section of an ovary courtesy of Kellogg
foundation. (www.academic.kellogg.cc.mi.us/herbrandsonc/bio201). Permission required
for reproduction.
The ovaries derive arterial blood from the right and left ovarian arteries, which leave the
abdominal aorta just below the renal arteries. Venous drainage occurs via a plexus of
veins (the pampiniform plexus) which drain into the ovarian veins, which lie alongside
the ovarian arteries. The right ovarian vein terminates in the inferior vena cava whereas
the left ovarian vein terminates in the left renal vein. Lymphatic drainage occurs via the
paraortic nodes, adjacent to the junctions of the ovarian arteries and the dorsal aorta.17
Some drainage also occurs through the inguinal nodes, via the round ligament and the
inguinal canal, and through the contralateral ovary via the uterine fundus.
Sympathetic autonomic fibres from the aortic plexus reach the ovaries along their
vascular supply. These fibres have their pre-ganglionic cell bodies in the spinal cord at
the T10 and T11 level. Parasympathetic autonomic fibres from the hypogastric plexus
supply the ovaries via the uterine artery.
1.2.3 Ovarian histology
Macroscopically, the each ovary consists of a capsule, a cortex and a medullar region.
The capsule consists of an outer germinal epithelium - a single layer of cuboidal or
squamous cells - with the fibrous tunica albuginea lying below. The central medullary
region contains connective tissue and the main blood vessels. The peripheral portion
surrounding the medulla, the cortex, contains ovarian follicles embedded in connective
tissue. The cortex is interrupted at the hilus
Several types of ovarian follicles can be identified in the adult ovarian cortex; primordial,
growing (primary and secondary) and Graafian. Primordial follicles occur just beneath
the tunica albuginea, but move deeper in the cortex as they mature to primary then
secondary follicles, such that the fully mature Graafian follicle may extend the full
thickness of the ovarian cortex, and bulge from the ovarian surface. The granulosa
epithelial cells, and the theca interna cells which surround them in the maturing follicle,
produce steroid hormones essential for follicular maturation and reproductive control.18
Figure 1.2- The pelvic anatomy with a cross-section of an ovary courtesy of Kellogg
foundation. (www.academic.kellogg.cc.mi.us/herbrandsonc/bio201)
1.3 The endometrium
1.3.1 Endometrial anatomy and histology
The endometrium, endodermal of origin
3, is a thin layer of mucous membrane lining the
interior of the uterus. Throughout reproductive life, the endometrium undergoes changes
during each menstrual cycle in structure and function, which prepare it for blastocyst
implantation and to support the growing embryo in the early phase of pregnancy. These19
changes are in general driven by the ovarian steroid hormones, which again vary with the
menstrual cycle, and are coordinated with the growth and maturation of ovarian follicles.
The end of each menstrual cycle is marked by menstruation, during which the thickened
endometrium sloughs off and is lost in the menstrual blood flow.
Figure 1.3- Haematoxalin and eosin (H&E) staining of histological specimen of the
endometrium magnified x100. http://www.ansci.wisc.edu/jjp1/ansci_repro/index.html.
No copyright application needed.
The endometrium consists of a basal layer and stoma covered by ciliated columnar
epithelial cells, which extend into the stoma to form the endometrial glands. Regeneration
of the epithelium after each menstrual cycle takes place from epithelial stem cells present
at the base of the endometrial gland, which remain after menstruation. The endometrium20
has also been characterised as being composed of two layers which differ in structure and
function, the thicker stratum functionale, i.e. functional layer, is sloughed off at
menstruation, while the stratum basale is retained and provides cells for the cyclic
regeneration of the stratum functionale. The stratum functionale is apposed on the
stratum basale.
1.3.2 The endometrium during the menstrual cycle.
During the menstrual cycle the endometrium varies from 1 to 6 mm in thickness. The 3
recognisable endometrial phases during the menstrual cycle are the proliferative, the
secretary and the menstrual phases. At the end of the menstrual phase (day 5 of the
cycle), oestrogen levels start to rise and this stimulates the ciliated epithelial cells at the
base of the endometrial glands to proliferate rapidly and migrate to cover the surface of
the endometrium. The stoma also proliferates and the spiral arteries, which supply blood
to the endometrium, lengthen. The proliferative phase continues until ca. 24 hours after
ovulation (i.e. ca. Day 15 of cycle), by which time the endometrium has reached a
thickness of ca. 3 mm.
The secretary phase then begins, lasting until ca. Day 28 of the cycle. Under the influence
of P from the corpus lutea, the endometrium becomes oedematous and can grow to ca. 6
mm in thickness. The endometrial glands enlarge and become tortuous, and the ciliated
epithelial cells within the glands differentiate to a secretary phenotype and produce
copious amount of mucoid product. This process occurs in preparation to implantation of
a fertilized egg.21
Figure 1.4- H&E staining of endometrium in the secretary phase.
http://www.ansci.wisc.edu/jjp1/ansci_repro/index.html. No copyright permission needed
The menstrual phase occurs if the ovum released at ovulation fails to fertilise. After the
corpus lutea degenerates, there is a rapid decline in hormone levels, particularly P, levels.
The spiral arteries contract, the endometrial glands stop secreting and the endometrium
shrinks. P withdrawal and the reduction in spiral artery blood flow cause the stratum
functionale to degenerate and slough off, until only the stratum basale remains. Spiral
artery blood flow still occurs however and it carries the degenerating endometrial lining
out of the body via the vagina (menses). Indeed, clotting is inhibited during this period of
menstrual flow, albeit blood loss is normally restricted except during brief periods when22
the walls of the spiral arteries are relaxed. The start of menses is conventionally
considered as Day 1 of the new menstrual cycle and the start of the menstrual phase,
which normally lasts for 5 days. The average blood loss in each menstrual phase is
between 35 and 50 millilitres (mls). Blood flow through the straight arteries maintains the
stratum basale.
In the absence of fertilization, a cessation of bleeding accompanies the growth and
maturation of a new ovarian follicle. The epithelial cells proliferate quickly and migrate
out to restore the surface epithelium as the proliferative phase of the next cycle begins.
In the absence of ovulation (as in anovulatory cycles) a corpus luteum does not form and
P is not produced. Thus the endometrium does not enter the secretory phase and
continues in the proliferative phase until menstruation.
1.3.3 Apoptosis in the endometrium
As discussed above, the endometrium is in a constant state of flux, developmentally
cycling between the proliferative, secretory and menstrual phases. Changes in hormone
levels are reflected at the cytological level, but overall endometrial homeostasis is
achieved by maintaining a balance between proliferation and apoptosis. Endometrial cell
behaviour is primarily governed by the ovarian steroids
5, although other molecules, such
as inhibin and activin, play key role. In animal models, proliferation and survival of the
endometrial glandular epithelium is dependent on E2, acting via the oestrogen receptor (α
and/or  isoform)
6-8. In contrast, P induces epithelial cell differentiation to the secretory23
phenotype, by down-regulating oestrogen receptor expression and by stimulating the
conversion of biologically active 17--oestradiol into the less active metabolite oestrone
9
10in cell culture. Subsequent reduction in the P concentration, or application of P
antagonists such as RU486, precipitates apoptotic degeneration of the glandular
epithelium
11. Dysregulated endometrial epithelial cell proliferation may lead to
hyperplasia and endometrial carcinoma, although there are thought to be several
pathways via which endometrial carcinogenesis occur and this will be discussed later.
Progesterone acts as the gate-keeper of the endometrium per say with regards to inducing
differentiation and apoptosis and halting uncontrolled proliferation.
Apoptosis is a process by which cells undergo ‘programmed’ cell death, i.e. through a
controlled sequence of intracellular events occurring in a regulated pathway. Apoptosis
was first noted 100 years ago, as cell loss (histolysis) occurring during embryonic
development. Events during apoptosis broadly comprise cell shrinkage, nuclear
reorganization, cell membrane blebbing and finally nuclear fragmentation to produce
apoptotic bodies which are phagocytosed by neighbouring cells or macrophages
12.
Apoptosis plays a significant role in the maintenance of cellular balance in differentiated
tissues which show a high cell turnover, such as the intestine and endometrium.
Although apoptosis has for some time been suspected to occur during the menstrual
cycle, it is only recently that this process has been studied in each menstrual phase. One
of the most studied proteins is bcl2, an inhibitor of apoptosis, which was originally
characterised as a ‘loss of function’ mutated form in a B cell lymphoma
13. Mertens et al24
investigated the endometrial expression of bcl2 during normal ovulatory menstrual cycles
and found expression was increased in the proliferative phase and decreased in the
secretory phase, especially in glandular epithelial cells
14. Ki67, a marker of proliferation
showed a similar pattern but with a later onset in the proliferative phase and a later
decline in the secretory phase than bcl2
15. It was concluded that bcl2 promotes cell
survival by preventing apoptosis. Certainly increases in E2 concentration and oestrogen
receptor expression, stimulate bcl2 and Ki67 expression as well as cell proliferation. P on
the other hand decreased the levels of bcl2, Ki67 and androgen receptor. Androgen
receptor levels remain high in PCOS endometrium and are more highly stimulated by the
elevated serum testosterone – this could modify endometrial epithelial cell behaviour
considerably. The expression of bcl2 persisted throughout the menstrual cycle in the
basal lamina and regenerative epithelial cells of the base of the endometrial glands,
presumably preventing apoptosis in these tissues, thus maintaining a source of epithelial
cells and a substrate for their growth, allowing reconstruction of the functional
endometrium after menstruation.
In a further study, Dahmoun et al noted a rapid increase in the apoptotic index,
determined by Bcl2 levels in the endometrial stroma and epithelium during the secretory
phase/menstrual phase transition, with a maximum on the second day of menstruation
16.
This occurred in parallel with a decline in the Ki67 index, indicative of reduced
proliferation, up to the second day of menstruation. The decrease in the Ki67
proliferation index appeared greater in the endometrial epithelium than the stroma,
suggesting that net cell loss is greater in the former. These changes are probably hormone25
dependant, as discussed above. Indeed, the late secretory phase decline in serum E2 and P
preceded the onset of apoptosis in the endometrial glands and stoma by 2 days, leading to
the conclusion that apoptosis may be of importance in hormone withdrawal-induced
endometrial gland involution during menstruation
17,18. It is possible therefore that
endometrial glandular hyperplasia may be induced by a reduction in, or absence of,
apoptosis, under conditions in which cyclical hormonal withdrawal is infrequent or
absent, for example in amenorrhoea or oligomenorrhoea, as it is known that anti-
apoptotic agents such as bcl2 are expressed in abundance in endometrial hyperplasia
19.
1.3.4 Inhibin and activin and the endometrium.
There other molecules that are also thought to be involved with homeostasis in the
endometrium. Inhibin and activin are such molecules.
Inhibins are dimeric glycoproteins composed of and α subunit and one of two  subunits.
They were initially isolated from the gonads and identified as modulators of FSH
production from the anterior pituitary gland
20. Activin, like inhibin consists of an α-
subunit but only one of the  subunits. The inhibin/activin subunits are homologues of
each other and belong to the transforming factor-beta (TGF-) family of proteins. In the
regulation of the endometrial menstrual cycle inhibin and E2 seem to be the negative
controls of FSH secretion that disappear at the time of the luteal regression
21. The precise
role of inhibin and activin in the endometrium are still unknown, however they are
thought to play an important role in the regulation of endometrial cell function, regulating
endometrial maturation and implantation process
22 . It has also been found that inhibin26
an activin are also synthesised in different compartments in the endometrium. Inhibin
being predominantly synthesized in the epithelium whilst activin, mostly in the stroma.
Activin A, inhibin A and betaglycan (inhibin binding molecule, which is a membrane
bound glycoprotein and operates as an inhibin receptor) are expressed and secreted by
healthy endometrium
23 and endometrial adenocarcinoma
24,24. However their exact role in
tumorigenesis has not yet been determined. It has been suggested that inhibin may act as
a tumour suppressor in the endometrium its expression gradually declines from
hyperplastic to malignant tissue.
1.3.5 Investigation of gene expression by microarray
Two main types of gene array exist: large generic arrays and small tailored arrays. The
former are available commercially or via collaboration with dedicated microarray
research laboratories. One well-established large generic technology is the Affymetrix
Genechip System
25, in which two-dimensional arrays of synthetic oligonucleotides (ca 20
mers) are synthesized using a combination of photolithography and solid phase DNA
synthesis. Affymetrix gene chips allow thousands of transcripts to be analyzed in a
single hybridization, and are ideal tools with which to search for unexpectedly regulated
genes. Indeed, the recently introduced Affymetrix Human Genome U133 Plus 2.0 Array
is considered by the company to be the ‘First and most comprehensive whole human
genome expression array’ and to probe the expression of 47,000 transcripts – virtually the
entire set of expressed transcripts. Specificity during hybridization is however dependent
on fragment length. Affymetrix circumvent this issue by having oligonucleotide spots at
very high density, allowing the expression of a target gene to be assessed by multiple27
spots representing ten or more sequences within the gene. spots of DNA containing
single base mismatches are also included to account for non-specific binding. Due to the
high number of spots and the complex computation required to provide gene expression
data, such microarrays are themselves expensive and are supplied within an even more
expensive system which includes a fluidics workstation and microarray scanner/detector,
as well as a computer with the required proprietary software for data analysis. While it
was possible to access an Affymetrix platform for this study, the cost of the microarrays
proved beyond the limited budget available. In addition, at the time of the study the gene
lists used to compile commercial arrays were inflexible and may have omitted genes of
interest. Such considerations are now less likely since the introduction of the very large
arrays such as the Affymetrix U133 Plus 2.0 array, which cover the vast majority of
possible transcripts produced by the human genome.
An alternative approach is for individual research laboratories to devise and produce
relatively small tailored gene arrays focused on their individual interests and needs.
These have the advantage of being cost-effective, which allows for sufficient replicates to
maximize experimental power. They also tend to be produced by arraying cDNAs of ca.
100 - 1000 bp, rather than smaller oligonucleotides, and therefore exhibit a greater
specificity of interaction between the target and probe cDNAs. Thus fewer spots are
required to determine the expression of a gene accurately and such microarrays tend to
have a greater sensitivity of detection. Tailored gene arrays encourage researchers to
perform well-planned, hypothesis driven experiments investigating the expression of a
focused set of transcripts. They also allow the use of radio- or fluorophor-labelled cDNA28
probes, which can determine gene expression changes in as little as 3-5 µg of total
RNA
26. The ability to use small amounts of starting material is useful when dealing with
the female reproductive tract as sometimes only small samples of tissue are available. In
our study, the endometrial harvesting method provided, at a maximum, one gram of
tissue. A reliable quantitative amplification method was used (as described in Chapter 2,
section 2.3.4., page 104) to generate fluorophor-labelled probe for microarray analysis, to
minimize usage of endometrial RNA.
As for many techniques used in molecular biology, microarrays rely on the
complimentarity of the DNA duplex for specificity, i.e. that the two strands of a DNA
duplex, if separated, will reassemble (hybridize) with base-pairing A to T and C to G
between the strands. In microarray analysis, multiple single-stranded DNA molecules of
defined sequences (targets) are each spotted on a solid support to form a grid array, where
they are available for hybridization with any complementary single stranded DNA
molecules (probes) in sample applied to them. Commonly, spots are 20 – 500 μm in
diameter and arrays contain of the order of 10
2 – 10
5 spots. Microarrays are generally
synthesized on nylon or glass
25 since single stranded DNA binds strongly and is
immobilized on these supports. Glass has several advantages over nylon however, in that
glass: has a surface which can be chemically altered enabling covalently attachment of
DNA; can sustain high temperatures and washes at high ionic strength and is structural
tougher; is non-porous allowing small hybridization volumes to be loaded; Has low
background fluorescence, hence does not contribute significantly to background ‘noise’
during detection of probes labelled with fluorophores. The main advantage of glass over29
nylon however is that two different probes (commonly one a test sample and one an
internal control) can be labelled with different fluorophores and simultaneously incubated
on a glass microarray in a single reaction, making data analysis easier and the results
more accurate and reliable. In contrast, Nylon arrays cannot be used with fluorescently
labelled probes thus can only be used to analyze a single sample, normally radio labelled,
at a time. The same array can be subsequently stripped and reprobed, however the
conditions used to strip the array often reduce the density of target DNA molecules and
thus the run-run comparability becomes unreliable. Effectively, Nylon microarrays are
more difficult to control for.
When using microarrays, the manipulation of samples prior to and during
experimentation, need to be rigorously controlled. For example, microarray analysis is so
sensitive that during gene expression analysis, responses to microenvironment (e.g.
position of culture dishes in an, or between, incubators) can be detected. Furthermore,
microarray processing is also prone to variability due, for example, to slight differences
in microarray preparation, sample probe preparation and labelling, wash efficiencies
and/or hybridization temperatures. Such variability can cloud data analysis of the effect
on gene expression of the primary modified parameter in the experiment, especially when
one is searching through thousands of genes, for a small subset of genes that may be
variant
27. The requirement to use suitable controls during microarray hybridization was
one reason why this study used glass microarrays hybridized simultaneously to test and
common internal standard samples, labelled with the fluorophores Cy3 and Cy5
respectively.30
A significant challenge when performing microarray analysis is in the primary and
downstream analysis of data. Each gene is likely to be variably expressed in each samples
and standardization becomes very difficult. Computational scientists have devised a
number of techniques for standardization of gene expression and there is still no
recognized best-practice method of data analysis.
1.3.6 Gene expression in the endometrium
As we have previously demonstrated, endometrial carcinogenesis is a multistep process
which is under genetic control. It thus seems reasonable to investigate the effects of the
altered hormonal environment, as is the case in PCOS, on the genetic profile in the
endometrium, in the context of carcinogenesis.
The development of gene microarrays has revolutionised molecular biology in recent
years. They allow simultaneous assessment of expression of thousands of genes
28.
Whether it is used to investigate genes responsible for a specific clinicopathological
feature or phenotype or genomic classification of tissue, they provide data which has the
potential to improve clinical outcome by adapting therapy based on the molecular
characteristics of a tumour
29. They provide information on a large catalogue of genes that
may be individually or collectively be targeted for research and also has the advantage of
revealing candidate genes that may be missed on a gene by gene approach.31
Microarrays have been used in some recent studies to investigate endometrial
carcinogenesis and the results suggest that genes are differentially expressed depending
on the type and the aetiology of endometrial cancer.
It is also clear that gene expression in the endometrium varies according to the type of
tumour
30. In endometrioid endometrial carcinoma, the type mostly associated with
oestrogen stimulation and accounting for more than 80% of all tumours, the loss of the
protein receptor protein expression is still unclear. However a study using
medroxyprogesterone acetate (MPA) –treated endometrial cancer cell-lines, demonstrated
that progestogens regulate the expression of certain proteins which are known to be
involved in tumorigenesis. These proteins are CD44, CPSG/Versican, Tenasein and
fibronectin
31.
CD44 is expressed on the cell surface and is involved in cancer cell matrix
interaction
32,33. CD44 can promote tumour growth and its increased expression is also
associated with increased myometrial invasion
34 as is CPSG /Versican
35, a proteoglycan.
Tenasein-C plays a role in tissue remodelling during embryonic development and is re-
expressed in many different tumours
36. It can stimulate proliferation and may be
correlated with increased invasion thus suggestively being viewed as a prognostic factor
for metastasis in certain cancers
37. Fibronectin-1, which is a major component of basal
lamina, is involved in proliferation, adhesion and migration
38. It is also known to
mediate cell-matrix adhesion by interacting with a wide variety of membrane and matrix
component such as fibronectin-1 receptor, integrin α51, collagen and CPSG.32
Fibronectin-1 is known to be down-regulated by progesterone in poorly differentiated
endometrial cancer cell line. These present observations in this study that progestogens
such as MPA down-regulates expression of CD44, CPSG, Tenasein-C and Fibronectin-1,
suggests that progesterone could play an inhibiting role in tumour cell invasion
39.
Other array studies have suggested increased endometrial expression of genes that are
involved cell secretion namely, Mammoglobin 2 (MGB2), Lactotransferrin (LTF),
Endothelin 1 & 3(END 1&3). Other genes are concerned with cell adhesion (CTNNA1),
transcription (NFYC, HOXB5, CHD3, REST), or even extra-cellular matrix remodelling
(HPSG2, MMP11).
MGB2 is over-expressed during implantation and is involved in glandular secretion in
hormone responsive tissues. It is also over-expressed in primary breast, stomach and
colon cancer
40.
Lactotransferrin is an iron-binding glycoprotein present in most exocrine secretions and
its m-RNA and protein are expressed in the uterus and over expressed in endometrial
cancer. Its role in carcinogenesis of the endometrium is still undetermined but in vitro
studies suggest that it promotes cell proliferation of normal and neoplastic endometrial
cells
41.
Endothelin 1 and its m-RNA are present in the human endometrium throughout the
menstrual cycle (maximally in the late secretory phase) and are known to provoke33
smooth muscle contraction
42. It is also known to be mitogenic on vascular smooth
muscle
43. Human endometrial carcinoma cells are also known to express endothelin-1
44.
Little is known about the function of endothelin-3 in the endometrium but is has been
found to be down-regulated during the window of implantation
45.
A more recent study of the endometrium has also revealed Oviduct-specific glycoprotein
to be differentially expressed as the endometrium changes from a benign state to a
neoplastic one
46. It was first identified in oviduct epithelium and has been thought to be
an early indicator for malignant transformation
47. OGP expression begins under
conditions of unopposed oestrogen exposure, which is a known risk factor for
endometrioid EC. It has recently been identified in the stem cells of the basalis layer of
the endometrium
46. It has been proposed that genetic alterations that induce endometrial
neoplasia are acquired sequentially by the non-shedding stem cells. Woo et al
demonstrated a correlation between loss of PTEN and gain in OGP expression along.
They also demonstrated a gain in staining in tissue where there has been prolonged
oestrogen stimulation such as is the case in non-typical and atypical hyperplasia.
Gene expression in endometrial tissue, whether benign or malignant is still a relatively
new area of study. As part of this research project we plan to explore this area further by
studying gene expression in the endometrium of women with PCOS and to determine
whether this changes in the presence of disturbed metabolic and hormonal environment.
1.4 The menstrual cycle and ovulation34
The menstrual cycle results in the preparation of the endometrium for implantation, the
production of a ripe fertilization-competent ovum at ovulation, and either the endometrial
implantation and support of the developing zygote if fertilization occurs, or the shedding
of the endometrial lining and unfertilized ovum in the menstrual blood flow if it does not.
The menstrual cycle is normally approximately one month long, although cycle length
may vary between 21 to 35 days, without associated pathology. It is regulated at the
endocrine level by the cyclical release of follicle stimulating hormone (FSH), luteinizing
hormone (LH) and prolactin from the anterior pituitary. FSH and LH govern the ovarian
biosynthesis of steroid hormones, primarily E2 and P.
The menstrual cycle is divided into a proliferative or follicular phase, commonly of 7 - 21
days (depending on the time required for follicular maturation), a secretory phase of
relatively constant in length (14 days), and a menstrual phase of 5 – 7 days. The ovaries,
uterus and cervix all undergo substantial changes during the cycle, as detailed below for a
typical 28 day cycle.
Day 1: Onset of vaginal menstrual bleeding during which the secretory endometrial
mucosa degenerates, sloughs off and is shed in the menstrual blood flow.
Day 5 – 14: The follicular phase begins at the end of menstruation and continues until
ovulation takes place. Increasing levels of pituitary FSH stimulate the development and
maturation of a cohort of follicles. One dominant follicle then acquire granulosa cells
which then response to the LH surge. The dominant follicle itself synthesizes increasing35
amounts of E2. E2 production rises steeply from day 10 and reaches a peak on day 13,
the concurrent rise in LH leading to ovulation. The uterine epithelium proliferates
throughout the follicular phase under the influence of E2, to provide a highly vascularised
surface receptive to the fertilized ovum. The cervix remains small and closed by highly
viscous mucus.
Day 14: Ovulation occurs and the ovum (egg) is released from its follicle and enters the
fimbria of the fallopian tube. During ovulation the cervical mucus becomes less viscous
and the os cervix enlarges, allowing sperm to pass through.
Day 14 – 28: The luteal phase begins as the corpus luteum develops from the now empty
Graafian follicle and starts to produce P. In response, the endometrium differentiates to
perform a secretory function, as discussed in Section 1.3. The effect of P on the
endometrium is maximal around day 22, when the embryo, if fertilization occurs, arrives
in the uterus from the fallopian tube. If fertilization has not occurred, E2 and P begin to
inhibit the release of hypothalamic gonadotrophin releasing hormone (Gn-RH) which
leads to degeneration of the corpus luteum. The resulting rapid drop in serum E2 and P
levels cause constriction of the endometrial blood vessels and endometrial ischaemia; the
uterine mucosa is shed and this begins another menstrual bleed. (See diagram below)36
Figure 1.5– Illustrate the menstrual cycle and the various endocrine, morphological and
histological changes that take place during this period. Reproduced courtesy of Dr Lam.
http://www.lammd.com/A3R_brief_in_doc_format/print/Estrogen_Dominance.htm37
1.4.1 Hormonal control of ovulation
GnRH, produced in the hypothalamus, stimulates the release of FSH and LH from the
anterior lobe of the pituitary gland. GnRH is released in a pulsatile fashion with a
frequency of 1-1.5 pulse/hour before ovulation and then up to 4 hours thereafter the
release of LH and FSH is also under the influence of other factors, such as the central
nervous system and E2 and P levels, by positive and negative feed-back. . A faster
frequency of GnRH release greatly reduces the amount of LH and FSH secreted by the
pituitary and is associated with anovulation. Slower GnRH release allows the
development of E2 synthesizing follicles, but ovulation cannot occur as the pituitary
requires several days exposure to GnRH pulses at 1 – 1.5 pulses/hour to allow it to
respond to the mid cycle increase in E2 with the pre-ovulatory LH surge.
During the follicular phase, the secretion of LH remains low, but on day 12 - 13, a
positive feed-back loop develops in which FSH-driven ovarian E2 production stimulates
further release of FSH and LH from the pituitary, which in turn stimulates greater
follicular E2 and P synthesis and release. This positive feedback induces a surge in serum
LH, FSH, E2 and P, the rapid increase in LH having a key role in initiating ovulation.
In the luteal phase of the menstrual cycle, negative feedback of E2 and P on FSH and LH
is established, thus E2 and P inhibit FSH and LH secretion. The rapid decline in FSH and
LH after ovulation prevents the maturation of further follicles, and also leads to a decline
in ovarian E2 and P production. Indeed E2 and P drop drastically by day 26 of the cycle,
resulting in the beginning of the menstrual bleed.38
1.5. Polycystic Ovary Syndrome
Descriptions of what is now described as Polycystic Ovary Syndrome (PCOS) can be
traced as far back as 1844, when Chereau described sclerocystic changes in the human
ovary
48. It was not until 1935, that Stein and Leventhal published their classic paper
formally describing PCOS in a group of infertile women
49.
PCOS is one of the most common endocrine conditions, present in 5-10% of women of
reproductive ages, although its aetiology is still unknown
50,51. It is a heterogeneous
disorder whose expression may vary from one individual to another and also temporally
within the same individual. The signs and symptoms ( as classified in table 1), associated
with this condition are menstrual cycle disturbances, obesity, infertility, acne, hirsutism
and other signs of hyperandrogenism, and polycystic ovary (PCO) morphology on
transvaginal ultrasound scan
50,52. Metabolic disturbances such as elevated serum
concentrations of LH, testosterone (T), insulin and prolactin are often present and these
may have profound implications on the long-term health of women with PCOS
53.
1.5.1 Aetiology
The causes of PCOS would appear to have a genetic component as there is a weak
tendency for it to cluster in families
54. Hyperandrogenaemia appears to be the strongest
inherited characteristic in familial cases. Genetic studies in PCOS are hampered by
several factors; PCOS is associated with infertility and this make linkage analysis of a
large pedigree, difficult. Furthermore, as PCOS is a heterogeneous condition, familial
studies cannot be easily compared because of the use of differing diagnostic criteria. In39
addition to this a male phenotype for the syndrome has not yet been clearly identified
55.
However despite all this, all studies seem to suggest that PCOS has a dominantly
inherited trait of low penetrance and variable expressivity
56.
Symptoms (% patients
affected)
Associated endocrine
manifestations
Possible late sequelae (%)
Obesity (38)
Menstrual disturbance (66)
Hyperandrogenism (48)
Infertility (73-anovulatory)
Asymptomatic (20)
↑Androgens
↑Luteinizing hormone
↑LH: FSH ratio
↑Free Oestradiol
↑Fasting Insulin
↑ Prolactin
↓ Sex hormone binding 
Globulin
Diabetes mellitus (11)
Cardiovascular disease
Hyperinsulinaemia
High LDL
Endometrial hyperplasia
Table 1.6 - shows the spectrum of clinical features of PCOS
The most studied genes are those involved in steroidogenesis and those involved in the
metabolic pathways involved in insulin action.
CYP17 (cytochrome P450 17-hydroxylase/17, 20-desmolase) - this encodes for 17-
hydroxylase/17, 20-lyase. Initial studies showed an association with PCOS
57 though
subsequent ones failed to confirm this
58.
CYP11A (cytochrome P450 side-chain cleavage enzyme), encodes for cholesterol side-
chain cleavage enzyme and one study found a link with hyperandrogenaemia in women
with PCOS
59.
CYP21 (cytochrome P450 21-hydroxylase) - encodes for 21-hydroxylase, the enzyme
responsible for most cases of congenital adrenal hyperplasia (CAH). Recent studies have40
found a significant prevalence of CYP21 mutations in women with PCOS with a normal
17-hydroxyprogesterone response to adrenocorticotrophic hormone (ATCH)
54.
Androgen receptor- The short trinucleotide repeat receptor CAG is known to be inversely
associated with androgen levels. The longer CAG alleles and biallelic means in exon 1 of
the androgen receptor is significantly more expressed in women with PCOS compare to
normal women
60.
Insulin receptor – A number of studies examining the insulin receptor for gene sequence
major mutations have been inconclusive so far
61.
Recently two studies have found linkage between a marker (D19S884 at chromosome
19p13.3) located near the insulin receptor gene and PCOS
61. Although the putative PCOS
gene in this region remain to be identified, likely involvement in signal transduction
mechanisms, leading to altered expression of a family of genes involved in
steroidogenesis and /or insulin action.
CaPLain-10- CaPLain-10 is a cysteine protease that has been shown to be associated with
susceptibility to type II diabetes. A recent study showed the 112/121-haplotype was
associated with higher insulin levels in African- American women and a higher risk of
PCOS in both African-American and Caucasian women.
As we mentioned , it is believed that multiple genes are disturbed in PCOS, due to the
heterogeneity of symptoms seen between patients, and that the expression of some of41
those functionally compromised genes are environmentally sensitive, for example to
nutrition and exercise.
While PCOS is now thought to be manifested biochemically from the foetal stages
onwards, the syndrome normally becomes apparent in adolescence. At this time it is
associated with increased weight gain at puberty, although it is not known whether this is
a result of the syndrome, or a feature which exacerbates the expression of other PCOS
62.
In the past, it was difficult to evaluate studies on PCOS, due to the lack of consensus over
diagnosis of the syndrome. In Europe, a combination of all the above-mentioned
symptoms was considered before making a diagnosis
2,63 , whilst in America, the
syndrome was diagnosed on findings of biochemical hyperandrogenism and ovulatory
dysfunction, in the absence of non-classical adrenal hyperplasia; the presence of PCO
morphology was not required
64. Recently however, agreed diagnostic criteria have been
produced by the ASRM/ESHRE (American Society Of Reproductive Medicine/
European Society for Human Reproduction and Embryology), where by two of the
following support a diagnosis of PCOS: chronic anovulation\oligo-ovulation; clinical or
biochemical evidence of hyperandrogenism; PCO on trans-vaginal ultrasound scan.
A number of interlinking factors are thought to affect the symptoms seen in PCOS. A
gain in weight worsens symptoms, whilst weight loss usually brings about an
improvement in the endocrine and metabolic features
65. It is clear that the feed-back
mechanism from the polycystic ovary to the pituitary and the hypothalamus is disturbed,42
secondary to abnormalities in the secretion of ovarian steroid hormones and also other
hormones such as leptin or inhibin
66.
One of the most common features of PCOS is hyperandrogenaemia and its ovarian source
(theca cells) is important in understanding the pathogenesis of the syndrome and its
sequelae. PCOS patients have an exaggerated ovarian response to gonadotrophin (both
LH and FSH) stimulation
67, resulting in hypersecretion of androgens (such as
androstenedione, testosterone, and DHT) by the ovary
67. It has been proposed that this
dysregulation in steroid production is due to an excess of LH secretion in the pituitary or
increased sensitivity to LH of the thecal cells of the ovary
68. Insulin and other growth
factors may also be implicated in this process. LH hypersecretion is found in ca. 40% of
women with PCOS and LH probably induces ovarian steroidogenesis whilst also
negatively influencing ovulation and oocyte maturation; hence the deleterious effect on
reproductive health
69. It is also believed that there is a defect in the ovarian-pituitary
negative feed-back mechanism whereby a still unidentified non-steroidal factor that
inhibits LH secretion, is absent in women with PCOS.
The action of LH is thought to be further enhanced by insulin and insulin growth factors
(IGF’s)
68. In fact, in addition to this, insulin and IGF’s are also known to increase
androgenesis via the theca cells and augment FSH action on the granulosa cells of the
ovaries
70. The action of insulin and IGF’s on the ovaries to promote steroidogenesis is
still not well known but it is thought to encompass both transcriptional and post
transcriptional actions including the stability of specific m-RNA. Insulin is known to43
rapidly increase m-RNA translation but there is no data to suggest that insulin or IGF’s
increase m-RNA translation of protein encoding for steroidogenesis. Marked ovarian
hyperandrogenaemia is associated with severe insulin resistance due to mutations that
interfere with binding or signalling as well as stimulating auto antibodies to the insulin
receptor
71. The resulting hyperinsulinaemia is thought to activate ovarian IGF type I
receptors and consequently increase androgen production via a synergistic effect of LH
and IGF. There seem to thus be a paradox where there is insulin resistance and yet insulin
seems to increase ovarian androgen production. This is explained by the fact that insulin
and IGF's- have multiple actions and their actions are mediated via multiple intracellular
pathways and finally, insulin can regulate ovarian androgenesis via its cognate
receptor
72,73. Insulin mitogenic and metabolic actions are known to be mediated via
distinct post receptor signalling pathways
74. Experimentally, selective insulin resistance
can be produced whilst its mitogenic effect can remain intact
71. Therefore a defect in
insulin clearance of glucose in muscle leading to a reduced disposal of glucose may not
disrupt or even enhance steroidogenesis in theca cells and suppress sex hormone binding
globulin production by hepatocytes and consequently increase androgen levels
75. This
hypothesis, of tissue specific actions of insulin, is supported is supported by several
observations. Insulin can modulate gonadotrophin-driven steroidogenesis by PCOS
granulosa cells in vitro
70. Insulin is also known to stimulate thecal cells androgen
synthesis via other mediators like inositolglycan rather than the standard pathway
involving GLUT-4 translocation. Finally there is some evidence to show that there may
be metabolic but not mitogenic alterations in insulin action
76. Evidence on the mechanism
of insulin resistance in PCOS is still not known but there is a belief that there is serine44
phosphorylation of the insulin receptor in the ovarian cells of women with PCOS with
selective induction of the 17,20-lyase activity, thus producing more androgen
77.
The ovary in women with PCOS also contains an abnormal accumulation of multiple,
small antral follicles, which are neither atretic nor apoptotic, but are arrested in their
development
78. The mechanism, by which a dominant follicle is selected, seems to be
disturbed. These small follicles seem to be under the influence of insulin-like growth
factor (IGF; which isoform), sex hormone binding globulin (SHBG), plasminogen
activator type 1 and leptin. Insulin is also known to directly stimulate ovarian stromal
cells androgen synthesis and to inhibit hepatic SHBG synthesis, thus increasing
circulating levels of free active testosterone
67.
Metformin, an insulin sensitizer, seems to decrease serum insulin concentrations in
women with PCOS, thus directly counteracting these effects of insulin and controlling the
abnormal biochemical profile commonly found in PCOS
79.
1.5.2 The treatment of PCOS
The treatment of PCOS consists mainly of controlling the symptoms of the syndrome in
an attempt to achieve short- and long-term goals. Short-term goals include regulation of
menses, treatment for infertility if required, control of hirsutism and acne, and
stabilization or reduction of weight. Long-term goals include the prevention of
endometrial hyperplasia and diabetes, avoiding obesity and the control of biochemical
risk factors associated with heart disease. Multiple concomitant therapies are often45
necessary in order to address the variety of symptoms exhibited in PCOS, but they may
also confer additive benefits with regards to the efficacy of treatment.
Lifestyle modifications such as calorific restriction and exercise can improve overall
weight, waist circumference, insulin sensitivity and fasting insulin levels in anovulatory
women with PCOS. Indeed, an intensive program of calorie restriction, exercise and
lifestyle changes for 6 months, resulted in the re-establishment of ovulatory cycles in
90% of previously amenorrhoeic anovulatory patients
80, while in another study, a mean
weight loss of 11.5% significantly improved insulin sensitivity in obese women with
PCOS
81.
Hirsutism and acne can be managed by a multidisciplinary approach involving the
gynaecologist, the endocrinologist and the dermatologist. Hirsutism can be treated by
mechanical hair removal, by shaving, plucking, depilation, electrolysis, intense pulse
light (IPL) or laser hair removal; however treatment is most effective when used in
combination with hormonal treatment in the form of an anti-androgen to decrease the rate
of hair growth. Recently, topical eflornithine which reduces the rate of hair growth, was
found to be most effective when used in combination to laser or IPL
82
The combined oral contraceptive pill (COCP) effectively controls many symptoms of
PCOS
83,84. In addition to regulating menstrual cycles, endometrial hyperplasia is
prevented and the incidence of acne and hirsutism is reduced, presumably because COCP46
suppresses pituitary gonadotrophin production by negative feed-back mechanism, thus
decreasing ovarian steroidogenesis.
The effects of hyperandrogenaemia can be controlled using anti-androgen therapy (with
or without COCP)
85. Such therapies either block the interaction between androgens and
the androgen receptor, thus preventing effects at the levels of gene expression, or inhibit
5α-reductase
86, the enzyme that converts the less active testosterone into its more active
metabolite androgen dihydrotestosterone, for example within the hair follicle.
Metformin, as mentioned above, is an insulin sensitizer widely used as a treatment for
PCOS
87. As such, it inhibits hepatic glucose production and increases peripheral tissue
sensitivity to insulin. In doses of 1.5 – 2 g per day, metformin decreases ovarian androgen
production, serum androgen and insulin levels. It also improves ovulatory rates and
menstrual cyclicity, in women who were previously suffering from ovulatory
dysfunctions
79.
In anovulatory women with PCOS, the first-line treatment to improve fertility is the
administration of clomiphene citrate, an antagonist of E2 followed by chronic low-dose
FSH, if the former alone is unsuccessful. GnRH agonists such Bursereline acetate, are
also used for ovulation induction in patients with high tonic LH levels, to improve
pregnancy and decrease miscarriage rates
88. Laparoscopic ovarian drilling is also used in
normal-weight patients with high LH tonic concentrations
89, since it decreases ovarian47
androgen production and improves ovulation rates. The biochemical alterations brought
about by this procedure are only temporary however.
Further investigation of the causes of PCOS will ultimately lead to a better ability to
direct therapy to manage the variety of symptoms encountered, or even to cure the
syndrome itself. Traditionally, treatment of PCOS has focused on controlling the overt
symptoms of androgen excess, correcting anovulation if fertility is an issue, and trying to
minimize the risk of endometrial hyperplasia. Recent therapies concentrate more on
correcting the metabolic disturbances dyslipidaemia or impaired glucose metabolism.
More randomized controlled studies are required to determine whether the traditional or
more recent approaches are better.
1.5.3 Polycystic ovarian morphology
A clear distinction has to be made between the presence of polycystic ovaries (PCO) and
PCOS. The former can be observed in women with regular menstrual cycles and in whom
there are no symptoms or signs of hyperandrogenism
90, thus a diagnosis of PCOS is not
supported. Historically, PCO were observed visually at laparotomy and confirmed by
histological analysis of an ovarian biopsy. Further studies identified consistent clinical
and endocrine abnormalities in some women with PCO, and the concept of PCOS was
developed. With the advent of ultrasonographic ovarian scanning it became clear that
some women with PCO do not display any of the other common symptoms of PCOS
91.
Indeed, the prevalence of PCO in the general population has been found to be as high as
25%
92.48
Fig 1.7 -shows a cross-section through a polycystic ovary. This picture was reproduced
courtesy of http://www.ansci.wisc.edu/jjp1/ansci_repro/index.html.
On histology, a PCO exhibits prominent theca, thickening of the tunica albuginea,
increased stromal volume and multiple cystic follicles. Good correlation has been shown
between ultrasound imaging and histopathological assessment when applied to the
diagnosis of PCO morphology
93. Indeed, histological diagnosis of PCO has on the whole
been superseded by ultrasonographic assessment, due to the relative non-invasiveness,
and ease and quality of imaging, provided by the latter technique. The most widely
quoted paper regarding ultrasonographic assessment of PCO morphology was published
in 1985 by Adams et al. An ovary was considered polycystic if it contained 10 or more49
follicles between 2 and 8 mm in diameter in one imaging plane, arranged peripherally
around a dense core of ovarian stroma, or scattered throughout an increased amount of
stroma. Ultrasound was original performed trans-abdominally, however this mode of
operation has largely been superseded by trans-vaginal scanning, which provides better
spatial resolution since the ovaries are closer to the vaginal wall, albeit at the cost of
increased invasiveness to the patient and decreased examination depth. Trans-vaginal
scanning also confers the advantage that the patient does not have to have a full bladder -
which is more comfortable and saves time.
While the definition of PCO morphology developed by Adams et al
94 has been of some
utility in PCOS research, recent international consensus has been achieved regarding
simplified uniform criteria to define PCO morphology
95. With modern high resolution
ultrasound machines operated by skilled personnel, and taking a trans-vaginal approach
especially in obese patients, a PCO is characterised by 12 or more follicles measuring 2 –
9 mm diameter and/or increased ovarian volume (>10 ml), calculated as 0.5 x ovarian
length x width x thickness. Follicle number must be estimated in longitudinal, transverse
and antero-posterior ovarian cross-sections and follicle size should be expressed as the
mean of the diameters measured in these three axes. If a dominant follicle (>10 mm
diameter) or corpus luteum is present, the scan must be repeated during the next cycle,
while any indications of an ovarian cyst necessitate further investigation.
In contrast to earlier definitions, follicle distribution and stromal echogenicity and
volume are no longer criteria for diagnosis of PCO; follicle distribution is variable50
between different PCO, and stromal echogenicity is an operator-dependent and a
subjective assessment criterion; stromal volume increases are though considered specific
to the PCO. Measurement of ovarian volume is however a good surrogate for stromal
volume in clinical practice. It should be noted that this definition does not apply to
women on the OCP, which is known to reduce ovarian volume in women with PCO,
although ‘polycystic’ features may persist. Furthermore, it requires that women with
regular menstrual cycles should be scanned in the early follicular phase (days 3-5 of
cycle), while oligo/amenorrhoeic women should either be scanned at random or after a
progestogen-induced bleed.
Although PCO are found in a significant number of patients with PCOS (nearly 70%)
63,
some women exhibit PCO in the absence of typical features of PCOS, such as
oligomenorrhoea and hyperandrogenaemia
90. These women are considered normal,
according to the consensus ESHRE/ASRM definition of PCOS, yet there is evidence to
suggest they also exhibit elevated levels of cardiovascular risk markers
96,disturbances in
insulin action and glucose homeostasis
97. The endometrium in such women may also be
less receptive to implantation
98.51
Fig. 1.8 a) - Ultrasound image of a polycystic ovary
Fig. 1.8 b) Laparoscopic appearance of a polycystic ovary. The ovary is enlarged and has a
smooth opaque appearance.
Both images were reproduced with permission of Dr Samuel Marcus – Director of the IVF-
fertility center, Chicago.52
1.6 Endometrial cancer
1.6.1 Epidemiology
Endometrial cancer (EC) is the most common gynaecological cancer in the Western
World. The United Kingdom incidence in 2005
99,100 was 6821 cases (2% of all reported
cancers). EC resulted in 1% of all cancer deaths in that year, though the overall 5-year
survival rate for EC is greater than 70%. EC occurs during reproductive and menopausal
life, with a median age of 61 years. Although the majority of patients are post-
menopausal at diagnosis, 5% present with the condition before the age of 40 and 20 -
25% will be diagnosed before the menopause. The incidence of EC has increased over
the last 3 decades igniting new debate as to whether it is linked to the use of exogenous
oestrogens or other environmental factors.
1.6.2 Aetiology
The OCP is thought to offer some protection against the development of EC, especially in
nulliparous women as, surprisingly, does cigarette smoking
101. Multiple risk factors for
EC have been described and may be classified into 3 main groups: variants of normal
anatomy and physiology; frank abnormality or disease(endocrine or metabolic); and
exposure to carcinogen
102. Obesity, nulliparity and late menopause can all be included
under the first group, with upper body or central obesity conferring the greatest risk
103.
Serum SHBG is depressed in obese women, especially those with upper body fat
localization
104, and it is possible such women have higher levels of free oestrogens53
(unbound to SHBG) available to stimulate the proliferation of normal endometrial
epithelial cells, as well as oestrogen-sensitive endometrial tumour cells.
Within the second group , diabetes mellitus (type II) is prominent, increasing the risk of
EC 2.8-fold, even after adjusting for weight, age and socio-economic status
105. The
relationship between unopposed oestrogenic stimulation of the endometrium in
anovulatory women and EC is also well-documented, such women having an increased
risk of EC which is counteracted by progestogen therapy
106. In some patients with EC, a
previous history of complex endometrial hyperplasia with atypia can be demonstrated.
An increased incidence of EC has also been found in association with tamoxifen
treatment of breast cancer, perhaps related to the oestrogenic effect of tamoxifen on the
endometrium
107.
A high index of suspicion of EC should be present when a post-menopausal woman
complains of vaginal bleeding, or pre-menopausal women with associated risk factors
present with persistent, inter-menstrual bleeding. Investigation, after the taking of a
careful patient history, involves a full blood count, a trans-vaginal ultrasound, an
endometrial biopsy and a hysteroscopy.
1.6.3 EC morphology
The most common EC cell type (75 – 80% of case) is endometrioid adenocarcinoma,
which is composed of malignant endometrial glandular epithelial elements, which can be
morphologically divided into the subtypes: ciliated adenocarcinoma; secretory54
adenocarcinoma; papillary or villoglandular; adenocarcinoma with squamous
differentiation (either adenoacanthoma or adenosquamous). Clear cell (4% of cases) and
papillary serous carcinoma (<10% of cases) of the endometrium are tumours that are
histologically similar to those noted in the ovary and the fallopian tube, and carry are a
worse prognosis than does endometrioid EC. Mucinous, squamous and undifferentiated
endometrial tumours are rarely encountered (each <1% of cases), while mixed tumour
morphology is noted in 10% of cases.
1.6.4 EC staging
A hysterectomy is required to determine the degree of myometrial and pelvic invasion.
Surgical staging criteria have been adopted by the International Federation of
Gynaecology and Obstetrics (FIGO) and by the American Joint Committee on Cancer
(AJCC) [REF; 30-32]. Stage I EC is confined to the corpus uteri, either within the
endometrium itself (Stage IA) or to less than (Stage 1B) or greater than (Stage 1C) half
the myometrial thickness. Stage II EC has not extended beyond the uterus but does
involve the corpus uteri and the cervix, either limited to endocervical glandular
involvement (Stage IIA) or with cervical stromal invasion (Stage IIB). Stage III EC
extends outside of the uterus but is confined to the true pelvis, either having invaded the
serosa and/or adnexa and/or peritoneum (Stage IIIA), the vagina (Stage IIIB) or the
pelvic and/or para-aortic lymph nodes (Stage IIIC). Stage IV EC exhibits more
widespread dissemination, either to the bladder and/or bowel mucosa (Stage IVA) or to
distant metastases including the intra-abdominal and/or inguinal lymph nodes (Stage
IVB).55
EC can also be grouped with regard to the degree of differentiation of the
adenocarcinoma; either ≤5% (G1), 6 – 50% (G2) or 50%≤ (G3) of cells exhibiting a non-
squamous or solid growth pattern. By mixing the FIGO staging criteria with this
differentiation based grouping, EC can be relatively precisely described with respect to
degree of spread and morphology/invasive potential
108.
1.6.5 The pathology of EC
Clinicopathological findings indicate that EC arises through a series of precursor lesions,
namely simple and complex hyperplasia, with or without atypia
109. These lesions are
thought to develop, survive and proliferate in response to unopposed and prolonged
oestrogenic stimulation of the endometrium, with the assistance of various growth factors
and cytokines
110. It is however an over-simplification to suggest that endometrial tumours
can be divided into oestrogen-dependent and -independent.
Recent evidence suggests that endometrial carcinogenesis occurs via several pathways,
namely hyperplasia, metaplasia, and de novo
110. This has lead to reclassification of the
histopathological criteria regarding endometrial carcinogenesis endometrial intra-
epithelial neoplasia (EIN) is proposed as the primary precursor lesion for EC
111.
Multistep genetic alterations are thought to take place to produce malignant tumours, and
three steps have been suggested to be important in endometrial tumorigenesis. In the first
step - initiation - a limited number of genetic disturbances are thought to be required to
produce EIN. In the second stage - promotion -a further tumour promoting events occur56
which amplify the effects of those earlier events, leading to immortalization and
uncontrolled proliferation. In the third stage – Tumour progression- further genetic
deficits occur to facilitate progression to a highly proliferative, metastatic phenotype
110
1.6.5.1 Initiation of EC
Initiation can occur via activation of proto-oncogene, inactivation of tumour suppressor
genes or by the effects of microsatellite instability on gene structure and expression.
Expression of the K-ras proto-oncogene has been detected in 10 - 37% of EC and 6 -
16% of atypical endometrial hyperplasia, whereas K-ras expression is undetectable in
simple and complex hyperplasia
112. The activated K-ras gene product, a 21 kD protein
(p21), produces an unregulated intracellular signal that induces cell proliferation
113. Its
activation is thought to be an early initiating event in the development of EC. K-ras
mutations are much more frequent in the well differentiated endometrioid EC type than in
any other type of endometrial tumour
114. Other oncogenes are also involved in initiation,
such as myb, fos, myc, fms and HER-2/neu, and their expression is associated with a
poorer prognosis when observed in EC
110.
DNA microsatellites are scattered throughout the genome, consisting of multiple repeats
of simple one to six nucleotide units. Microsatellites based on the CA dinucleotide repeat
are the most common in humans, occurring at >10,000 sites throughout the genome
115.
Microsatellite instability (MSI) is characterized by changes in microsatellite length due to
variation in the number of repeat units within the microsatellite. This type of alteration57
can be detected only if many cells are affected by the same change, thus it is an indicator
of clonal expansion, e.g. in neoplasia. MSI is believed to be caused by defects in genes
coding enzymes involved in DNA-mismatched repair (MMR). Several genes, such as
MSH2, MLH1, PMS1, PMS2, GTBP, are involved in DNA mis-matched repair in the
human, but the loss of MLH1 expression due to hypermethylation of its promoter,
specifically leads to deficiencies in endometrial MMR capacity. Indeed, MLH1 -
promoter methylation seems to be a key early event in endometrial carcinogenesis
116.
Tumour suppressor genes encode proteins that normally inhibit or modulate cell
proliferation. Perhaps the most investigated tumour suppressor gene is p53, which has
been found to be mutated in a variety of tumours including EC
117. Mutations impacting
on p53 tumour-suppressor function are more common in poorly differentiated
endometrioid type EC, and p53 over expression (the mutated or wild type of p53 still
binds to antibody when investigated with immunohistochemistry) is associated with
advanced clinical stage, myometrial invasion, and distant metastatic PSread
118. Therefore,
inactivation of p53 is likely to be a late event in carcinogenesis
119.
PTEN (Phosphatase and Tensin Homolog Deleted on Chromosome 10), on the other
hand, seems to be inactivated early in the carcinogenic pathway in EC
120; it was
identified as a candidate tumour suppressor gene by a number of study groups
111. PTEN
is often mutated in many human tumour types such as endometrial, prostate,
glioblastomas and breast cancers
121. PTEN encodes a 403-amino acid protein, which is a
member of the tyrosine phosphatase family. It inhibits the phosphatidylinositol 3-kinase58
/Akt signalling pathway by removing the phosphate in D3-phoPShate group of
phoPShoinositide-3, 4, 5-triphoPShate (PIP3)
122. Dephosphorylation of PIP3 is a critical
determinant for controlling cell growth, proliferation, and survival. Inhibition of PIP3
causes blocking of Akt signalling, which in turn, ends up with an increased activity on
some pro-apoptotic molecules. Therefore, PTEN plays an important role in cell survival
and apoptosis because it inhibits cell cycle progression by down-regulating Cyclin D1
and activates pro-apoptotic molecules through Akt-dependent and independent
pathways
123. PTEN also inhibits the integrins, a large family of specific cell surface
receptors for extracellular matrix proteins, which have a major role in cell adhesion,
migration and invasion. Integrins also have intracellular functions, in that they integrate
the extracellular environment into intracellular signal transduction pathways, and also
link that environment to the cytoskeleton. Thus integrins initiate intracellular signals,
which modulate cell morphology, migration and proliferation
124.
1.6.5.2 Promotion of EC
Promotion is the second step in EC carcinogenesis. It involves the dysregulation of
cellular proliferation, ultimately resulting in the clonal expansion of an initiated cell
under the influence of tumour promoters, and also leads to immortalization
110. Several
studies have found that cells are generally monoclonal in endometrial carcinoma and
complex hyperplasia with atypia, whereas they are generally polyclonal in simple and
complex hyperplasia without atypia, as well as in normal tissue
125. This suggests that
most simple and complex hyperplasia without atypia constitute a general proliferative
reaction in a tissue, hence the polyclonality, which can be referred to as true hyperplasia.59
The tissues exhibiting monoclonality, i.e. many complex atypical hyperplasia and some
simple/complex hyperplasia without atypia, are in fact precancerous neoplasia
125.
Cellular transformation or immortalisation is also required for promotion since a normal
cell stops proliferating after ca 70 – 100 cycles of cell replication and becomes senescent.
This process is thought to be regulated by telomere length at the tips of chromosomes.
DNA polymerase is unable to duplicate the tips of chromosomes, so a small amount of
DNA is lost with each cell division. To prevent the loss of important genes, chromosomal
ends consist of long, non-coding, repetitive sequences known as telomeres. After 70 -100
cell cycles however, the telomeres in somatic cells have eroded below a critical limit,
which shuts down cell replication. The reverse transcriptase telomerase elongates
telomeres, which must occur at some stage in development otherwise the chromosomes
derived at fertilization would be eroded such that they could not support the cell
replication required for subsequent development. Indeed, telomerase is active during
gametogenesis but is undetectable in the vast majority of adult somatic tissues.
Telomerase is however activated in most malignant tumours, including EC, where it is
assumed to support cellular immortalisation
126. Telomerase activity is also pronounced in
highly regenerative tissue, including the endometrium, presumably to prevent stem cells
‘burn out’. Endometrial telomerase is most active in the proliferative phase of the
menstrual cycle and is under the influence of sex hormones. Thus telomerase activity
correlates with cell proliferation, and it is probable that telomerase has critical role in
tumour promotion – via its induction of cell immortalization.60
Another aspect of promotion is that apoptosis become inhibited. Apoptosis is a process of
controlled cell death following a defined physiological pathway
127. When apoptotic
mechanisms are disturbed, the cell does not die and can continue to grow with a
malignant phenotype
128. Mutations in oncogenes such as p53 and bcl2 can inhibit
apoptosis allowing the survival of uncontrollably proliferating transformed cells
117.
1.6.5.3 Metastasis of EC
The last step in carcinogenesis within the endometrium - metastasis - involves
progressive genetic events which influence cell proliferation, proteolysis, adhesion,
migration and angiogenesis
110. After promotion, there is local invasion by tumour cells
into the surrounding tissues. Degradation of the epithelial basement membrane and
underlying extracellular matrix (ECM) is a critical histological marker for the transition
of carcinoma from in situ to invasive. The ECM is composed of proteins and
carbohydrates including collagen, fibronectin, elastin and proteoglycans. During
invasion, cancer cells activate fibroblasts and recruit macrophages, and produce or
stimulate the production of, crucial enzymes required for basement membrane and ECM
destruction.
Matrix metalloproteinases (MMP) constitute a family of endopeptidases composed of at
least 16 gene products that are involved in the degradation of ECM macromolecules and
subsequent tissue destruction in a variety of pathologic conditions. MMP-2 (gelatinase)
and MMP-9 are both secreted in human endometrial carcinoma. MMP-7 is significantly61
activated in advanced EC and may be a key proteolytic enzyme in its invasion and
metastasis, proliferation, proteolysis, adhesion, migration and angiogenesis
129.
1.7 Endometrial hyperplasia as a precursor of EC
The course of endometrial hyperplasia is similar to dysplasia of the cervix. Some of these
lesions spontaneously revert to normal, or do so after medical therapy, whilst many
persist as hyperplasia; some may however progress to carcinoma
130. A diagnosis of
endometrial hyperplasia requires histopathological analysis of an endometrial Pipelle
biopsy, usually obtained from symptomatic women who present with dysfunctional
uterine bleeding. Unlike the cervix, there is no reliable screening method to detect
changes in the endometrial architecture (an endometrial biopsy is taken on clinical
indication basis) Most endometrial hyperplasia is thought to arise from persistent,
prolonged oestrogenic stimulation of the endometrium and the most common cause of
this is a succession of anovulatory cycles
131. Hyperplasia may also however result from
hyperoestrogenaemia, as a result of excessive endogenous oestrogen synthesis or
exogeneously administered oestrogen
132.
1.7.1 Histology of endometrial hyperplasia
The gross appearance of an endometrial cavity which contains hyperplastic tissue varies.
Often the endometrium is thickened or polyploid, and large quantities of tissue are
obtained at curettage. In other patients however, particularly post-menopausal women,
the curettings are usually scanty and only small foci of hyperplasia can be found. In62
general, hyperplasia involves excess proliferation of both stroma and endometrial glands.
The glands are tubular or slightly convoluted and of variable size and shape; occasionally
some of the glands may be cystic and dilated. Secretory activity is usually absent or
sporadic. Mitotic activity is not as prominent as in the proliferative endometrium.
Nucleoli are prominent and there is little budding of the glandular epithelium into the
lumen
In 1984, the World Health Organization (WHO) adopted a new classification based on
the study of Kurman et al (1984)
133.
Histological diagnosis Cytological atypia Architectural pattern
Simple
Complex
Absent
Absent
Regular
Irregular: glands crowded back to back
Simple atypical
Complex atypical
Present
Present
Regular
Irregular: glands crowded back to back
Table 1.9: Criteria for histological diagnosis of endometrial hyperplasia
132.
In endometrial hyperplasia, there is an increase in the gland-stroma ratio, and various
abnormal patterns of tissue architecture have been noted. Glands may vary in shape and
size and may also become irregular in outline. The most important distinction in
endometrial hyperplasia is whether or not nuclear atypia are present. Cells showing
atypia have an increase nuclear-cytoplasmic ratio, due to enlargement of the nucleus
134,135. Often such cells have lost their normal polarity and are irregular in outline.63
Hyperchromatic changes also occur due to nucleolar clumping. Atypia is an important
factor with regard to the malignant potential of the lesion
136.
The WHO classification of endometrial hyperplasia has been challenged recently, as it is
subject to unacceptably high inter- and intra-observer variability, for a number of
reasons
137. Firstly, morphological changes in normal endometrium during the menstrual
cycle are extremely variable, and are influenced by numerous factors, such as age and
hormone therapy
138. Consequently, normal and hyperplasic endometrial biopsies have a
large number of overlapping morphological features, making it difficult to discern
between the two
139. Secondly morphology may vary greatly within the same
endometrium: areas with normal appearance are found adjacent to areas with simple
cystic abnormality and/or complex proliferation. Furthermore, the WHO criteria give the
impression that non-atypical simple and complex hyperplasias are easily distinguished
from each other; in practice this is not the case. There is evidence that both these forms of
hyperplasia have minimal risk of progression to carcinoma
140 and that both require
similar treatment in the form of progestogens
141. It would therefore seem more
appropriate to group non-atypical simple and complex hyperplasia under one category,
that of non-atypical endometrial hyperplasia
142.
According to the WHO criteria, atypical hyperplasia can also be subdivided into simple
and complex categories. However it is argued that simple atypical hyperplasia is rare
132
and difficult to separate histologically from complex atypical hyperplasia, since features64
such as crowding of the glands, stratification of the epithelium and proliferation of the
stroma are often intermixed in one specimen.
The risk of an atypical hyperplasia within this classification scheme progressing to a low-
grade carcinoma ranges from 15 to 40%. The wide variation reflects different diagnostic
criteria and interpretations of what constitutes atypical hyperplasia, however this type of
lesion should always be considered as an early form of cancer
140,143.
More recently, there has been a shift to re-name atypical hyperplasia as endometrial
intraepithelial neoplasia (EIN)
110. This term is used to describe monoclonal endometrial
pre-cancers, characterized by morphological features that have been documented to
increase the risk of cancer (discussed in section 1.6.5.2.). These features include volume
percentage stroma <55%, cytological demarcation, exceeding 1mm minimum in diameter
(at the exclusion of differential diagnoses for example, cancer, polyps secretory
endometrium or artefacts).
Immunohistochemical biomarkers have further improved the detection limit of pre-
malignant endometrial disease. The tumour suppressor gene PTEN is mutated in 83% of
endometrial adenocarcinomas
144. As this process is thought to occur at, or near the time
of, initiation of carcinogenesis, pre-malignant and malignant glands can be distinguished
by the loss of this marker. Thus immunohistochemical analysis of PTEN protein
expression in EIN showed lesion-wide loss of PTEN protein in 63% of lesions studied,
suggesting that these glands are monoclonal outgrowths from an abnormal PTEN-null65
cell. PTEN-null glands can also be identified by immunohistochemistry in overtly
‘normal’ endometrial tissue, and such glands may represent an early stage of
carcinogenic initiation. It is likely that the PTEN gene acts as a gatekeeper for
endometrial carcinogenesis, being (at present) the initial genetic change observed in the
endometrial epithelium which appears to predict the development of EC.
1.8 Is PCOS associated with EC?
Women with PCOS may have several months or more between menstrual periods. Thus
the endometrium is exposed to oestrogen and in the proliferative phase for abnormally
long periods of time, even permanently in amenorrhoeic women, before the progesterone
surge around ovulation causes endometrial differentiation and entry into the secretory
phase. Progesterone levels fall if fertilization does not occur and the endometrium
degenerates and is lost in the menstrual blood flow. In women with PCOS therefore, the
endometrium is subjected to unopposed oestrogenic stimulation, and remains within the
uterus, for abnormally long periods of time.
The treatment of women with polycystic ovary syndrome (PCOS) has been influenced for
more than 50 years by the belief that PCOS is associated with an increased risk of
endometrial cancer (EC). It was theorized that unopposed oestrogen stimulation, and thus
endometrial proliferation, was likely to cause endometrial hyperplasia which could lead
to EC. EC is age-related, 5% of patients being aged <40 years, 20% aged 40 - 50 years
and 75% >50 years. A reproductive lifetime of unopposed oestrogen stimulation may
have a role in EC in post-menopausal women; it may also have aetiological significance66
in pre-menopausal patients. Legros and colleagues
145, after studying a group of self-
selected women with PCOS, concluded that they should receive progesterone therapy to
reduce their EC risk. Experimental and epidemiological evidence for an association is
sparse however, as discussed below.
When an association between PCOS and EC was first proposed, a primary characteristic
of cancers was understood to be their uncontrolled proliferation. Thus it seemed logical
that if excessive proliferation occurred in the endometrium due to unopposed oestrogen
action, it could induce EC. Understanding of cancer has progressed and the logic of this
hypothesis is less certain, however, the assumption that EC is a risk in women with
PCOS still underpins treatment strategies quoted in the Royal College of Obstetricians
and Gynaecologists Guidelines for Good Clinical Practice
146 (Disorders of the Menstrual
Cycle), the Health Information website of the National Library of Medicine, USA,
Medline Plus, and in internationally recognized textbooks of gynaecologic oncology.
Approximately 10% of women suffer from PCOS so it is important that correct treatment
is provided if an associated risk of EC is present, as substantial numbers of women could
be affected. Equally, it is medically and economically important that treatment is
provided only to those at risk. Thus the presence and severity of the risk of EC in women
with PCOS, and the characteristics of the at risk population, need to be accurately
determined. As discussed below, it is apparent that such risk assessment has not been
adequately performed and though EC has a number of aetiological factors, evidence for
the link between PCOS and EC is at best circumstantial.67
Over the years, various publications have investigated the possible effects of unopposed
oestrogenic stimulation on the risk of EC in women with PCOS. To investigate the
research relevant to this proposed association, and to obtain evidence allowing an
assessment of risk and at-risk group characteristics to be made, a literature search was
performed on Medline (covering biological/medical science articles from 1957 to 2002),
the Cochrane database and EMBASE. In addition, searches were performed in the
archives of the Royal College of Obstetricians and Gynaecologists and on all theses
submitted at the Royal Free Hospital Medical School in the last five years. These
searches were performed using the terms polycystic ovarian disease, polycystic ovary
syndrome, polycystic ovaries, endometrial hyperplasia, endometrial carcinoma and EC.
The search included case reports, clinical trials and all other publications dealing with
one or all of the above subjects
PCOS was first described by Stein and Leventhal in 1935
147, yet there are relatively few
publications thereafter, reporting on single instances or small series of patients, which
link PCOS and EC. The first of such publications, by Speert et al. in 1949
148(15 years
after the first description of what is now known as PCOS by S and L), described 14
young women with EC, the majority of whom may have suffered from PCOS, since they
exhibited primary infertility and ovaries described as cystic, sclerotic or ‘hyaline’, with
no histological evidence of ovulation. Speert concluded that endometrial carcinoma in
young women was not as rare as previously thought, and that abnormal bleeding in non-
pregnant women warranted investigation with endometrial curettage.68
It 1957, Jackson et al. specifically linked EC and Stein-Leventhal syndrome
1. Clinical
and pathological data were reported on 43 patients with Stein-Leventhal syndrome, the
majority being obese, hirsute, hypertensive and infertile, and presumably suffering from
PCOS. Sixteen of these cases were identified retrospectively, from among ‘several
thousand patients’ with EC, by examining surgical ovarian biopsies. The other 27 were
prospectively diagnosed with Stein-Leventhal syndrome by examination and ovarian
biopsy. Endometrial tissue from 15 of the 27 cases was examined, 13 showed
‘thickening’ of the endometrium, 2 were atrophic and none were cancerous.
Nevertheless, the authors concluded that ‘our most important observation in Stein-
Leventhal syndrome concerns the complication of endometrial carcinoma’. They also
suggested that ovarian wedge resection be evaluated in preventing endometrial
carcinoma, since it improved the other signs and symptoms encountered in Stein-
Leventhal syndrome. The main conclusion has not been challenged over the following 45
years, and the Jackson et al. study continues to be described as showing a 37%
prevalence of endometrial malignancy in women with polycystic ovaries.
It is now apparent that the study of Jackson et al. has serious irregularities. Two patient
groups were described. In one group, 16 of ‘several thousand’ EC cases had ovaries
consistent with Stein-Leventhal syndrome on retrospective analysis. Assuming ‘several
thousand’ to be 2000 cases, the best case scenario for the author’s conclusions, this
suggests 0.8% of EC cases have PCO. Recent research indicates however PCO
morphology is seen in 10 – 20% of women. Thus the data presented by Jackson et al. has69
an inordinately low incidence of PCO in EC patients, and could even be taken to suggest
that PCO morphology has a protective influence on the risk of EC, rather than being a
positive risk factor for EC as suggested by the authors. In fact, the observation of only 16
cases of PCO in several thousand EC cases must raise suspicions regarding the accuracy
of the histopathological analysis in this study. Alternatively, it raises the possibility,
though slight, that EC ameliorates PCO morphology. More likely is that only 16 cases
were found because of the difficulty in noting PCO morphology in ovaries from post-
menopausal women, as seen in this study (Chapter 4), and the likelihood that the ‘several
thousand’ EC cases investigated were predominantly post-menopausal, since even today
the median age of EC diagnosis is 61 years.
Another point is that in the prospectively assessed Stein-Leventhal group of 27 cases,
even though Stein-Leventhal is concluded to be a risk factor for EC, no EC cases were
noted in the 15 patients assessed by endometrial biopsy. Thickening was noted in 13, but
the relevance to EC of this observation is, at best, open to question. The statistical
approach used is also suspect. Adding the 16 patients with PCO and EC to the 27 with
PCO but not EC, to give an EC prevalence in PCO sufferers of 16/43 (37%) is invalid. If
‘blonde hair’ is substituted for PCO as the patient characteristic in this approach, the
faults in this approach are manifest. Jackson et al. also did not attempt to explain the
Liedig-like and Sertoli-like cells in the ovaries. In addition, the study may have been
subject to selection bias as it was done retrospectively on surgical biopsies.70
Coulam et al
149, in1983 studied a cohort of 1270 women with chronic anovulation and
assessed their risk factors for developing neoplasia. The observed number of
malignancies was similar to that expected in the general population (30 and 29.8,
respectively). When the site of neoplasia was considered however, the endometrium was
the only site at increased risk. It was concluded that a risk of EC had to be considered in
patients with chronic anovulation. Only some of these patients would have had PCOS
however, thus this study only provides circumstantial evidence linking PCOS and EC.
The possibility that women with PCOS may have other disturbances that are unique to
them that may predispose them or protect them from EC was not considered. For
example patients with PCOS are insulin resistant
150 and tend to have high circulating
levels of insulin in the body. Insulin in turn is a potent endometrial mitogen
151.
In 1984, Gallup et al
152 studied EC patients with respect to their age and potential risk
factors. It was found that 14.4% of 111 patients with EC were 40 years or younger.
These younger EC patients tended to have well differentiated tumours compared to
patients in the older age group. They were also more obese and likely to be nulliparous,
and 31.2% had PCO morphology, albeit the prevalence of PCO was not reported in the
older EC patient group. This study seems to confirm an association between EC and
aspects of Stein-Leventhal/PCOS, such as infertility, obesity etc. However the prevalence
of PCO morphology in the young EC patient group (31.2%) is greater than the estimated
prevalence of PCO in the general population. It is certainly greater than noted in the study
by Jackson et al., perhaps because PCO morphology was more easily recognized in the
younger women. Indeed, this may be why the prevalence in the older patients was not71
described. The sample size in this study is relatively small however – 111 patients of
which 16 were <40 years, and 5 were <40years with PCO morphology.
In 1991, Dahlgren
153 retrospectively studied 70 women with EC in Sweden, aged
between 31 - 45 years. Subsequently, the same authors recruited 99 women aged 46 - 65
years, suffering from the same condition. Both groups were compared to 1746 control
women, aged between 39 - 65 years, randomly selected from a population-based study
performed in the city of Goteborg. All cases were studied by examining hospital records
and a questionnaire. Hirsutism, high body mass index and hypertension were more
common in both groups of EC patients, compared to the age-matched control groups.
Nulliparity and infertility were more common in the younger EC patients. The controls
used the combined oral contraceptive pill more often (more prevalent usage) than women
with EC (there was however no difference in duration of use by either groups). There was
a negative correlation with cigarette smoking. These findings seem to indicate that
untreated ovarian dysfunction similar to that present in PCOS, with unopposed oestrogen
stimulation of the endometrium, is associated with EC in young women. Cigarette
smoking seemed to have a protective effect.
It could be argued from this study that there was potential selection bias since the cases
came from a large area with mixed urban and rural background whereas the controls all
came from only one large city. There also may have been information bias; for example,
information about hirsutism can be very subjective. What is perceived, as excess hair72
growth by one person may not necessarily be so for another. There was also no mention
of the measures taken to reduce recall bias.
Lastly in 1991, Escobedo et al
154 studied 399 women with EC and compared them to
3040 controls. They found that the former group had more ‘ovarian factor’ infertility than
in the control group. However they did not specifically look at the incidence of PCOS in
those patients.
Most publications otherwise have been in the form of literature reviews and case reports
but little work concerning case studies or randomized trial is documented. It is also
surprising to find that most of the studies that are quoted as providing evidence for an
association between PCOS and EC, did not included controls. This omission brings the
conclusions of such studies into question.
1.8.1: Proposed mechanism by which PCOS may predispose to EC
There are a number of mechanisms by which patients with PCOS are thought to develop
endometrial carcinoma. The oldest and perhaps the most established is that prolonged
unopposed oestrogen stimulation of the endometrium can induce oncogenic changes, as
first postulated by Jackson
1 in 1957. Since this time however, other studies have been
performed and their results used in support of additional mechanisms.
For example, Jafari et al
155 in 1978 studied six cases of adenocarcinoma of the
endometrium associated with Stein-Leventhal syndrome (PCOS), of average age 27.873
years. They found that adenocarcinoma associated with PCOS was well differentiated
and had a good prognosis. They proposed that the elevated levels of LH seen in PCOS
increased production of androstenedione and testosterone, and that the effect of these
androgens may be a causal factor in the development of well differentiated
adenocarcinoma in oestrogen hyperstimulated endometrium. Jafari et al also noted that
progesterone, is deficient in Stein-Leventhal syndrome and that progesterone receptors
are expressed in endometrial tissue, and when occupied, may modulated oestrogen
receptor activity and reduce endometrial cell growth potential. Hence they proposed that
the depressed progesterone levels in PCOS may be permissive to the development of
adenocarcinoma in the oestrogen hyperstimulated endometrium. They also suggested that
although unopposed oestrogen stimulation seems to be the predominant factor in the
development of endometrial carcinoma, Stein-Leventhal syndrome and adenocarcinoma
of the endometrium both were associated with metabolic and endocrine effects. This fact
suggested some potential hypothalamic and pituitary roles in the development of the two
disorders.
In a study by Konishi et al
156 in 1996, LH and hCG receptor expression was assessed by
immunohistochemistry in endometrial biopsies (20 normal and 24 abnormal, the latter
subdivided into 9 exhibiting simple endometrial hyperplasia, 6 complex hyperplasia, 6
atypical hyperplasia and 3 overt endometrial carcinoma). Fifteen of the 24 patients were
40 years old or younger and all were anovulatory. Serum levels of LH, FSH, prolactin,
Oestradiol and testosterone were measured by radioimmunoassay. LH and HCG receptor
expression was detected in 19 of the 21 biopsies exhibiting hyperplasia. Expression74
appeared stronger in the glandular cells of complex and atypical hyperplasia, relative to
simple hyperplasia and normal endometrial glands. The 3 carcinoma specimens showed
strong expression of LH and HCG receptors compared with normal endometrium, as
expected. They concluded that LH and HCG receptor over expression is a feature of
complex and atypical endometrial hyperplasia and endometrial carcinoma in younger
anovulatory women, many of whom were PCOS sufferers.
Ho et al, in 1997
157, conducted a study in Singapore to determine the incidence of EC in
endometrial hyperplasia and try to identify patients at risk of EC. They retrospectively
studied 116 patients who had simple, complex or mixed (simple with complex focus)
endometrial hyperplasia, with or without atypia and without coexisting endometrial
carcinoma, between January 1991 to December 1994, selected by screening the database
of the histopathological laboratory at a teaching hospital. The selected patients' notes
were reviewed and a second endometrial biopsy performed five years later. They found
that 29 patients had endometrial hyperplasia with atypia and 87 without atypia on the first
biopsy. The incidence of endometrial carcinoma in the second biopsy was 27.6% in those
with endometrial hyperplasia with atypia and 3.4% in those without atypia; all carcinoma
cases were found to be stage 1 adenocarcinoma. The incidence of PCOS and sub fertility
was elevated in case of endometrial hyperplasia with atypia, but not in cases of
carcinoma. After reviewing patient records, no predictive factors for endometrial
carcinoma were apparent.75
This study assessed whether endometrial hyperplasia with atypia was a precursor for the
development of endometrial carcinoma. The fact that many patients with PCOS tend to
develop atypical hyperplasia, which was associated with an increased probability of
endometrial adenocarcinoma, was used to conclude that women with PCOS people are at
increased risk of developing EC.
More recently, Elliot at al
151, in May 2001, presented two case reports and a short
literature review. They write that multiple mechanisms may be responsible for the
increased risk of EC. In the context of PCOS, endometrial carcinoma need not be
associated with abnormally high levels of oestrogen or insulin alone. Yet the chronic
anovulatory or oligo-ovulatory state of PCOS is characterised by high oestrogen levels
and hyperinsulinaemia but little or no progestogenic activity. They postulate that this
ultimately results in endometrial hyperplasia, which is thought to be a precursor of
malignancy. Tonically elevated serum insulin levels up-regulate aromatase expression
and oestrogen synthesis in the endometrial glands and stroma. This has an additive and
deleterious effect in woman who are hyperinsulinaemic and anovulatory, as is the case in
many women with PCOS, since chronic oestrogen hyperstimulation of the endometrium
is exacerbated. So for a non-hysterectomised woman with PCOS, endometrial
hyperplasia represents a common end-point of two distinct pathophysiological processes.
They also mention that in vitro, insulin and insulin growth factors seem to act as potent
mitogens in specific cell subpopulations. EC cell lines demonstrate such activity. This76
may explain why, once present, atypical endometrial hyperplasia advances to frank
carcinoma in as many as 30% of cases.
There have been subsequent studies linking endometrial hyperplasia and EC. Studies
investigating the link between p53 expression and endometrial hyperplasia, e.g. Kaku et
al
158, have characterised two classes of endometrial carcinoma. In Type 1 EC, which is
associated with prior endometrial hyperplasia, unopposed oestrogen secretion is thought
to be an important determining factor. Such tumours tend to occur in younger patients,
and the tumours exhibit less myometrial invasion and limited up-regulation in p53
expression, and have better prognosis. In contrast, type 2 EC tumours are not associated
with prior endometrial hyperplasia. They tend to occur in older patients, to exhibit p53
over expression and to have poorer prognosis.
Fabjani et al
159, in 2000, investigated genetic alterations in endometrial hyperplasia and
cancer. They found that some genetic microsatellite markers, such as D1S518, D3S2387
and D8S1992, were predictive of the ability of endometrial hyperplasia to progress to
endometrial carcinoma. They also found that a deletion from chromosome 8p was
frequently found in endometrial hyperplasia, as well as EC. This finding supports the
hypothesis that chromosome 8 contains tumour suppressor genes and that their deletion
occurs early during endometrial tumorigenesis.
The literature review performed has however also revealed studies that do not support the
view that PCOS predisposes to EC. In 1978, Ramzy et al
160 assessed the histological77
appearance of ovaries from 15 patients in whom endometrial adenocarcinoma had
developed before the age of 40 years, from 21 age-matched controls and from 25 patients
diagnosed with Stein-Leventhal syndrome (i.e. PCOS). The features assessed included
type and size of cysts, presence and number of primary follicles, corpora lutea, corpora
albicantia, and the presence of stromal luteinization and sclerosis. It was found that the
ovaries of patients less than 40 years old who have endometrial carcinoma were more
similar to normal ovaries than to polycystic ovaries. The authors concluded that abnormal
ovarian function may be a predisposing factor for EC in young women, however if such a
defect of ovarian function exists, it is not apparent on visual examination of the ovary.
This study seems to contradict the hypothesis that women with polycystic ovaries (an
ultrasound criterion for diagnosing PCOS) are at increased risk of developing
endometrial carcinoma. However more recent findings suggest that there is a proportion
of women with polycystic ovarian morphology, but without the associated endocrine
disturbances. Similarly, according to the recent ARSM/ESHRE consensus definition for
PCOS, it is possible for patients to exhibit endocrine and ovulatory disturbances
characteristic of PCOS (i.e. Stein Leventhal syndrome), in the absence of polycystic
ovarian morphology.
In 1998, Pierpont et al
161 published the results of a long-term follow-up study (average 30
years) of the mortality of 786 women in the UK with PCOS diagnosed between 1930 and
1979. The authors calculated standardized mortality ratios (SMR) to compare the death
rates, from a variety of causes, in these women with national rates. Breast cancer was the78
commonest cause of death in women with PCOS; the standardized mortality ratio
indicated the death rate was higher than in the national rate. The overall death rate from
cancer in women with PCOS was however lower than the national rate. Endometrial
carcinoma was not separately discussed, and it must be assumed that it was included in
the “other” category, which represented only a small fraction of the total number of
deaths before 75 years of age. If PCOS was a strong predisposing factor for endometrial
carcinoma we would expect the standardized mortality rate to be higher for this condition
when compared with national rates.
The literature study performed reveals how little evidence there is linking PCOS per se
with endometrial carcinoma. To attempt to assess the strength of this linkage, a case
control study involving patients with endometrial carcinoma and age-matched controls
was performed in which the proportion of patients from each category who had features
suggestive of PCOS was assessed. This study is discussed in Chapter 4.
Another potential line of study is to examine endometrial biopsies from patients with
PCOS and endometrial carcinoma using microarray analysis to assess gene expression. If
PCOS and EC are strongly linked, similarities in gene expression between the two classes
should exist, especially for genes known to be involved in oncogenesis. Such a
correlation with in gene expression with women with EC, might not be seen in all women
with PCOS, but may only occur in a subgroup of women with PCOS at-risk of EC. If
identifiable using microarrays however, analysis of the patient histories in such a group
may allow identification of easily characterised risk-factors or markers for the at-risk79
group. Such a finding will allow targeting of screen strategies and treatment to this group,
which will save lives and money. This approach and investigation is discussed in Chapter
6.
PCOS and chronic anovulation seem to be treated synonymously in most of the literature
available. Though the two conditions overlap, insulin resistance and its repercussions
characterize many cases of PCOS but are not found in non-PCOS chronic anovulation.
Hence it is not correct to consider PCOS and chronic anovulation as interchangeable
conditions; although PCOS is the commonest cause of anovulation, there are numerous
other aetiologies which have very different endocrine and metabolic profiles.
One of the dilemmas faced by PCOS patients and their physicians is when to intervene if
amenorrhoea is present. Such women may not have periods for months and they are the
ones who are thought to be at greatest risk of developing EC due to unopposed oestrogen
stimulation and failure of the endometrium to be shed and regenerated again. Currently
doctors treat women with the oral contraceptive pill or progestagens every 3 months to
ensure a withdrawal bleed, believing that this is the ‘safest’ options to reduce the risk of
EC. This treatment regime is not base on any concrete evidence and more research is
needed in this area so that guidelines may be implemented.
In conclusion, this literature review has shown there is not enough evidence on which to
design management guidelines for treatment of the risk of endometrial carcinoma in
women with PCOS.80
1.9 Hypothesis
For more than fifty years clinicians have been advising and treating women with PCOS in
the belief that they have a high risk of developing EC. Having reviewed the relevant
literature, it is clear that the association between PCOS and endometrial carcinoma has
never been clearly demonstrated in elaborate well-controlled studies.
PCOS is responsible for creating a hyperoestrogenic state
162, an endocrine environment
known to favour the development of endometrial malignancies. PCOS is also strongly
associated with endometrial hyperplasia, a variant of which - atypical hyperplasia - is
known to be a precursor of EC. Insulin resistance and hyperinsulinaemia, which are also
commonly seen in PCOS, are also risk factors for the development of endometrial
carcinoma, insulin having a potent mitogenic effect on the endometrium, at least in vitro.
It is however incorrect to assume that PCOS is a significant risk factor for endometrial
carcinoma on the basis that both conditions share similar features in their
pathophysiology. PCOS is a heterogeneous condition, the aetiology of which is still not
fully understood. It may be that some women with PCOS have innate protection from EC
and/or do not exhibit some risk factor symptoms, while others are more susceptible
and/or have risk factor symptoms. Certainly, this is suggested by the contrasting
incidence rates of the two diseases. EC is the most common gynaecological cancer in the
Western world - its incidence in the UK being approximately 6891 cases per year - yet
this rate is small in comparison to 750000 women with PCOS. If there was a direct81
association between the two conditions, the incidence of EC should be higher. Obviously
the proportion of women with and without PCOS who develop EC is important in
determining this risk- one justification for doing the study.
It is also generally assumed that women with EC arising in a hyperoestrogenic
environment have a better prognosis, as tumours tend to be well-differentiated and less
aggressive
155. Again, the evidence for such an association is not clear. As discussed
previously endometrial carcinogenesis has a distinct pathogenesis and it has also been
observed that some EC tumours arising in a hyperoestrogenic environment, may display
aggressive behaviour, depending on whether they arise in an atrophic or hyperplastic
background.
Clinicians have a responsibility to treat patients according to the best possible evidence.
Women with PCOS, who are not trying to conceive often present to their general
practitioners, complaining of secondary amenorrhoea or oligomenorrhoea. Some women
may have menstrual cycles of six to eight weeks duration, whilst others may only have
one menstrual bleed per year or none at all. In order to minimize the development of
endometrial hyperplasia in these women, the treatment options are usually the oral
contraceptive pill or progestogens to induce withdrawal bleeds. Although the
contraceptive pill is a good option, it is not without risk, especially when patients are
obese - as is often the case in PCOS. This leaves the administration of progestogens and
although there is little evidence regarding the efficacious frequency of administration,
most clinicians in the United Kingdom believe it is “safe” to induce withdrawal bleeds82
every three months in amenorrhoeic women to protect them from the risk of EC. Again,
this belief has not been validated by in-depth, well controlled research investigations.
Thus patients are treated at some expense and risk, with limited evidence to support the
necessity of treatment and its efficacy. This thesis attempts to provide such evidence.
Women with PCOS exhibit several characteristics which are considered to be risk factors
for EC - obesity, hyperinsulinaemia, hyperoestrogenaemia and lengthened menstrual
cycles. These characteristics alone are enough to increase an individual’s likelihood of
developing EC regardless of the fact that they have PCOS or not. It is still unclear
whether PCOS confers a greater risk to women where EC is concerned. The studies
described in this thesis were also designed to explore this area of uncertainty.
The hypotheses to be investigated are that:
A) PCOS is associated with EC.
B) The type of endometrial carcinoma arising in women with PCOS carries a better
prognosis.
C) The risk of EC is confined to a subgroup of women with PCOS.
To test these hypotheses, the following studies were performed.
To test hypothesis A, this thesis aims to investigate the degree of association between
PCOS and EC. To facilitate this, a retrospective study was performed in which the83
ovaries of patients who had had a total abdominal hysterectomy and bilateral
salpingoopherectomy for EC were histologically assessed for evidence of PCOS. As a
control group, ovaries from women who had had the same operations for benign
gynaecological problems were also assessed. This investigation allowed an assessment to
be made as to whether the incidence of PCO morphology, a marker of PCOS, is more
common in patients with EC than in controls, and thus whether PCO morphology is
associated with EC.
To test hypothesis B, this thesis aims to ascertain whether women with PCOS have a
worst prognosis when they have developed EC. To achieve this aim, a study was
performed in which immunohistochemistry was used to assess the expression of p53,
bcl2, ki67 and Cyclin D1, as surrogate markers for tumour prognosis, in endometrial
tumours from women with and without PCO morphology.
To test hypothesis C, this thesis aims to determine whether a specific subgroup of women
with PCOS are at increased risk of developing endometrial carcinoma. To achieve this, a
second study was designed to investigate gene expression using microarray analysis, in
the endometrium of women with PCOS, well characterised with regard to serum
biochemistry, patient history and endometrial histopathology were used to characterize
gene expression Particular attention was focused on genes implicated in oncogenesis,
particular in the endometrium. The interaction between gene expression and
characteristics defining PCOS in each patient was investigated to attempt to define a84
group of patients, exhibiting certain serum, histological, or biometric characteristics, with
endometrial gene expression suggestive of endometrial dysplasia and risk of EC.85
Chapter 2
METHODS86
2.1 The prevalence of polycystic ovarian morphology in
women with endometrial cancer
This study was designed to assess the incidence of PCO morphology in women with
endometrial cancer compared with a control group. If endometrial cancer is associated
with PCOS, a greater proportion of women with endometrial carcinoma should exhibit
PCO morphology than in the control group.
2.1.1 Study design
This retrospective cross-sectional study was carried out between December 2002 and
December 2003 at the Royal Free Hospital, London (RFH). Archived sections of both
whole ovaries from each subject were evaluated for the presence of PCO morphology.
Ethical approval for this study was obtained from the RFH and UCH Research Ethics
Committees (Ethics no. 5252, valid from April 2002 to April 2003, then extended to
April 2004).
2.1.2 Subjects
Patients diagnosed with endometrial cancer who had had total hysterectomy with bilateral
salpingoopherectomy at the RFH between 1986 and 2001 (N = 42), or at UCH between
2000 and 2003 (N = 81), were included. The control group consisted of 83 patients who
had the same operative procedure, or a bilateral salpingoopherectomy, at the RFH or
UCH, between 1990 and 2003, for reasons other than gynaecological malignancies.87
The SNOMED computer database is kept by the Pathology Department, RFH. It stores
the location of archived samples and histopathological results for all tissue biopsies
collected from patients since 1990. Results for biopsies prior to 1990 are stored on
microfiche. A SNOMED-like database was also available at the Department of
Pathology, UCH. These resources were used to access histopathology reports for ovarian
sections from the selected patients and to allow retrieval of archived sample sections
from both ovaries from each subject for further investigation. All slides were H&E slides
that had been stored at room temperature in the Pathology Departments at each hospital.
2.1.3 Histological characterization
Originally, it was thought that the stored histological assessments, performed and
recorded directly after the biopsies were taken, could be used to determine whether PCO
morphology was present. It was found however that these assessments often failed to
state clearly whether an ovary was not polycystic, nor did they contain the requisite
detailed description which would allow PCO morphology to be deduced. Indeed, this was
a common problem encountered several times during the course of the work in this thesis
- histopathologists in the past have tended not to report PCO morphology if this was not
mentioned by the clinician who completed the request form. This was perhaps because
the detrimental effects of PCOS on general health were not as well recognized as they are
now.
It was necessary therefore to reanalyze the ovarian sections from each patient and to
assess them microscopically for features of PCO morphology. Ovaries were classified as88
polycystic if they showed a three-fold increase in capsular width (the capsule is
considered to be normal if it is one-cell thick, and this was a histopathology criteria
before the ESHRE\ARSM agreed diagnostic criteria was published), peripherally (this
study was devised and started before the agreed ESHRE/ARSM ultrasound diagnostic
criteria was published hence peripherally arranged cysts were included rather than
multifollicular ovaries) arranged regular follicular cysts (>8 per whole ovary section),
stromal thickening and an absence or decreased abundance of corpora albicantia (<5 per
whole ovary section). All sections from the RFH archives were assessed independently
by the author, Dr P. Menon and Dr J. Crow (both consultant histopathologists at RFH),
while slides from UCH were assessed by the author, Dr E. Benjamin (consultant
histopathologist at UCH) and Dr J. Crow. Ovarian sections from endometrial cancer
cases and controls were obtained and examined at the same time, the examiners being
blinded as to which category any slide belonged. The slides were examined using an
electric light microscope (Nikon phase contrast, 1.25, Japan), first at x100 magnification,
to estimate the number of follicular cysts and corpora albicantia, then at x200
magnification to determine the presence of stroma thickening and to estimate the capsular
width.89
2.1.4 Statistics
The medical statistician at the Royal Free Hospital was consulted for statistical input.
More details about the statistical test are provided in Chapter3, section 3.6, page 124.
2.2 The expression of cell-cycle and apoptotic proteins in the
endometrium of women displaying PCO morphology
This study was designed to assess whether endometrial tumours arising in women with
PCO, carry a better or worse prognosis than endometrial tumours arising in women with
no evidence of PCO.
2.2.1 Study design
This study was conducted at the RFH between November 2001 and July 2003 and at
UCH between November 2000 and July 2003. Ethical approval for this study was
obtained from the RFH and UCH Research Ethics Committees (Ethics no. 5858, obtained
March 2002 and extended through to December 2003). Endometrial tumour biopsies
were obtained from patients diagnosed with endometrial cancer between these dates, one
group exhibiting PCO morphology and one group normal ovarian morphology.
Endometrial tumours sections were analyzed by immunohistochemistry for expression of
the cell cycle regulatory proteins Cyclin D1 and Ki67, and the apoptotic proteins p53 and
Bcl2. These proteins were selected as evidence suggests that their expression is related to
tumour prognosis. The intensity of staining for these proteins between the PCO and non90
PCO associated endometrial tumours was then compared to assess whether there was any
difference in these prognostic indicators between the groups.
2.2.2 Subjects
A sub-group of the subject cohort detailed in Section 2.1.2 was used in this investigation.
This sub-group was comprised of patients diagnosed at the time of the study (2000 –
2003), from whom endometrial tumours biopsies could be obtained which were suitable
for immunohistochemical staining for the selected prognostic indicators. The sub-group
consisted of 27 patients diagnosed with endometrial carcinoma, but no other
gynaecological cancers. Analysis of ovarian morphology showed that 11 subjects
exhibited PCO morphology, and 16 (controls) did not. The 16 controls were age-matched
with the 11 subjects exhibiting PCO morphology.
2.2.3 Sample preparation
Immediately after retrieval, endometrial tumours were paraffin embedded and were
stored in the Pathology Department of the host hospital at room temperature. When
required, endometrial tumour blocks were retrieved from storage and 5 µm sections were
cut by a microtome and mounted on 3-aminopropyltriethoxysilane (APES) coated glass
microscope slides.
Immunohistochemistry
Standard immunohistochemical techniques were applied to the slide mounted paraffin-
embedded 5 µm endometrial tumour sections and sections of normal ovary, as an91
appropriate positive control tissue. Slides were normally manipulated whilst in standard
18 slide racks and all washes were performed in standard 500 ml glass troughs.
Sections were deparaffinized in xylene (3 x 5 min), rehydrated in methanol (3 x 5 min),
incubated with 3% (v/v) hydrogen peroxide for 10 min to block endogenous peroxidase
activity, then twice washed in tris-buffered saline (TBS; pH 7.4) for 5 min. Antigen
retrieval was performed by microwaving the sections in 400 ml 10 mM citrate buffer (pH
6.0) for 10 min at full power (800 W) then 5 min with no heating
163. Cooling was
allowed to take place at room temperature for 30 min in distilled water, then sections
were washed in phosphate buffered saline (PBS; pH 7.4) for 2 x 5 min. Non-specific
protein binding capacity was blocked by incubating section for 15 min with either normal
rabbit serum (Dako, Ely, UK) diluted x10 in PBS (Cyclin D1, p53, Bcl2) or normal goat
serum (Dako) diluted x10 in TBS (Ki67)
163-165. After washing in PBS, sections were
incubated with appropriately diluted primary antibodies, which were replaced by PBS in
negative controls (Table 2.1).
Antigen Source Clone dilution Antigen
retrieval
Cyclin D1 Novocastra DCS-6 1: 100 Yes
Bcl2 Dako
M0887
124 1: 100 Yes
p 53 Dako M7001 DO-7 1: 100 Yes
Ki67 Immunotech IM0505 MIB-1 1 : 25 Yes
Table 2.1: Primary antibodies used for immunohistochemical staining of cell cycle (Ki67,
Cyclin D1) and apoptotic (p53 and Bcl2) proteins.92
Unbound primary antibody was then removed by washing sections in PBS for 3 x 10 min,
after which they were treated for 45 min with either biotinylated rabbit anti-mouse IgG
(Dako) diluted x200 in PBS (Cyclin D1, p53, Bcl2) or with goat anti-mouse IgG (Dako)
diluted x200 in TBS (Ki67). Again unbound antibody was removed by washing in PBS
for 3 x 10 min, after which sections were incubated with streptavidin-biotin-horseradish
peroxidase complex (Dako) diluted x200 in TBS for 30 minutes. Sections were
developed with 3, 3’-diaminobenzidine solution (Sigma-Aldrich, Poole, Dorset, UK),
counterstained with Mayer’s haemalum (Merck, Lutterworth, Leics, UK), dehydrated in
methanol, cleared in xylene and mounted in DPX.
Figure 2.2 illustrates the principles of immunohistochemistry- Free reproduction from
http://en.wikipedia.org/wiki/Immunohistochemistry.93
2.2.5 Assessment of immunostaining intensity
Two sections from each biopsy block were assessed. The slides were selected by Dr
Crow as the most representative of that block. The sections were viewed under a light
microscope at x100 magnification and scored by two independent observers (Ouma
C.Pillay, L. Wong Te Fong). Sections were scored on two separate occasions by each
observer to ensure reproducibility. A mean of the 3 readings were obtained. (O.C. Pillay,
scoring only was taken into consideration but they were all verified blindly first by L.
Wong Te Fong. Intra-observer and intra-section variability, the latter assessed on
adjacent sections, was less than 5%.
Sections were scored positive for Cyclin D1, Bcl2 and p53 if >10% of tumour cell nuclei
were stained; positively scored structures appeared brown on a blue background. This
value was chosen as a firm cut-off in the staining just above the negative control
background level. The Ki67 staining index was expressed as the percentage of positively
stained tumour cell nuclei relative to the total number of tumour cell nuclei in 4/5
randomly selected fields on a section
163-165. (The biopsies were all derived from solid
blocks of tumour). The staining index for a biopsy was then calculated as the mean of the
staining indices of each section from the biopsy assessed (a mean of 3 readings was
calculated).94
2.2.6 Statistics
Differences in immunostaining were tested by Fishers Exact Test (Cyclin D1, Bcl2, p53)
or Student t test (Ki67). P < 0.05 was taken as the threshold level of significance.
2.3 Differential gene expression in the endometrium of
women with PCOS.
This study was designed to determine whether a specific subgroup of women with PCOS
is at increased risk of developing endometrial carcinoma. Gene expression was analyzed
in endometrial biopsies from a well characterised group of women with PCOS. The
interaction between gene expression, particularly the expression of genes implicated in
oncogenesis, and characteristics defining PCOS in each patient was investigated, to
attempt to define a sub-group of patients at risk of endometrial dysplasia and EC.
2.3.1 Study design
This prospective study was conducted at the RFH between September 2003 and July
2004. Ethical approval for the study was obtained from the Royal Free & University
College Medical School Ethics Committees (ethics no.6219, March 2003-March 2004;
extended for another 12 months to March 2005).
Endometrial biopsies were obtained from women with PCOS, the subjects being well
characterised with regard to serum biochemistry, patient history, biometric data and
endometrial histopathology. RNA was isolated and microarray analysis, performed in95
collaboration with the Department of Pathology, University of Cambridge, was used to
assess gene expression in the endometrial biopsies. Particular attention was focused on
genes implicated in oncogenesis, particular in the endometrium. The interaction between
gene expression and characteristics defining PCOS in each patient was investigated to
attempt to define a group of patients, exhibiting certain serum, histological, or biometric
characteristics, with endometrial gene expression suggestive of endometrial dysplasia and
risk of EC.
2.3.2 Subjects
Fifty patients, diagnosed with PCOS according to the ESHRE consensus diagnostic
criteria
95, were recruited. To make this diagnosis, all subjects had assessment of: ovarian
morphology by transvaginal ultrasound; menstrual cyclicity and evidence of
hyperandrogenaemia (acne, hirsutism, balding) by clinical inspection and patient history;
biochemical status by serum analysis for testosterone, sex hormone binding globulin
(SHBG), LH and FSH.
During recruitment, all the subjects received an information sheet regarding the study and
gave informed consent. At the next consultation, held in the morning after an overnight
fast, a detailed medical history was taken, and their weight, height, waist/hip ratio and
systolic and diastolic blood pressure were measured. A blood sample was also taken,
serum immediately prepared by centrifugation at 1000gf for 15 min, and
comprehensively analyzed using standard laboratory methods by the Department of
Chemical Pathology, RFH, for LH, FSH, testosterone, SHBG, free androgen index,96
androstenedione, Oestradiol, progesterone, 17-hydroxyprogesterone, insulin, cholesterol
and fasted glucose. A glucose tolerance test was then performed in which the patient
drank 498 mls of “Lucozade” containing 75 g of glucose. After 2 hr a repeat blood
sample was taken and processed for serum glucose estimation as for the fasted blood
sample.
The patients subsequently attended clinic for a Pipelle (Laboratoire C.C.D, Paris, France)
endometrial biopsy, on days 4 – 7 of their menstrual cycle if normally cycling or mildly
oligomenorrhoeic (i.e. cycling >4 times/year, or at a random time if cycling <4
times/year. Patients who were amenorrhoeic were seen at any time. Two endometrial
samples were taken, one was snap frozen in a sterile tube on dry ice within 5 minutes and
stored at -80C for later RNA isolation, the other was fixed in formalin and sent to the
Department of Histopathology, RFH, for histopathological assessment. All patients
received 1 gram of azithromycin to protect against ascending infection related to the
biopsy.
2.3.3 Isolation of endometrial RNA
Total RNA was isolated from the endometrial biopsies using Qiazol according to the
manufacturer’s instructions (Qiagen Ltd., Crawley, UK). This method is essentially a
commercial modification of the acid guanidinium thiocyanate-phenol-chloroform RNA
extraction method
166. Because microarray analysis is expensive, time consuming and
highly sensitive to the quality of the RNA, the isolated endometrial RNA was repurified,97
by DNase I digestion and subsequent RNeasy MinElute column. This provides RNA
suitable for microarray analysis
2.3.3.1 Primary isolation of endometrial total RNA
Endometrial biopsies were retrieved from the -80C freezer onto dry ice, but immediately
prior to homogenization, each was allowed to warm at room temperature for 1 min.
Biopsies (50 – 100 mg) were however still frozen when added to a pre-weighed 13 ml
test tube (Sterilin Ltd, Hounslow, UK) containing 1 ml of Qiazol reagent, thus RNA
degradation would have been limited. After reweighing, to allow determination of the
amount of tissue used, tissues were immediately dispersed using a rotary homogeniser
(Model X120, Status Ltd, Germany) at maximum setting for 20 s. Samples were left on
the bench for 5 min, then combined with 0.2 ml chloroform in an autoclaved eppendorf
tube, shaken vigorously for 30 s, then left on the bench for 3 min. Samples were
centrifuged at 12000 g for 15 min, and the overlying RNA containing clear aqueous
phase was collected into a fresh eppendorf tube, taking care to avoid contamination with
the DNA interface. An equal volume (ca. 0.6 ml) of isopropanol was added and, after
vigorous mixing, the tubes were incubated for 2 hr at -20 °C to allow RNA to precipitate.
After re-centrifugation (as above), the RNA pellet was twice washed by resuspension in 1
ml 75% (v/v) ethanol and centrifugation at 12000g for 5 min. The RNA pellet was air-
dried for 20 min, dissolved in 50 nml nuclease-free water (Ambion, Applied Biosystem,
Warrington, UK) at 65°C for 10 min with vortexing, and then stored at -20 °C.98
2.3.3.2 Spectrophotometric determination of RNA concentration
RNA samples were diluted with nuclease-free water (normally 2 µl RNA in 800 µl water)
and the absorbance read at 260 and 280 nm, in a quartz cuvette, against a blank consisting
of nuclease-free water. RNA concentration was estimated based on the assumption that a
solution of 40 µg/ml RNA has an absorbance of 1 at 260 nm. An A260/A280 ratio of 1.8
- 2.0 indicates reasonably pure RNA, whereas a ratio much below 1.7 is indicative of
protein contamination. Only RNA with an A260/A280 ratio of >1.4 was selected for re-
purification in this study.
2.3.3.3 Analysis of RNA integrity by agarose gel electrophoresis
RNA (2µl, containing 2 - 10 µg) was mixed with 8 µl RNA sample buffer (16 µl; Table
2.2), heated at 65 °C for 15 min, and then immediately chilled on ice. Samples were
mixed with RNA loading buffer (2.0 µl; Table 2.2), before loading onto gels (1% w/v
agarose, 18% v/v formaldehyde in 1X MAE; Table 2.2). Gels were run in 1X MAE at
100 - 120 V for 0.5 - 1 h, until the bromophenol blue tracking dye had migrated 80% of
the lane length. Gels were then visualized under UV transillumination, revealing
ethidium bromide chelated to the RNA, and photographed using a Kodak DC40 digital
camera. A 28S/18S rRNA ratio of approximately 2:1 is indicative of reasonably intact
RNA. RNA degradation is indicated by a decline in this ratio, and also by excess
smearing in the region of the gel below the 18S rRNA band. Only intact RNA was used
for downstream analysis.99
Figure 2.3: shows a photograph of analysis of RNA integrity by agarose gel
electrophoresis.
2.3.3.4 RNA repurification
It was apparent that the initial RNA isolates required repurification. RNA is prone to
degradation by nucleases (RNases) which are present in tissue and in the environment;
Spectrophotometric analysis (Section 2.3.4) indicated some RNA samples were
contaminated with protein, perhaps including RNases. Furthermore, reagent contaminants
from the isolation procedure can interfere with cDNA synthesis and other downsteam100
processes. Gel analysis (Section 2.3.4) also suggested some RNA samples were
contaminated with genomic DNA, which would interfere with microarray analysis. RNA
was therefore treated with RNase-free DNase I (Qiagen, Crawley, UK) to remove
genomic contamination and repurified using the RNeasy MiniElute kit (Sigma-Aldrich
Ltd, Poole, UK), both according to the manufacturer’s instructions, to remove DNase I,
RNases, other proteins and organic contaminants.
DNase I treatment of RNA samples was performed in 100 µl reactions, containing 50 µg
RNA, 2.5 µl RNase-free DNase I (2.7 Kunitz units/µl; Qiagen, Crawley, UK), 10 µl x10
reaction buffer and nuclease-free water to 100 µl, incubated for 15 min at room
temperature (25C). Samples were then purified with the RNeasy MiniElute kit (Sigma-
Aldrich Ltd, Poole, UK). After DNase I treatment, 350 µl of guanidinium-containing
buffer RLT and 250 µl of 100% (v/v) ethanol were added with mixing to each reaction.
Reactions were then applied to an RNeasy MinElute column in a 2 ml collection tube and
centrifuged at 12,000 g for 15 s. The flow-through was discarded and the column and
bound RNA washed in 500 µl buffer RPE, to remove protein, and centrifuged at 12,000 g
for 15 s. The column was further washed in 500 µl 80% (v/v) ethanol, centrifuged at
12,000 g for 2 min, transferred to a fresh collection tube and centrifuged at 12,000 for 5
min to dry it. The column was transferred to a fresh collection tube and purified RNA
was eluted in 30 µl nuclease-free water by centrifugation at 12,000 g for 2 min.101
2.3.3.5 Analysis of purified RNA integrity and concentration
Reverse transcription and subsequent microarray analysis of RNA samples is a time
consuming and expensive process. To avoid analyzing defective RNA samples, the
quantity and quality of the repurified RNA samples was analyzed prior to these
procedures using the Agilent 2100 bioanalyser
The Agilent 2100 bioanalyser consists of a single use cartridge containing a gel column
through which up to 12 RNA samples, diluted to approximately 200 ng/µl, can be
sequentially electrophoresed. The output from the cartridge passes through a
Spectrophotometer cell, tuned to 260 nm, capable of detecting RNA and DNA.
Electrophoresis is performed once the samples are loaded, along with a set of RNA size
markers, and controlled via the PC-based Agilent bioanalyser software interface set on
the Eukaryote Total RNA Nano protocol. This protocol provides an output for each
sample consisting of an electropherogram, the total RNA concentration, the abundance of
28S and 18S rRNA relative to the total and the 28S/18S rRNA ratio. Samples which
appeared partially degraded or overly dilute were not further investigated.
2.3.4 Probe generation for gene microarray analysis
To generate probe from the endometrial RNA for microarray analysis, it was necessary to
reverse transcribe the RNA to complementary DNA (cDNA), this being less prone to
degradation. In many studies, cDNA has been directly labelled with fluorophores or
biotin, and applied to microarrays. This however requires large amounts of RNA to
ensure a reasonable level of sensitivity on the microarray. To ensure multiple arrays102
could be performed if required, and to use a methodology which provides unparalleled
sensitivity for genes expressed at low levels, it was decided to use the SMART PCR
cDNA synthesis kit (Clontech, St Germain-en-Lahaye, France) allied to Cy3-dCTP and
Cy5-dCTP cDNA labelling in this study.
The Clontech SMART (Switch Mechanism At the 5’ end of Reverse Transcript) PCR
cDNA synthesis method, first reverse transcribes RNA to cDNA from a specialized
primer (SMART CDS IIA primer), which anneals at the 3’ polyA tail of mRNAs. The
reverse transcriptase used also has terminal transferase activity and it adds several non-
complementary cytidine deoxyribonucleotides at the 3’ end of the first strand cDNA
product. A second primer (SMART TS IIA primer) anneals to them, since it has a 3’
rGrGrG sequence, providing a template for continuation of first strand synthesis, tagging
the cDNA with a 3’ extension complementary to the SMART IIA primer. Both primers
contain a common sequence motif of 25 bases; one motif is therefore present in the
cDNA in the incorporated 5’ SMART CDS IIA primer, and a complementary motif is
present at the 3’ end in the SMART TS IIA primer complementary sequence. Thus all
cDNA species can be amplified by polymerase chain reaction (PCR) with a common
primer made up of the first 23 bases of the common motif (the PCR primer IIA).
In the method used in this thesis, the cDNA first strand product was amplified by PCR
for a limited number of cycles, to ensure that proportional representation of each mRNA
species was maintained in the cDNA mixture (REFS). This provided substantial amounts
of endometrial cDNA suitable for highly sensitive microarray analysis. This cDNA was103
labelled with dCTP-Cy3 using random octomer primers and Klenow DNA polymerase I
fragment extension. Normal proliferative endometrial RNA was used as a control and
was labelled in the same manner as the test endometrial samples, except with dCTP-Cy5.
After purification, each Cy3 labelled cDNA sample was hybridized to a microarray with
an aliquot of the Cy5 labelled control. After incubation and washing, probe signals on the
arrays were detected using a laser scanner, capable of independently detecting
fluorescence from Cy3 and Cy5 labelled probe at 575 nm and 670 nm, respectively, after
excitation with green (532 nm) laser and red (653 nm) laser light, respectively. Signals
from the Cy5 labelled controls were used to standardise the Cy3 signals on each array,
since variation in the Cy5 intensities would be related to differences in hybridization and
detection efficiencies between arrays. Corrected Cy3 signals on each array provided
measures of the expression of multiple genes in the original endometrial RNA sample
from which the cDNA applied to the array was generated. Statistical analysis was
performed to compare gene expression between arrays and to correlate differences with
endometrial histopathology and PCOS-related serum biochemical and biometric
parameters.
2.3.4.1 Reverse transcription
Re-purified DNase I-treated total RNA (0.5 µg) was mixed with 1 µl each of 10 µM
SMART CDS IIA primer (5'-AAGCAGTGGTATCAACGCAGAGTACT30VN-3', N =
A, C, G, or T; V = A, G, or C) and 10 µM SMART TS IIA primer (5'-
AAGCAGTGGTATC AACGCAGAGTACGCrGrGrG-3', rG = (guanosine104
ribonucleotide), and made up to 5µl with RNase-free water. The mixture was incubated at
72C for 2 min, and placed on ice. 2 µl first-strand buffer (5x; 250 mM Tris-HCl, pH 8.3,
375 mM KCl, 30 mM MgCl2; Clontech), 1 µl 100 mM dithiothreitol (DTT; Clontech), 1
µl 10mM dNTPs (Promega) and 1µl Powerscript reverse transcriptase (Clontech) were
added as a mastermix to the RNA/primer mixture, giving a total reaction volume of 10 µl.
Reactions were incubated at 42C for 60 min to allow reverse transcription, then stored at
-20C.
2.3.4.2 cDNA amplification by PCR
PCR for each cDNA sample was performed in 100 µl reactions, containing 75 µl of
RNase-free water; 10 µl of x10 PCR buffer; 2 µl of 10 mM dNTP; 5 µl of 25 mM MgCl2;
4 µl of PCR primer IIA (5'-AAGCAGTGGTATCAACGCAGAGT-3') and 2 µl Amplitaq
DNA polymerase (5 U/µl; Applied Biosystems, Foster City, USA). These were all
prepared and added as a mastermix to improve pipetting accuracy. Each reaction also
contained 2µl of cDNA, produced in Section 2.3.4.1, to make a final volume of 100 µl.
PCR was performed on a SMART A62 PCR machine. The block was pre-warmed to
95C, and the heating profile consisted of a 95C/1 min step to denature nucleic acid
secondary structure and non-Specific interactions, followed by 15 cycles of 95C/10 s;
65C/10 s; 68C/6 minutes, after which samples were kept at 4C until unloaded and
stored at -20C.105
2.3.4.3 Light sensitivity – a warning
The Cy-3 and Cy-5 fluorophores are light-sensitive, light absorption causing molecular
breakdown and fluorescence quenching. Microarrays are also light sensitive as they contain
Cy-3 labelled pGEM bacterial plasmid dots for orientation. Light may also damage the
DNA arrays directly, and the Cy-3/Cy-5 labelled probes applied to them. Therefore when
using Cy-dyes, their derivative products and microarrays, exposure to light was kept to a
minimum. All were stored in light-proof boxes, manipulated in low light conditions, and/or
pipette into light-proof tubes.
2.3.4.4 Cy3 and Cy5 labelling of probe cDNA
Cy3 or Cy5-dCTP labelling was performed using the BioPrime DNA labelling system
(Invitrogen, Paisley, UK). A Cy5-dCTP labelling control was included for each Cy3-dCTP
labelled sample. 21 l of PCR amplified cDNA from Section 2.3.4.2 was aliquoted into a
sterile thin-walled 0.2 ml tube. To this was added 20 l of 2.5x random prime buffer. The
sample was mixed, pulse spun and incubated at 95C for 5 min, then placed on ice. 5 l of
10x Low C-dNTPs (2 mM dCTP, 5 mM dATP, dCTP, dGTP), 2 l of 1 mM Cy3 or Cy5-
dCTP (Amersham Pharmacia Biosciences, Little Chalfont, UK) and 1 l of DNA
polymerase I Klenow fragment D (40 U/l), were then added. After mixing, the 50 l
reactions were incubated for 2 hours at 37C. 5 l of STOP buffer was then added to
quench the reaction.106
2.3.4.5 Cy3 and Cy5 labelled probe purification
Labelled probes were purified using Autos G50 resin columns (Amersham Pharmacia
Biosciences, Little Chalfont, UK) which operate on the size exclusion principle. The resin
was resuspended by vortexing, the bottom closure snapped off, and excess column buffer
was removed by centrifugation at 2000g for 1 min. The column was then transferred to
another collection tube and the whole Cy3 or Cy5 labelling reaction from Section 2.3.4.3
was applied to the centre of the top of the column. Columns were spun at 2000g for 1 min,
the eluate contained Cy3 and Cy5 labelled cDNA, unincorporated nucleotides were retained
in the column resin.
2.3.4.6 Estimation of Cy3 and Cy5 incorporation
1 l of each column eluate was analyzed using a nanodrop ND-1000 Spectrophotometer
(Nanodrop Technologies Inc, Delaware, USA), which performs spectral analysis between
250 and 750 nm on 1 – 2 l samples. The associated software analyses absorbance data,
providing estimates of cDNA and Cy3 or Cy5 label concentrations, allowing label
incorporation to be calculated. The machine was zeroed when required using nuclease-free
water.
2.3.4.7 Precipitation of purified Cy3 and Cy5 labelled probes
Prior to precipitation, all purified Cy5 labelled controls were pooled and mixed to ensure
the internal standard applied to each microarray was uniform. Each Cy3 labelled product
was then combined with an equal aliquot of Cy5 labelled product pool (ca. 100 l total
volume) in a light-tight container. To this was added with mixing 5 l of human Cot-1107
DNA (1 mg/ml; Invitrogen, Paisley, UK), 10 l of 3 M sodium acetate (pH 5.2), and 250 l
of 100% ethanol. Probe was precipitated overnight at -20C (or for >2 hours), pelleted by
centrifugation at 12000g for 15 min, washed with 75% ethanol, centrifuged again at 12000g
for 5 min and left to air dry for 15 min after discarding the supernatant. Thus each Cy3
labelled test sample was in a minute volume with an equal volume of Cy5 labelled control,
ready to be dissolved and applied to a microarray.
2.3.5 Performing microarray analysis
2.3.5.1 The microarrays
The arrays were custom-made cDNA arrays, with ~8000 genes spotted in duplicate. This
included controls and housekeeping genes spotted in each of the blocks for QC purpose.
The genes included those known to be important in cell adhesion, apoptosis, signalling, cell
cycle regulation, ECM remodelling and angiogenesis. The arrays were provided courtesy of
the department of Pathology Cambridge University and funded by the BBRSC.
2.3.5.2 Microarray prehybridization
All washes of cover-slips and microarrays throughout the prehybridization and
hybridization procedure were in 50 ml in Falcon 50 tubes, with rocking at room
temperature, unless otherwise noted.
Ridged cover slips were stored in 70% ethanol and were washed twice in ultrapure water,
generated using a MilliQ (Millipore, Watford, Hertfordshire) system, once in isopropanol
and then air-dried. A cover slip was gently placed over each microarray, with the cover slip108
edge 1 mm from the bottom of the array and the ridges toward the array, thus producing a
glass sandwich with a pocket for fluid samples over the array of ca. 50 l volume.
Hybridisation buffer (40% v/v deionised formamide; 5x SSC; 5x Denhardt’s solution; 1
mM sodium pyrophosphate; 50 mM Tris-HCl (pH 7.4); 0.1% w/v sodium dodecyl sulphate)
was warmed to 50C, mixed and 50 l slowly applied to the pocket at labelled end of the
array, such that the buffer was slowly drawn into the pocket by capillary action without
forming bubbles within the pocket or a fluid droplet which touched the label. Each array
was immediately placed in a hybridization chamber, with 10 ml humidifying solution (40%
v/v deionised formamide; 5x SSC) on a flat pad of tissue in the bottom, pre-equilibrated in a
water bath at 50C. Pre-hybridisation was allowed to take place for 2 hr.
Cover slips were then removed by soaking the microarrays in x2 SSC. The cover-slips were
soaked in 70% v/v ethanol, washed as above and air-dried. The prehybridized microarrays
were washed once in 2x SSC, with rocking, for 5 min, then twice in ultrapure water, once in
isopropanol and air-dried. Prior to application of probe solution and hybridization (Section
2.3.5.3), cover slip-microarray sandwiches were prepared in the same way as for pre-
hybridization.
2.3.5.3 Microarray hybridization
Air-dried pellets of Cy3-labelled sample cDNA and Cy5-labelled control cDNA, from
Section 2.3.4.7, were each dissolved in 54 l solution containing 50 l hybridization buffer,109
2 l human Cot-1 DNA (1 mg/ml; Invitrogen, Paisley, UK), 1 l polydeoxyadenosine 5’
phosphate (polyA, 8 g/l; Amersham Pharmacia Biosciences, Little Chalfont, UK) and 1
l yeast tRNA (4 g/l), for 5 min at room temperature, then 2 min at 95C, with mixing.
Dissolved probes were then centrifuged at 12000g for 5 min and kept at 50 C until loaded
on to microarrays.
Once prepared, 50 l of probe solution was loaded onto each array as quickly as possible, in
the same manner as for pre-hybridization (Section 2.3.5.2). After loading, microarrays were
immediately placed in a hybridization chamber, with 10 ml humidifying solution (40% v/v
deionised formamide; 5x SSC) on a flat pad of tissue in the bottom, pre-equilibrated in a
water bath at 50C. Hybridisation was allowed to proceed for 16 - 18 hr.
2.3.5.4 Post-hybridization microarray washing
After hybridization, the cover slips were removed by immersing microarrays in 2x SSC.
Cover-slips were washed in 70% ethanol and stored in 70% ethanol for re-use. Microarrays
were washed twice for 5 min in 2x SSC, twice for 5 min in 0.1x SSC with 0.1% w/v SDS,
and twice for 5 min in 0.1x SSC. The microarrays were then dip-rinsed successively in 0.1x
SSC, ultrapure water and isopropanol, before being clamped in a plastic frame to aid
manipulation, placed in an empty 50 ml test tube and centrifuged at 250g for 2 min to dry.
Care was taken to ensure the identification label was at the bottom of the array, to prevent
contamination of the microarray surface with gum from the label. The slides were stored in
the dark at room temperature and scanned as soon as possible, certainly within 7 days.110
2.3.6 Microarray scanning
Microarrays were scanned to obtain Cy3- and Cy5-labelled probe intensities (at 532 nm
and 635 nm, respectively) hybridized at each target DNA spot, using an Axon
Instruments 4100A scanner (Molecular Devices Corporation, 1311 Orleans Drive,
Sunnyvale, CA 94089-1136, U.S.A.) with GenePix pro 4.1 software, according to the
manufacturers’ instructions. The microarray slide was first insert into the scanner with
the microarray downwards and identifier barcode at the front. Filters appropriate for Cy3
and Cy5 detection were selected (575DF35 and 670DF40, respectively), as were the
green (532 nm, excitation of Cy3) and red (653 nm, excitation of Cy5) lasers. A preview
scan was performed at 40 μm resolution to allow selection of the appropriate array area
for high resolution scanning, and adjustment of the photomultiplier tube gain settings so
that the total array signal through the Cy3 and Cy5 detection channels was broadly equal
(i.e. the count ratio field approximates 1.0). A high resolution scan at 10 μm resolution
was performed for primary data acquisition, and the images acquired through each filter
were saved in uncompressed TIFF file image format.
2.3.7 Image analysis
Image analysis was performed using the program GenePix version 3.1. The Cy 3 and Cy5
filtered TIFF images were opened and amalgamated. A grid tool was overlaid over the
image, automatically aligned then manually adjusted, so that each array spot was
contained within an individual circular element on the grid (diameter ca 130 μm).
Intensity estimates for Cy3 and Cy5-fluorescence from each array spot were then111
collected and saved as a spreadsheet amenable to manipulation in the software packages
Excel for Windows and Genespring 4, which listed the array ‘address’ and associated
Cy3 and Cy5 fluorescence intensities
The hypothesis underlying microarray analysis is that the measured probe fluorescence
intensity on each arrayed gene spot is proportional to the expression level of that gene.
Biologically relevant patterns of expression are identified by comparing measured mean
expression levels for each sample type on a gene-by-gene basis. Before the levels can be
compared, data has to be processed to eliminate questionable or low-quality
measurements and to adjust the measured intensities using factors provided by the
common internal standard (Cy5-labelled), to compensate for bias and variability and thus
facilitate effective comparisons.
Most microarray experiments investigate the relationships between related biological
samples based on patterns of gene expression, and the simplest approach looks for genes
that are differentially expressed. If we have an array that has N gene-spots, and compare
an experimental and a reference sample (E and R, respectively), then the expression ratio
(T) for a gene x is
Tx = Ex/Rx
Expression ratios provide an intuitive measure of expression changes but they also have
the disadvantage of treating up- and down- regulated genes differently. Genes up-
regulated by a factor of 2 have an expression ratio of 2 whereas those down-regulated by
the same factor, have an expression ratio of 0.5. The commonest used transformation of112
the ratio in these situations is the logarithm base 2, which has the advantage of producing
a continuous spectrum of values and treating up- and down-regulated genes in the same
way.
Typically, the first transformation applied to expression data is referred to as
normalization and this adjusts the individual hybridization intensities, to balance them
appropriately so that meaningful biological comparisons can be made. Data has to be
normalized for a number of reasons such as differences in: The quantity and/or quality of
sample RNA; Reverse transcription efficiency; Probe labelling efficiency; Microarray
hybridization and washing efficiency; Detection efficiencies between the fluorescent
dyes; Systematic biases in measured gene expression levels. Conceptually, normalization
is similar to adjusting the expression level of a target gene measured by northern blotting
or RT-PCR, relative to the expression of one or more reference genes whose levels are
assumed to be constant between samples.
There are a number of normalization processes that may be used but the Lowess
normalization was used in this study. Lowess normalization has the advantage of
removing intensity dependent effects which can arise as a result of transformation of data.
The starting point for Lowess normalization is an intensity/ratio plot. Lowess detects
systematic deviations in the ratio/intensity (R-I) plot and corrects then by carrying out a
local weighted linear regression as a function of the intensity and subtracting the
calculated best-fit average ratio from the experimentally observed ratio for each data113
point. Lowess uses a weight function that de-emphasies the contributions of data from
array elements that are far (on the R-I plot) from each point.
Figure 2.4 shows a plot of intensity data after lowess normalization. (courtesy of
www.obgyn.cam.ac.uk/.../loess) -normalisation.htm. The arrow points to a significantly expressed gene.
2.3.8 Statistics
Primary fluorescent intensity data was analysed using the software package Genespring
which has been specifically designed for analysis of microarray data.
A Spearman correlation (non-parametric data) was performed between hormones and
genes.114
Array analysis method -
1. The primary intensity results files (*.gpr files) were filtered by removing data
associated with empty spots and internal calibration spots which contained pGEM
plasmid dilutions.
2. The arrays were normalised per spot and per chip using an intensity dependent
Lowess procedure.
3. Array data was filtered by removing data from ‘flagged’ gene-spots. If a gene was
flagged in 15 of the 20 arrays, all data for that gene was omitted.
4. Array data was also filtered on the basis of the expression intensity of the internal
standard at each gene-spot, i.e. the Cy5 intensity value. Expression data for a gene-spot
was omitted if it was below an intensity threshold, set at the mean background on all
microarrays plus 1 standard deviation interval. This threshold was calculated to be 950,
the maximum intensity being 63,999, since the background on the arrays was somewhat
high. If the expression intensity of the internal standard at a gene-spot was below this
level in 7 of the 20 arrays, all data for that gene was omitted. Filtering in steps 4) and 5)
left a gene list of 3975 genes, having removed genes the expression of which was at a
low intensity level barely above background which could not be accurately quantified.
5. On the basis of the expression of these 3975 genes, cluster analysis was performed
using a condition tree with a Spearman correlation.
6. Selection of genes was then performed, to find those the mean expression level of
which were modified more than 1.75-fold between the different samples types, at a p
value <0.05 by two-tailed Students t test. This produced a list of 15 genes for the H vs.115
PL comparison, 63 genes for the H vs. PS comparison and 75 genes for the PL vs. PS
comparison.
7. To view which genes are common or different between the sample groups, a Venn
diagram was constructed, showing for the 100 genes in total varying between the
samples sets, the numbers of genes different between each samples set comparison in a
colour coded format. These genes are then listed in the same colour coding, along with
clone ID, gene description and for each sample type, the mean normalised ratio (values
for duplicate), mean internal control (Cy5) intensity value (values for duplicate) and the
mean experimental sample (Cy3) intensity value (values for duplicate).
8. Gene lists were also prepared for each comparison main sample type comparison,
i.e. H vs. PL, H vs. PS and PL vs. PS, including fold change, significance level and gene
function. The ratio values here represent the mean normalised ratio of the biological
replicates (the range of the normalised ratio in all samples in that group)
9. Finally, cluster analysis was performed using a condition tree with a Spearman
correlation based on the expression of the 100 genes defined after filtering in steps 1) –
6)
2.4.0 Validation of data By Real-Time PCR
RT-PCR quantifies the initial amount of the template specifically, sensitively and
reproducibly and seems to be preferable to other forms of quantitative RT-PCR that
detect the amount of final amplified product at the end-point. Real-Time PCR monitors116
the fluorescence emitted during the reaction as an indicator of amplicon production
during each PCR cycle (i.e. in real time) as opposed to the end-point detection.
Quantitative real-time RT-PCR was performed to validate microarray data, using
TaqMan methodology on an ABI prism 7900 analyzer, according to the manufacturer’s
instructions (Applied Biosystems, Warrington, UK). 4 genes were targeted which were
differently expressed between groups, 2 genes (osteopontin, OPN, and Drosophila disc-
large 1 tumour-suppressor like-7, DLG7) had high signal intensity on the microarrays and
2 (asialoglycoprotein receptor 1, ASGPR1, and cell division kinase 8, cdk8) had signal
intensity below the Cy5 signal intensity threshold applied. cDNA was first produced from
each endometrial RNA sample by reverse transcription with random hexamers using 2 µg
of total RNA with 200 IU Superscript RT (Invitrogen Life Technologies, Applied
Biosystem, Warrington, UK).117
Figure 2.5 showing the principle of RT-PCR- courtesy of Dr Frank Orme. An electronic
tutorial. Merritt College, Oakland, USA. Free reproduction.
Taqman gene expression assays consist of a 20X mix of unlabelled PCR primers and
Taqman MGB probe (FAM dye-labelled). These assays are designed for the detection
and quantification of specific genetic sequences in RNA samples converted to cDNA.
Gene expression using Taqman Gene expression assays is performed as the second step
in a two-step reverse transcription- polymerase chain-reaction (RT-PCR) protocol on any
ABI prism Sequence Detection System Instrument. All Taqman Gene expression assays118
are optimized to work with either Taqman Universal PCR Master Mix (P/N 4304437)
and with cDNA.
Specific real-time PCR assays were performed for each gene with simultaneous in tube
estimation of 18S rRNA as internal standard, the specific primers and probes being
supplied as assays on demand, target gene probes being TAMRA labelled and 18S probe
FAM labelled (Applied Biosystems, Warrington, UK). The mix was then run through a
thermal cycler. Denaturing was allowed to happen for 40 cycles of 15 seconds at 95˚C
then annealing and extension occurred in another 40 cycles of 60 seconds at 60˚C.
Master mix for 95 runs was prepared and consisted of 12.5 μm of master mix, 1.25 μm of
18s rRNA, 1.25 μm of probe and 5 μm of RNAse –free water.
5 μl of cDNA was then added.
Expression levels in each endometrial RNA sample were calculated by the ddCt method,
and mean expression levels in the three groups were compared by ANOVA.
We also correlated the ratio of expression for each gene to the value for the different
parameters tested for such as cycle length, insulin levels, and testosterone levels.119
Chapter 3
The prevalence of polycystic ovarian
morphology in women with endometrial
cancer120
3. Prevalence of Polycystic Ovaries in women with endometrial
carcinoma.
3.1 Introduction
For a number of decades, there has been a general assumption that women with PCOS are at
increased risk of developing endometrial carcinoma. This is thought to be due to the fact that
these women are subjected to high oestrogen and insulin levels.
However as was discussed in Chapter 1, section 1.8, conclusive evidence for such an
association is lacking and the results of some studies contradict this assumption. For
example Ramzy found that ovarian morphology in women with endometrial cancer was
similar to normal women than to women with PCOS. Similarly, a study was undertaken to
look at the prevalence of PCO in patients with endometrial cancer.
3.2 Hypothesis
Polycystic ovarian morphology is more prevalent in patients with endometrial carcinoma
than in controls.
3.3 Aim
To demonstrate whether patients with endometrial carcinoma show histological evidence of
polycystic ovaries.121
3.4 Ethics
Ethics approval was first granted for the study from the Royal Free Hospital Medical School
ethics committee for the study to be performed between June 2002 to June 2003 and this was
later extended for another year by chairman’s action. Ethics approval for the same study was
also sought from the University College Hospital (UCL) Medical School and was granted for
a year stating August 2003
3.5 Methods
Study design, population and case selection
The experimental group (n = 128) comprised all patients who had been diagnosed with EC,
for whom archived ovaries and endometrial tissue were available, following total
hysterectomy and bilateral salpingoopherectomy at the Royal Free Hospital (RFH), London
between July 1987 and July 2003 or University College Hospital (UCH), London, between
July 2000 and July 2003. The control subjects (n = 83) were age-matched (± 5 years) to the
experimental subjects, and were derived from a larger group of patients with benign
gynaecological conditions operated on in the hospitals above over the same time periods, for
whom archived ovaries and, in most cases, endometrium were available. Controls had also
undergone total hysterectomy and bilateral salpingoopherectomy or bilateral oopherectomy.
No other selection criteria were applied and patients with gynaecological cancers other than
EC were excluded.122
The Royal Free Hospital Histopathology department keeps a data base, known as “Snomed”.
This contains the details of all patients who have had surgical specimen examined for
histology from 1990 up to date. A similar database is kept at UCL.
The ovaries of each patient were independently assessed by the main investigator and the
histopathologists at respective centres.
Assessment of ovaries
The prevalence of PCO morphology in subjects operated on for EC or for benign
gynaecological conditions was assessed by examination of archived Haematoxalin-eosin
stained 5 µm ovary sections from each patient. In clinical histopathological practice, PCO
morphology is often diagnosed using a qualitative assessment
167,168. The criteria used to
diagnose PCO were those described in 2.13.
3.6 Statistics
The difference in PCO prevalence between the EC and control group was tested using Chi-
squared analysis, with a Mantel-Haenszel correction to adjust for differences in age
distribution, and using Fishers Exact Test in age-restricted groups.123
3.7 Results
subjects controls
No. of patients 128 83
Mean age 63.9 51.6
No. PCO 11 7
% PCO 8.59 8.75
Table 3.1 shows the patients demographics.
Investigation of patient records revealed there was no significant difference in the ethnicity
profile between subjects with EC or benign gynaecological conditions (Table 3.2). It also
showed that patient records could not be used to determine consistently and without bias
whether patients had PCOS. Archived ovarian sections were therefore investigated from
each subject, to determine the prevalence of features consistent with PCO morphology as a
surrogate for PCOS.
Overall the prevalence of PCO was comparable in women with EC or benign gynaecological
conditions (11 of 128 [8.59%] versus 7 of 83 [8.75%], respectively, p = 1.00). Post hoc
Power analysis indicated the experiment had a Power of 0.834 and 0.999 to detect a 2- or 3-
fold increase, respectively, in PCO prevalence in the EC set at p < 0.05; no significant
difference was however noted. Ethnicity appeared not to influence PCO prevalence as in the
EC set, 10 women with PCO were Caucasian and one was of unknown ethnicity, while in the
benign controls with PCO, 6 were Caucasian and one was of Indian-Asian origin. When
subjects were subdivided by age (Fig. 3.1), there were again no differences in the prevalence
of PCO between the EC patients and benign controls, albeit non-significant effects were124
noted in women aged 20 – 39 years and 40 – 49 years. When subjects were divided into two
groups aged <50 years and ≥50 years (50 years being the average age of menopause), the
prevalence of PCO in patients aged <50 years was greater in those with EC than in controls
(10 of 16 [62.5%] vs. 6 of 22 [27.3%], respectively, p = 0.033;  = 0.153 by post hoc Power
analysis). No difference was noted in PCO prevalence in patients aged ≥50 years.
Data reported for each ethnic group are the number of subjects (N), the % of total cases and
the % of cases for which ethnicity data was reported. Ethnicity data was not reported in
some cases, primarily from the early years of the study. The proportion of patients in each
ethnic group did not differ significantly between EC and control subjects; neither did the
proportion of unreported cases.
Table 3.2: Ethnicity data for subjects with endometrial cancer (EC) and benign
gynaecological disease (Controls), obtained retrospectively from patient records.
EC cases Controls
Ethnicity N % of total % of reported N % of total % of reported
Caucasian 91 71.1 95.8 48 57.8 88.9
Asian Indian 2 1.6 2.1 3 3.6 5.6
Asian Other 1 0.8 1.1 0 0.0 0.0
African-Caribbean 1 0.8 1.1 3 3.6 5.6
Unreported 33 25.8 29 34.9
Total 128 83125
Fig 3.3- A pie chart representing the proportion of cases with PCO morphology.
Fig 3.4-A pie chart representing the proportion of controls with PCO
morphology.
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However we did find that there was a significant difference (Chi-squared test) in the
prevalence of PCO in the younger patients with endometrial cancer when compared to
controls of a similar age-group, as illustrated in figure 1.
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Figure 3.5- A bar chart representing the prevalence of PCO morphology in women with
endometrial cancer and in controls, as a function of patient age (data = patients with
PCO/total number of patients).
3.8 Discussion
The results obtained for this prevalence study questions the relationship between PCOS
and endometrial cancer. PCO as a marker of PCOS as it is a known fact that a great
percentage of people diagnosed with PCOS will also exhibit PCO morphology
169. . The127
number of women with PCOS in the UK is around one million (affecting 10 % of the
reproductive population aged 20-50). If we arbitrarily assign the risk of EC to be as low
as 1% in PCOS women, this would give an incidence of EC of 10,000 each year.
However according to the Office for National Statistics, in 2005, in the UK, the incidence
of endometrial cancer was 6891. (5% of all female cancers
99,100,170,171). This raises doubt
as to whether the two conditions are really linked. It could be that only a sub-group of
PCOS women only are at risk of developing EC.
As discussed in the introduction to this thesis, endometrial carcinoma arises from a
number of pathways and originates from a number of different endometrial environments.
Some tumours arise from a background of unopposed stimulation of high levels of
oestrogen whilst other tumours do not depend on high levels of oestrogen to develop.
Whilst PCOS is associated with high levels of circulating oestrogens, it may be that the
condition also confers a protective effect on the endometrium. Hyperoestrogenism is not
the only characteristic of PCOS and it may be that there yet unknown biochemical or
molecular factor that offers some immunity to the endometrium in the presence of
hyperoestrogenism. As mentioned before, there are a number of key steps in endometrial
carcinogenesis. Mutation is one key step and is involved as an early change in
microsatellite instability
116,172. After the menopause, when the endometrium is no more
subjected to the high oestrogen levels, it may be that the hormonal environment in PCOS
women becomes similar to that found in women without PCOS. This would explain why
after adjusting for age-differences in the study that was conducted, no significant
difference was found in the presence of polycystic ovarian morphology. However128
Winters et al, in a cohort of 84, pre, peri and post menopausal women with PCOS, found
that there were differences in the levels of serum testosterone. Pre and post-menopausal
women with PCOS were found to have increased levels of testosterone compared to
PCOS women who were perimenopausal and (ages between 42 and 47). This finding was
supported further by a study in which post-menopausal women undergoing coronary
angiography were scanned and up to 45% of them were found to have pco in addition to
biochemical disturbances similar to those found in PCOS
173. These studies confirm that
post-menopausal women with PCOS will continue to be subjected to an altered
biochemical environment and a large number of them will also display PCO morphology.
Another possible explanation for these findings may be that this study centred entirely on
detecting ovarian morphology (PCO) as a marker of PCOS. Consequently, it is likely that
some women with endometrial carcinoma with no evidence of PCO but biochemical
evidence of the condition will have been allocated to the control group and missed
altogether. Absence or reduction in the number of corpora albicantia was an essential
criterion for an ovary to be scored positive for polycystic ovarian morphology. This
feature denotes that the ovary has had impaired ovulation. This was taken as one of the
essential markers to score an ovary as polycystic in attempt to minimize the problem that
some patients will not necessarily have ovarian features of PCOS. . However the
consensus definition of PCOS allows this diagnosis in women with regular menstrual
cycles (if they have symptoms of hyperandrogenaemia) and in such cases the number of
corpora albicanta would not necessarily be reduced. It can also be argued that the
ultrasound features of PCO are a transient finding in the ovary and that at the time that129
the ovaries were removed there was no evidence of PCO but on histological examination,
features such as capsular thickening, stromal hyperthecosis and absence of hallmark of
ovulation, are not transient. Elting et al
174, followed women ageing women with PCOS
and found that those who developed regular cycles towards the end of their menstrual life
tended to have fewer follicular cysts that those with irregular cycles. Again that may
explain why PCO was not found in some of the older patients, as some of them may have
developed regular cycles.
According to the ESHRE/ARSM diagnostic criteria for the diagnosis of PCOS, although
PCO on ultrasound is one of the criteria necessary, it is not a prerequisite. There are
subgroups of women who will exhibit the symptoms of hyperandrogenaemia,
hyperinsulinaemia and may not necessarily have suffered from chronic anovulation. An
attempt was made to address this point by trying to retrieve the patients records for
examination but this had to be abandoned as some of these patients had been seen at an
early time and their records had already been destroyed or sent to archive record keeping
and it was impossible to retrieve these within the time frame in which this study was
conducted. Another problem that was faced was that record keeping by medical staff was
unreliable. Many patients were not asked specific questions about their menstrual cycles,
fertility or symptoms of PCOS (or possibly documentation was lacking) However some
patients were being seen for the first time when they had been menopausal for at least a
decade and their recall of menstrual and subfertility history was likely to be inaccurate in
some cases. Similarly, as most doctors believed that PCOS is linked to endometrial130
cancer, it probably had been considered unnecessary and inappropriate to investigate
patients with endometrial cancer for PCOS.
For the purpose of this study, polycystic ovarian morphology was diagnosed using
criteria usually applicable to pre-menopausal ovaries where oestrogen levels and action
on the architecture are intact. However it is not well documented what happens to a post-
menopausal ovary. The ovary is known to atrophy after the menopause, but less is known
about the faith of the capsule, the follicular cyst, the stroma and the corpora albicantia
after the drop in oestrogen levels. It is possible that we have missed some polycystic
ovaries due to the fact that the architecture has change in these patients. Previously,
histopathologists would often fail to report polycystic ovarian morphology as its
significance was overlooked. Our finding of no increase prevalence in the post
menopausal women with endometrial carcinoma could in fact result from a failure to
identify the altered ovarian morphology in this group. However Birdsall et al published
their work in 1998 where they found that polycystic ovaries could be diagnosed in up to
50% of postmenopausal women on ultrasound scan
175. Alternatively PCO and
endometrial cancer may be unassociated conditions in post menopausal women.
Another interesting finding was that polycystic ovarian morphology was significantly
more common in younger patients (20-40 years old) with endometrial carcinoma. It is
possible that polycystic ovaries may constitute a risk factor for endometrial cancer in
women aged 20 – 49, (the reproductive years). After this, the hormonal changes
occurring in the menopause may remove the putative endometrial cancer stimulating131
effect of the presence of the polycystic ovary. One of the mechanisms by which patients
with PCOS are thought to develop cancer is via unopposed oestrogenic stimulation of the
endometrium resulting from chronic anovulation. Indeed, it has been proposed that
agonist-bound progesterone receptor-A inhibits the transcriptional effects of oestrogen
receptor in the human reproductive system
176. Thus the lack of a luteal phase
progesterone surge in anovulatory women with PCOS may leave the oestrogen receptor
unduly active at an abnormal time in the menstrual cycle, with the risk only removed
after the menopause, which would explain our finding of more PCO in young women
with endometrial cancer. Women with PCOS suffer from a high incidence fibromyoma,
myohypertrophy and endometrial hyperplasia
177, perhaps due to unopposed oestrogen
stimulation of the endometrium. PCOS is associated with hyperinsulinaemia and insulin
resistance
178, worsening with increasing age
179. Aside from exacerbating the
hyperandrogenaemia by enhancing aromatase activity
180, these endocrine factors may
underlie the association between PCO and EC, since insulin and IGF-I stimulate EC cells
in vitro
181.
Hyperandrogenaemia has been associated with EC in post-menopausal women on the
basis that those with testosterone levels in the upper quartile, have an approximate three-
fold increased risk of EC
182. The lack of association between PCO and EC in post-
menopausal women in the present study may reflect the hypoestrogenic environment in
post-menopausal women. Alternatively, the absence of an increased prevalence of PCO
morphology in women aged ≥50 years with EC, may be because it is difficult to identify
such morphology in this age-group. PCO can however be reliably identified in post-132
menopausal women by ultrasonography
183 and it is unlikely that the histological analysis
used in this study would be less sensitive. Thus it is probable that elements of PCO
morphology remain after the menopause and, if present, would have been detected in this
study. Indeed, hyperandrogenaemia commonly persists in post-menopausal women with
PCOS
183.
A limitation of this study is that subjects were characterised as having PCO rather than
PCOS. It was impossible to identify women with PCOS from patient records,
consistently and without bias, because the clinical and endocrine details required were
infrequently recorded for these subjects, who were being treated either for EC (many of
whom were post-menopausal) or other gynaecological disorders unrelated to PCOS.
Subject follow-up could also not be performed as many were untraceable or deceased.
Between 25 and 50% of women with PCO morphology exhibit symptoms supportive of
PCOS
92,184. In the present study the concordance between PCO morphology and PCOS
was likely to be higher, since the definition of PCO morphology used included the
criterion that a reduced number of corpora albicantia were present, suggestive of
impaired ovulation. Such a criterion has not been previously used and, if satisfied in
association with the presence of more than 8 cystic follicles, is supportive of a
retrospective diagnosis of PCOS. It is possible that a few subjects with normal ovaries
may have had symptoms of hyperandrogenaemia (part of the recently agreed diagnostic
criteria) and ovulatory dysfunction supportive of a diagnosis of PCOS
95. Indeed, an
ovary was classed as normal if <8 follicles were present, even if ovulatory dysfunction
was indicated by the absence of corpora albicantia. This group of patient with no133
histological evidence but possible biochemical disturbances would have been missed and
could have influenced the results. This situation seldom occurred however; few ovaries
classed as normal had a limited prevalence of corpora albicantia. It is also possible that
some of the controls operated on for benign gynaecological conditions may have had
occult endometrial tumours. The level of contamination of the control group was
probably insignificant however since the subjects had been assessed by a gynaecologist
and endometrial histopathological assessment was made in most cases as hysterectomy
was performed. Finally, no endometrial cancers were noted in post-operative records
when hysterectomy was not performed, albeit these records were sometimes limited in
the length of follow-up.
3.9 CONCLUSION
This study was performed to compare the prevalence of polycystic ovaries in women
with endometrial cancer with women without endometrial cancer. We did not find the
prevalence of pco to be raised overall in women with endometrial cancer. However, when
we stratified women into different age groups, we found that women younger women
with endometrial cancer seem to exhibit polycystic ovaries. We also found that there are
no set criteria to assess polycystic ovaries in women and the condition in post
menopausal women is even less described. This potentially would be an area of future
research.
These results challenge the assumption that women with PCOS have a greater risk of
developing endometrial cancer.134
Chapter 4
THE EXPRESSION OF PROGNOSTIC
MARKERS OF ENDOMETRIAL
CANCER IN THE ENDOMETRIUM OF
WOMEN WITH POLYCYSTIC OVARIES135
4.0 The expression of prognostic markers of endometrial
cancer in the endometrium of women with Polycystic Ovaries.
4.1 Introduction
The incidence of endometrial cancer is on the increase in the UK. It is the fifth most
common cancer in women in the UK with around 6,891 cases diagnosed in 2005 alone,
accounting for around 5% of all female cancers. The clinicopathologic features vary,
including age at diagnosis, histologic characteristic, DNA ploidy, hormonal receptor
status and clinical course. This is likely to reflect a complex aetiology involving both
endogenous and exogenous factors
129. Various factors that seem to influence the risk of
endometrial cancer and the prognosis. For example, there is clearly a genetic component
as women with the gene for hereditary non-polyposis colorectal cancer carry a 10-fold
increased risk of developing endometrial cancer compared to the general population
185.
Environmental factors are also important and the increase in frequency of endometrial
carcinoma has been attributed to dietary and hormonal factors as well as an ageing female
population
186. Other factors considered to have an influence in the prevalence and
prognosis of EC include increased BMI, exogenous oestrogen treatment , especially when
unopposed by cyclic progestogens, and hormonal disturbances as seen in diabetes
mellitus or hormone producing tumours of the ovary
186. It is however, generally believed
that tumours that arise in women with PCOS, tend to be well differentiated and carry a
better prognosis. Jafari et al
155 carried out a prospective study involving 6 patients with
known PCOS who had been diagnosed with endometrial cancer. The subjects had an age
range of 23 to 33 years and all had a total abdominal hysterectomy and bilateral136
salpingoopherectomy. 5 patients were found to have well differentiated tumours and 1
had a moderately differentiated tumours. After 15 years of follow-up, they were all found
to be disease-free.
To investigate the hypothesis that women with PCOS and EC exhibit well differentiated
tumours which carry a good prognosis, a second study was performed. The expression of
p53, Cyclin DI, Ki 67 and bcl2 was assessed in the tumours of women with polycystic
ovaries. These proteins were chosen as specific prognostic markers for endometrial
cancer as we discuss below.
P53 – The nuclear protein encoded by the p53 gene acts as a tumour suppressor. It is
essential in the modulation of cellular responses to cytotoxic stress by contributing both
to cell cycle arrest and programmed cell-death
12. Mutations of the p53 tumour suppressor
gene have been found in about 10-20% of endometrial carcinomas
187. As p53 mutations
rarely occur in cases of endometrial hyperplasia, it is thought to be a relatively late event
in carcinogenesis. p53 mutations often result in overexpression of mutant p53 protein,
which is conformationally altered and functionally defective with a longer half-life than
the normal wild- type counterpart, thus permitting in immunohistochemical detection of
the protein product
188.
Cyclin D1 is a cell cycle protein whose over-expression may be associated with gene
amplification or transcriptional dysregulation in cancers. This over-expression in
endometrial glands increases progressively in intensity and extent from normal to137
neoplastic endometrium
189. The pattern of Cyclin D1 over- expression also suggests that
this is an early event in carcinogenesis. Cyclins, cyclin-dependent kinases, and tumour
suppressor gene products interact and regulate the normal cell cycle
190. Cyclin D1 and
cyclin-dependent kinases are required for completion of the G1/S transition in normal
mammalian cells
190. Cyclin D1 dysregulation in endometrial carcinoma contributes to an
increase in the proportion of cells in transition from G1 to S phase. Cyclin D1
overexpression may be one of several mechanisms involved in endometrial neoplasia,
and proliferative endometrial glands and stroma, even when actively mitotic do not over
express Cyclin D1
191. Cyclin D1, in in-vitro studies has been seen to be rendered
insensitive to degradation by threonine 286 mutation and this Cyclin D1 mutant induces
transformation in murine fibroblasts
192. Moreno-Bueno et al
193 found similar mutations in
proline 287, which is required for a number of enzymatic functions. The authors
proposed that a combination of the mutations in threonine 286 and proline 287 probably
cause conformational changes that would impact on enzyme function.
Bcl2 is an anti apoptotic protein associated with a 14; 18 chromosomal translocation and
is primarily a mitochondrial membrane protein. It is thought that increased bcl2 staining
correlates with a good prognosis. When the expression of this protein is decreased,
programmed cell death is up-regulated and this in turn stimulates proliferation
13. We have
discussed Bcl2 in more details in chapter 1, section 1.3.3.
Ki67 is a recognized indicator of cell mitotic activity and an increased expression of this
protein indicates an increased in cell mitotic activity and proliferation. Ki67 expression is138
normally elevated in the proliferative phase of the menstrual cycle with glandular
epithelium showing the strongest expression. Stromal staining of Ki67 is more apparent
in the secretory phase but is still lower than that of the endometrial glands in the
proliferative phase
194.
4.2 Hypothesis
Women with polycystic ovary syndrome and EC have tumours with a better prognosis
than women with EC who do not have PCOS.
4.3 Aim
The aim of the study was to assess the expression of Cyclin D1, Bcl2, P53 and Ki67 (as
surrogate markers of prognosis, in endometrial tumours of women with and without
polycystic ovaries).
4.4 Ethics
Ethics approval was granted for the study to be undertaken from July 2002 to July 2003,
by the Royal Free & University College Medical School. An extension was subsequently
granted for another year.139
4.5 Materials and Methods
In the study detailed in Chapter 3, patients with endometrial cancer were selected and
assessed the prevalence of polycystic ovarian morphology. 11 patients were identified
and the endometrial tumours of the patients were then selected for
immunohistochemistry. Controls were patients who had endometrial cancer but did not
exhibit pco morphology. Controls were selected if they fell in the same age-range as the
subjects.
Immunohistochemistry
Standard immunohistochemical techniques were applied to paraffin-embedded 5 µm
endometrial tumour sections and ovary sections (as an appropriate positive control tissue;
165), mounted on 3-aminopropyltriethoxysilane-coated slides as described in 2.2.4.
The sections were viewed under a light microscope at x100 magnification and scored by
two independent observers (OCP, LWTF) as described in 2.2 .5.
4.6 Statistics
Differences in immunostaining were tested by Fishers Exact Test (Cyclin D1, Bcl2, p53)
or Student t test (Ki67). P < 0.05 was taken as the threshold level of significance.140
4.6 Results
Endometrial tumours which stained positively for Cyclin D1 tended to be more prevalent
in women with PCO than in those with normal ovaries (4 of 11 [36.4%] versus 1 of 16
[6.25%], respectively, p = 0.071; Table 4.1, Figure 4.1). No differences were noted in the
prevalence of Bcl2, p53 or Ki67 staining tumours. (In all cases, endometrial tumours
from women with PCO or normal ovaries expressed p53 at a moderate to strong level.
The prevalence of Bcl2 positive endometrial tumours was also comparable in women
with PCO or normal ovaries (ca. 75%), as was the Ki67 staining index (ca. 35%).
In all cases p53 expression was moderate to strong. Endometrial cancer Bcl-2 expression
was similarly unaffected by ovarian morphology with 8 from 11 positive (75%) in
women with pco compared with 12 from 16 positive (72.5%) in normal ovaries.
Similarly the endometrial tumour Ki67 staining index in women with polycystic ovaries
(39% was not significantly different from that in women with normal ovaries (30%).
subjects controls
No. tumours tested 11 16
%p53 +ve 82 100
%cyclin D1+ve* 36.4 6.25
%bcl2+ve 75 72.5
%Ki67+ve 39 30
Table 4.1 shows the results obtained in each group, after immunohistochemistry.141
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Figure 4.2- Cell cycle (Ki67, cyclin D1) and apoptotic (p53 and Bcl2) protein expression
in endometrial tumours from women with normal or polycystic ovaries (*P = 0.071).142
Figure 4.3- Immunohistochemistry showing expression of p53 in the endometrium of
women with PCO.
Figure 4.4- Expression of Bcl2 in the endometrium of women with PCO.143
Figure 4.5- Expression of cyclin D1 in the endometrium of women with PCO.
Figure 4.6: Expression of Ki67 in the endometrium of women with PCO.144
4.7: Discussion
This study showed that Cyclin D1 expression (a marker of tumour prognosis) was greater
in endometrial cancers from women with PCO. However the expression of Bcl2, Ki67
and p53 in endometrial tumours was not different in this subgroup of women when
compared to women without PCO.
Our results challenge the belief that endometrial tumours in patients with PCOS are less
aggressive and have a better prognosis. The implications of this may involve greater
vigilance and aggression in treating PCOS women who develop endometrial cancer.
Although the expression of cell cycle and apoptotic proteins bcl2, p53 and Ki67 in
endometrial tumours was unaffected by ovarian morphology, cyclin D1 expression was
elevated in endometrial tumours from women with polycystic ovaries. The significance
of this change is unclear but it may suggest however that raised cyclin D1 expression is
involved in the pathogenesis of endometrial tumours in women with polycystic ovaries. It
was previously thought that endometrial carcinogenesis occurs by two pathways, type 1
tumours arising from unopposed oestrogen stimulation on a background of endometrial
hyperplasia (discussed in Chapter 1, section 1.6.), while type 2 tumours arose in atrophic
endometrium, usually in older patients. Recent studies suggest greater complexity
involving perturbation of multiple processes such as ras proto-oncogene expression,
microsatellite instability, apoptosis, tumour immortalization (via telomerase activation),
tumour suppressor gene expression, proteolysis, adhesion, angiogenesis and clonal145
expansion
110. It may be that patients with PCOS develop endometrial cancer via a
pathway that involves cyclin D1, perhaps as a response to the modified endocrine
environment in these women.
Cyclin D1 is a cell cycle protein, member of the G1 Cyclin family that regulates the G1/S
transition in the cell cycle, whose over-expression may be associated with actual gene
amplification or transcriptional dysregulation in cancers
190. Over-expression in
endometrial glands increases progressively in intensity and extent from normal to
carcinomatous endometrium
189. The pattern of over- expression also suggests that this is
an early event in carcinogenesis. Oestrogen promotes endometrial growth and
progesterone inhibits its proliferation and progesterone will strongly inhibit c-Jun (a
member of the activating proteins family AP-1 involved in endometrial growth)
recruitment to the cyclin D1 promoter
195. This modulation of AP-1 activity and cyclin D1
expression via c-Jun may be a potential pathway of progesterone-induced growth
inhibition in endometrial cancer cells in women with PCO who have defective
progesterone production
196.
One limitation of this study is that the sample size of endometrial cancer available for
staining was very small. The limitations of the previous study had an impact on this
study. We selected endometrial cancers which were associated with polycystic ovarian
morphology, using this a marker of PCOS, however, according to the Rotterdam
diagnostic criteria, patients with a history of oligo/anovulation and or clinical or
biochemical signs and symptoms of hyperandrogenaemia can also be diagnosed as146
having pcos. It was impossible to determine from the patients notes whether they had
showed signs and symptoms of pcos due to a lack of documentation at the time by
clinicians (some of the patients were seen at a time where the links between pcos and
endometrial cancer were not being investigated). This study can be considered as a pilot
study for a much larger one as we nowadays have stricter diagnostic criteria for pcos and
most cancer cases are treated in tertiary designated cancer centre which will make access
to a greater number of endometrial cancer tissue samples.
4.8 Conclusion
This is the first study of its kind in the sense that it directly looks at markers of prognosis
in tumours associated with PCO and those not associated with PCO. We found that there
was no significant difference in the expressions of p53, ki67and bcl2 in the two groups,
Furthermore, cyclin D1 expressing endometrial tumours tended to be more prevalent in
women with PCO rather than normal ovaries, albeit this difference was of marginal
significance. It may though suggest that cyclin D1 over-expression is involved in the
pathogenesis of endometrial tumours in women with PCO. Certainly, these results
provide no support for the contention that the prognosis of EC is better in women with
PCOS. The significance of this finding is open to many interpretations as the role of
cyclin D1 in endometrial carcinogenesis is still unclear. For more than 50 years after an
association between PCOS and endometrial carcinoma was first suggested, the nature of
this association remains unclear. The hypothesis that women with PCOS tend to develop
a better prognosis tumour is not necessarily disproven but on the contrary doubts are
being raised about this statement. The results do not directly assess survival with147
endometrial carcinoma but are indicative of cell-cycle dysregulation when this tumour
changes occur in association with PCO.148
Chapter 5
GENE EXPRESSION IN THE
ENDOMETRIUM OF WOMEN WITH
POLYCYSTIC OVARY SYNDROME149
5.1 Introduction
In Chapters 3 and 4, an association between PCOS (using PCO as a marker of PCOS)
and EC was not demonstrated, albeit the small number of women with EC who were less
than 50 years of age exhibited an increased abundance of PCO morphology relative to
age-matched controls. This suggests that a specific group of women with PCOS – those
who are pre-menopausal - are at increased risk of developing endometrial cancer.
As discussed previously, there is no single treatment which alleviates the wide range of
symptoms associated with PCOS. For women whose main concern is fertility, effective
treatment with clomiphene citrate, metformin, ovarian drilling or FSH, is available.
Treatment is also available for the cutaneous sequelae of PCOS associated
hyperandrogenaemia, such as acne and hirsutism (roaccutane, Spironolactone, laser
therapy, vaniqua). To reduce the risks of developing type 2 diabetes and cardiovascular
disease, PCOS patients are advised about lifestyle changes such as diet and exercise.
There is however, surprisingly little evidence and data regarding the treatment options
available for PCOS women suffering from oligo/amenorrhoea, who are concerned about
their risk of developing endometrial hyperplasia and carcinoma.
It is likely that unopposed oestrogenic stimulation of the endometrium is an important
risk factor for EC in women with PCOS. The observation in Chapter 3 that EC and PCO
morphology are associated in women less than 50 years of age (i.e. pre-menopausal) is
consistent with this proposal. To investigate this possibility, gene expression was
assessed by microarray analysis in endometrium from women with PCOS who150
demonstrated either: normal menstrual cycles and proliferative phase endometrium;
oligo/amenorrhoea and proliferative endometrium; or oligo/amenorrhoea and endometrial
pathology exhibiting both proliferative and hyperplasic characteristics. Endometrial
hyperplasia is consider a precancerous lesion predisposing to EC, thus changes in gene
expression related to hyperplasia might also be expected to occur in proliferative phase
endometrium from women with PCOS who are oligo/amenorrhoeic but not when they are
normally cycling.
5.2 Hypothesis
The hypothesis investigated in this study is that in women with PCOS, the endometrium
of those who are oligo/amenorrhoeic expresses genes that are related to carcinogenesis
and are seen in endometrial hyperplasia, but not in the endometrium of those who are
normally cycling.
5.3 Aim
I. To investigate endometrial gene expression in women with PCOS.
II. To investigate which types of histological state of the endometrium of women with
PCOS express more genes that are associated with carcinogenesis.151
5.4 Ethics
Ethical approval for the study (Project number 6719) was granted by the Royal Free &
University College Medical School Ethics Committee in July 2003. Patients were
recruited over a period of twelve months between July 2003 and July 2004.
5.5 Methods
5.5.1 Subject selection
Mr. Paul Hardiman heads weekly infertility and joint gynaecology/endocrinology clinics
where patients with PCOS are referred. All referral letters from General Practitioners
were vetted and patients with a history suggestive of PCOS were contacted regarding
enrolment into the study.
Chapter 2 describes in detail the selection criteria and the various investigations
requested. Strict inclusion criteria were applied to select endometrial samples for
microarray investigation.
-All endometrial biopsies exhibited simple hyperplasic( no atypical hyperplasia was
found) and/or proliferative morphology
-All included subjects exhibited data for biochemical tests (the tests are discussed in
Chapter 2, section 2.3.2, page 96), blood pressure, BMI, age and Ferriman and Galway
score within 3 standard deviations from the mean value for these parameters. The mean
value for each parameter was calculated for all the patients and only patients, whose data
set fell within 3 standard deviations or less from the mean, were included.152
Finally, 20 subjects were selected for endometrial microarray analysis on the basis of
whether they exhibited normal menstrual cycles and proliferative phase endometrial
morphology (n = 10; PS), oligo/amenorrhoea and proliferative phase morphology (n = 5;
PL) or oligo/amenorrhoea and hyperplasic morphology on a proliferative phase
background (n = 5; H). The twenty subjects selected also had good quality RNA
extracted from their endometrial biopsy and this was confirmed by analysis on Agilent
RNA analyser. These tissue comparisons were selected on the basis that they best
represented the early transition from normal proliferative tissue to an abnormally dividing
tissue such as hyperplasia where cells were likely to have been exposed to deranged
hormonal environment. Although the normally cycling women were under the influence
of insulin and androgen (both known to be to influence gene expression), the influence of
these hormones was likely to be less than in the other two groups. This is because the
normally cycling women’s endometrium would also have been under the influence of
progesterone. Hence, the three tissue groups were selected on the basis that all the groups
would be under the influence of hormones to varying degree (which in turn will affect
gene mutations or silencing in their endometrium). These three groups were also thought
to best represent the natural progression of the endometrium when it undergoes changes
associated with growth. Group 1- Women with PCOS, regular cycles (< 32 days- PS,
these women were having regular cycles 6 month prior to having biopsy and blood tests)
and proliferative endometrium- As these women will be cycling, they are expected to be
influenced to a lesser extent by increased levels of insulin and androgen and will also be
under the influence of progesterone. The genetic mutations/silencing expected will be
associated with PCOS itself.153
a) Group 1- Women with PCOS, regular cycles (< 32 days - PS, these women were
having regular cycles 6 month prior to having biopsy and blood tests) and
proliferative endometrium- As these women will be cycling, they are expected to
be influenced to a lesser extent by increased levels of insulin and androgen and
will also be under the influence of progesterone. The genetic mutations/silencing
expected will be associated with PCOS itself.
b) Group 2- Women with PCOS, prolonged cycles (>32 days- referred as PL for
long cycles.) and proliferative endometrium- The endometrium of these women
will be exposed to the effect of increased levels of insulin and androgen and
unopposed oestrogen (lack of progesterone).
c) Group 3- Women with PCOS, irregular cycles (>32 days- H) and hyperplastic
endometrium- These women will exhibit the changes in Group 2 (PL group) along
with gene expression associated with hyperplasia.
PCOS is a heterogeneous condition where the signs of symptoms may be manifest at one
time and very circumspect at other times. When the syndrome starts to express itself in
the form of irregular menstrual cycles, the endometrium becomes exposed to various
hormonal imbalances which may or may not affect growth.
Comparing gene expression from the endometrium in each group will give valuable
information on genetic changes that occur as a result of prolonged oestrogen stimulation.
This is thought to be the mechanism by which women with PCOS develop EC; however
this study will be looking at this effect at a very early stage at the molecular level-154
If group a (PS) and b (PL) are compared, we hope to get information about the direct
effect of prolonged cycles, androgen and insulin levels on the endometrium.
If group b (PL) and c (H) are compared, this study aims to demonstrate the genetic
changes associated with the morphological shift from proliferative endometrium to
hyperplasia
Comparing group a (PS) and c (H), we hope to assess the combined effect of both
prolonged unopposed oestrogen stimulation, increased androgen and insulin levels and
morphological tissue change from a benign to an early neoplastic state.
The endometrial biopsies were snap-frozen and stored at -80°C, then processed as
described in Chapter 2, section 2.3.3.1-2.3.3.3, in order to extract RNA for microarray
analysis. Extracted RNA was purified and processed to prepare probe for microarray
analysis as described in Chapter 2, section 2.3.3.4. The reference RNA applied on all
microarrays comprised of pooled endometrial RNA isolated on day 7 of the menstrual
cycle from 3 subjects. These subjects were selected on the basis that they had regular
menstrual cycles and did not suffer from PCOS and had not used any form of hormonal
supplements in the six months before they underwent endometrial biopsy. Sample
pooling is often required when RNA is in limited supply and to minimize biological
variation. Reference RNA was provided by Dr Andrew Sharkey, Department of
Pathology, Cambridge University.155
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1 24 250 PL 13 26.45 28 y y y
2 27 90 H 12 22.86 17 y y y
3 23 7 PS 12 23.03 15 y y y
4 30 6 PS 11 20.70 Not
given n y y
5 28 7 PS 16 16.53 35 y y y
6 26 7 PS 12 24.54 7 y y y
7 33 90 H 15 20.94 22 y y y
8 22 7 PS 11 34.53 15 y y y
9 18 18 PL 13 25.10 20 y y y
10 31 5 PS 15 22.31 Not
given n y y
11 25 7 PS 13 24.97 3.8 y y y
12 28 6 PS 10 23.71 20 y y y
13 20 30 PL 13 35.28 20 y y y
14 35 7 PS 14 21.45 10 y y y
15 32 60 PL 11 21.67 15 y y y
16 30 250 H 11 24.00 22 y y y
17 29 70 PL 12 37.18 20 y y y
18 27 7 H 14 19.72 22 y y y
19 31 122 H 11 29.14 21 n y y
20 34 6 PS 11 35.09 15 y y y
Table 5.1 showing patient demographics and timing of biopsy.156
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1 13.4 5.5 4.4 13 33.8 11 3.1 161 126 6 5.2 6.8 proliferative
2 14.2 4.8 3.3 19 17.4 17.6 2.6 186 111 6.4 3.4 3.6 hyperplasia
3 7.8 5.5 2 29.5 6.8 12.2 2.1 19 5 4.3 5.9 proliferative
4 9.2 6.7 2.7 94 2.9 16 2.6 293 11 4.7 5.8 proliferative
5 13 7.7 2 16 12.5 11.3 3 110 19 5.8 4.6 5.9 proliferative
6 6.1 6 1.7 91 1.9 8 1.2 5.4 4.8 4.4 proliferative
7 10.2 5.4 1.6 40.8 3.9 11.2 2 208 43 5.4 3.7 4.8 hyperplasia
8 5.4 6.1 2.3 27 8.5 3 144 58 5.8 5.2 5.8 proliferative
9 11.7 6.9 2.3 17 13.5 13.2 1.2 159 116 6 4.1 6.5 proliferative
10 18.5 5.8 4 44.2 9 12.5 3 10 3.7 4.6 proliferative
11 7.1 6.4 2.9 49.3 5.9 10.4 2.6 229 23 3.8 5.1 4.8 proliferative
12 7.3 9.7 2.4 34 7.1 10.8 1.4 139 132 3.8 4.9 6.1 proliferative
13 27.8 6.9 3 14.9 20.1 1.3 1.5 446 30 4.1 4.9 6.9 proliferative
14 8.5 4.8 2.3 63.4 3.6 9.4 2 116 17 5.9 4.8 5.1 proliferative
15 16.9 5.3 3.1 29 10.7 11.8 2.1 170 120 5.5 4.6 4.3 proliferative
16 6.4 2.2 1.6 59 2.7 11.6 36.4 563 97 4.4 4.6 4.6 hyperplasia
17 0.4 1.7 1.2 19 6.3 12.2 1.2 180 114 5.6 4.4 6.3 proliferative
18 22 4.6 5.5 59 9.3 13 2.6 317 10 5.4 4.4 5.4 hyperplasia
19 12.2 5.7 3.7 45.5 8.1 15 2.1 214 61 6.6 4.3 5.3 hyperplasia
20 4 9.1 2.1 42.6 4.9 1.8 243 76 4.8 proliferative
Table 5.2- shows all the biochemical profiles and histological report of each patient in the
study157
PS
n= 10
PL
n= 5
H
N=5
Progesterone (nM)
Mean- 3.875
2.27 1.82 9.14
Testosterone (nM)
Mean- 2.705
2.44 2.8 3.14
FAI
Mean – 9.45
6.31 16.88 8.28
Insulin (nM)
Mean- 62.8
40.6 101.2 64.4
Oestrogen (nM)
Mean- 228.1
183 223.2 297.6
Table 5.3- shows the mean values of Progesterone, testosterone, free androgen index,
insulin and oestrogen in the three groups studied (short cycle proliferative - PS, long
cycle proliferative- PL and the hyperplasia- H).
Because of the non-normality of distribution in T, progesterone, E2 and Insulin, a
nonparametric test of significance was utilised. This Kruskall-Wallis test showed that two
hormones varied between the subject groups: mean E2 was significantly higher in the
hyperplasic (297.6 nM) than in the PL (long cycle) (223.2 nM) or the PS (short cycle)
(183 nM) groups (Chi Square = 5.99, df=2, p<.05), and mean insulin was significantly
higher in the PL (101.2 nM) than the PS group (40.6 nM) (Chi Square = 6.04, df=2,
p<.049).158
There was a significant difference in FAI level between long cycling (PL), regular
cycling (PS), and hyperplasic (H) patients (F=4.74, df=2, 17, p<.023). Post hoc
comparisons using the LSD test show that the long cycling PL patients had significantly
higher FAI than both the regular cycling PS (p<.007) and hyperplasic patients (p<.047).
However using a Bonferroni post-hoc test the difference remained significant only
between the long cycling and regular cycling patients (p<.022).
5.5.2 Choice and preparation of microarray
The HMN2 microarrays used in this study were produced by the Center for Microarray
Resources at the Department of Pathology, Cambridge University (Tennis Court Road,
Cambridge, CB2 1QP, UK). The composition of the arrays makes them an invaluable
tool for the analysis of ‘novel’ gene involvement in endometrial function. Each array is
constructed from ~1500 Mammalian Gene Collection full-length cDNAs, ~1000 hand-
selected clones of angiogenesis related genes and ~5000 Soares Normalised Human
Testis library clones. The ~7500 clones, together with a collection of control clones, are
available duplicated as a ~18,000 feature array built on the Corning GAPSII surface. 900
genes are known to be specifically involved in endometrial function, such as apoptosis
and extracellular matrix remodelling, as well as house-keeping genes. More information
about the arrays can be obtained at
http://www.path.cam.ac.uk/resources/microarray/microarrays/.159
These arrays were chosen because they have been used in the Cambridge Laboratories to
generate good results. They also contained genes that are known to be activated during
proliferation processes such as carcinogenesis such as apoptosis, cell-matrix remodelling,
growth and cell repair. The microarrays were hybridized to probe cDNA in a manner
similar to that used in Southern blotting
197.
Array generation
The arrays were generated by Dr A. Brown and his team in the Molecular Biology
Department, Cambridge University using the following method: The arrays were made
by first generating PCR-amplified cDNAs which were then suspended in 150 mM
NaPO4, (pH 8.5)/0.001% SDS. These were spotted onto bar-coded CMT-GAPSII
surfaces (Corning). The spotter used was a Biorobotics MicroGrid (Genomic Solutions
Ltd), using microspot 2500 pins (Genomic Solutions Ltd). After spotting was completed,
the slides were baked at 80C for 2 hours, and then washed in 1% BSA/3x SSC/0.1%
SDS at 55C for 20 minutes. The slides were subsequently incubated in boiling MilliQ
purified water for 2 minutes to denature the cDNAs; washed for 5 minutes in MilliQ
purified water; rinsed in propan-2-ol and finally dried by centrifugation.
RNA preparation
Chapter 2, section 2.3.3.1-2.3.3.5, pages 98-103, describes in great detail the method of
RNA extraction.160
Good labelling and optimal hybridization of probe material is dependent upon high
quality RNA. Several issues need to be considered from the moment that tissue is
collected to facilitate the preparation of high quality RNA. In this study, tissue was snap-
frozen in dry ice within seconds of collection, minimizing RNA degradation. Labelling
of degraded or contaminated RNA will invariably produce misleading results.
The amount of tissue available was limited; hence a method of RNA extraction which
would produce high yields was chosen. Of a variety of method tested, QIAZOL (Qiagen,
Hilden, Germany) produced a good RNA yield with acceptable levels of purity. The
RNA obtained was then purified by column purification using the Rneasy Minikit
(Qiagen, Hilden, Germany).
The RNA yields were determined by spectophotometry at 280 and 260 nm. The integrity
and purity were then determined by using an Agilent Technologies 2100 Bioanalyser
(Agilent technologies UK limited, Cheshire, UK) (as described in Chapter 2, section
2.3.3.8).
Production of labelled cDNA from RNA samples
Reverse Transcription is used to produce cDNA from total cellular RNA. To ensure
multiple arrays could be performed if required, and to use a methodology which provides
unparalleled sensitivity for genes expressed at low levels, it was decided to use the
SMART PCR cDNA synthesis kit (Clontech, St Germain-en-Lahaye). cDNA samples
were then subjected to Cy3-dCTP and Cy5-dCTP cDNA labelling to produce probe for161
use in microarray analysis. (Details of the procedure are outlined in Chapter2,
section2.3.4, page 102)
Hybridization
Hybridisation buffer (40% v/v deionised formamide; 5x SSC; 5x Denhardt’s solution; 1
mM sodium pyrophosphate; 50 mM Tris-HCl (pH 7.4); 0.1% w/v sodium dodecyl
sulphate) was used and this has been used repeatedly in Cambridge with good results.
Hybridisation was allowed to occur in a water-bath at 50C for 16-18 hours. Optimal
hybridization conditions ensured that the maximum microarray sensitivity and data of
high quality are achieved. It also allows even very low abundance genes to be detected
and differential expression determined.
Background agents such as Cot-1 DNA and polyadenylic acid are used to minimize
background. (Details outlined in Chapter 2, section 2.3.5.2, page 108)
Data normalization and analysis
After image acquisition and conversion of the image into spot intensity, the large volume
of data obtained were stored onto a spreadsheet for further analysis.
Before analysis took place the, the raw intensity data was log transformed and any values
attributed to background were eliminated. A scatter plot was then created to further
identify spot artefacts and display the effects of normalization on the data.
When extracting biologically relevant data from gene arrays, the main problem is making
comparisons between arrays. Numerous factors influence the signal generated for any162
particular spot; for example, the quality of the specimen (protein contamination, RNA
degradation), arrays quality and image processing (efficiently quantifying spot signals
and background correction). Finally there is variation between samples which may be
attributed to reverse transcription efficiency, hybridization method efficiency and label
incorporation into probe cDNA.
Figure 5.4 shows a hybridized and labelled microarray chip as seen through an image
analyzer. A green spot represents an over-expressed gene whilst the red spot represent an
under-expressed gene, relative to the control endometrial RNA run in parallel with each
experimental sample on each chip.163
In this study, some mathematical adjustments were made to the datasets to allow
meaningful comparisons between different samples on different arrays. This is termed
normalisation and the method used in this study for analysis was the internal reference
method, where a constant internal standard was used on all arrays and a set of
predetermined genes (housekeeping genes) which were expected to give consistent signal
intensities between different samples, was used
26. Normalisation is explained in greater
depth in Chapter 2, section 2.3.7, page 112.
In the majority of microarray experiments, the expression of only a few genes will be
altered by the condition under investigation; whilst the rest of the transcripts probed by
the array should be unchanged. When plotting an intensity graph of signal generated by
internal standard against signal generated by experimental sample at each spot on an
array, ideally, all constantly expressed genes should fall on the diagonal line y = x.
The aim of any microarray experiment is usually to identify differentially expressed
genes between two sets of samples treated in two different ways , with a measure of
statistical significance
26. The most common statistical testing used is the paired t-test
(where there is only one categorical factor, but an anova test is used when a number of
categorical factors). The t-test works on the null hypothesis of equal mean expression
levels between the two samples (controls and reference). Various other tests may be
applied. In this study, Genespring analysis was also used.164
5.6 Statistical analysis using t-testing:
The mean intensity for the duplicate spot for each gene, Chapter 2 section 2.3.8, page
115, details the preliminary handling of data. After Loess correction and screening for
genes expressed at low level, microarray expression data for 3975 genes was investigated
by cluster analysis with a Spearman correlation (Figure 1). Cluster analysis tended to
group the endometrial gene expression patterns from normally cycling women (PS
samples) together, and the patterns from oligomenorrhoeic women with (H samples) and
without (PL samples) hyperplasia together, albeit there were deviations from this pattern.
At a simple level this suggested endometrial gene expression varied with menstrual
cyclicity, however good group definition could not be obtained probably because the
effects of the relatively few differentially expressed genes were masked by the many
genes which were not differentially expressed. (Chapter 2, section 2.3.7, 112)
Primary fluorescent intensity data was analysed using the software package Genespring
which has been specifically designed for analysis of microarray data.
A Spearman correlation (non-parametric data) was performed between hormones and gene165
5.7 Results
After Genespring analysis of the normalized data, a total of 100 genes showed significant
gene expression changes between the various tissue types:
15 genes were altered in expression when comparing the hyperplastic to the long
proliferative endometrial samples. (H versus PL; Venn diagram)-Comparison 1
75 genes were found to be differentially expressed when comparing the long proliferative
to the short proliferative endometrium. (PL versus PS; Venn diagram)-Comparison 2
63 genes were found to be differentially expressed when comparing the hyperplastic to
the short proliferative endometrium. (H versus PS; Venn diagram)- Comparison 3
5 genes were differentially expressed in comparison 1 and not in comparison 2 or 3.
23 genes were found to be altered only in comparison 2 and not in 1 or 3.
20 genes were found to be altered in only comparison 3 and not in 1 or 2166
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Figure 5.5- A Venn diagram showing the three tissue comparisons and the altered gene
distribution between the three groups. (Please refer to table in CD provided with file
name PCO gene list to see gene name and expression level)
White- All 3 tissue-type comparisons- only 1 gene was common.
Yellow- genes variably expressed in the H versus PL and H versus PS comparison.
Purple- genes expressed variably H versus PL and PL versus PS comparison.
Turquoise- genes expressed variably PL versus PS and H versus PS comparison
Red- genes variably expressed only in the H versus PL comparison.
Green- genes variably expressed only in the H versus PS comparison
Blue- genes variably expressed only in the PL versus PS comparison167
PCOS (D...
Selected Condition Tree: PCOS (Default Interpretation) above bkg genes
Colored by: PCOS (Default Interpretation)
Gene List: Above bkg (3975), IRAT96_08_D04 selected
PCOS (Default Interpretation) abo...
Figure 5.6- A Spearman correlation test was used to a correlate gene expression to
biochemical markers and cycle length and a Bonferroni correction was also used where
data was skewed. As can be seen this does a good job in dividing the samples into three168
groups, there are some PS with PL, but the H have grouped as a four with one outlier
but even this is more similar to the hyper than the PL or PS.
all...
Selected Condition Tree: all genes changing
Colored by: PCOS (Default Interpretation)
Gene List: changing all groups (100)
all genes c...
Figure 5.7- This second correlation tree was obtained after further sieving out genes
which were unqualified.169
GENE Accession
Number
Expression ratio with p value by
t-test
H/PL H/PL ‘p’ H/PS ‘p’
TPX2, microtubule-associated protein homolog
(Xenopus laevis) AI024647 0.488 0.066 0.657 0.138
Discs, large homolog 7 (Drosophila) BC010658 0.503 0.085 0.636 0.158
Immunoglobulin lambda constant 1 (Mcg
marker) BC012876 2.543 0.070
H/PS H/PL ‘p’ H/PS ‘p’
Human placental protein 14 (PP14) gene,
complete cds. M34046 0.167 0.391 0.052 0.012
Glutathione peroxidase 3 (plasma) AI040990 0.404 0.281 0.224 0.053
IGFBP 3 AI032308 0.685 0.581 0.320 0.040
IGFBP 3 NM_000598 0.668 0.545 0.336 0.041
H19, imprinted maternally expressed
untranslated mRNA BC006831 0.714 0.393 0.519 0.034
Homo sapiens BAC clone RP11-20N16 from 2,
complete sequence. AC009469 0.705 0.407 0.552 0.040
NDRG family member 2 BC011240 1.307 0.390 1.770 0.056
NDRG family member 2 BC010458 1.289 0.405 1.850 0.029
IGFBP 5 BC011453 1.437 0.362 1.929 0.022
IGFBP 5 L27560 1.516 0.249 2.054 0.009
Hypothetical protein LOC128344 AI041071 1.188 0.639 2.213 0.048
Hypothetical protein MGC35194 AI027239 1.455 0.164 2.411 0.024
PL/PS PL/PS ‘p’ H/PS ‘p’
Osteopontin, bone sialoprotein I X13694 0.285 0.071 3.531 0.181
Osteopontin, bone sialoprotein I J04765 0.297 0.073 3.500 0.186
Integral membrane protein 2A AI028165 0.336 0.024 1.773 0.043
Chemokine (C-C motif) ligand 3 M23452 0.353 0.051 1.314 0.157
Hypothetical protein DKFZp761D221 AI041262 0.362 0.060 1.171 0.705
Apolipoprotein C-I BC009698 0.416 0.038 1.554 0.218
ov39c10.x1 IMAGE:1639698 3', mRNA
sequence. AI024974 0.497 0.032 1.424 0.123
Major histocompatibilty complex, class II, DQ
alpha 1 BC008585 0.554 0.046 1.680 0.179
Deiodinase, iodothyronine, type II U53506 1.846 0.019 0.798 0.495
Glycoprotein hormones, alpha polypeptide V00518 3.387 0.075 0.491 0.374
PL/PS; H/PS PL/PS ‘p’ H/PS ‘p’
ov40b04.x1 STN_Hs_cDNA IMAGE:1639759 3'
similar to gb:X12451 Cathepsin L precursor
mRNA AI025084 0.490 0.031 0.533 0.044
Cathepsin L NM_001912 0.512 0.021 0.544 0.027
ov60b08.x1 IMAGE:1641687 3' similar to
gb:X12451 Cathepsin L precursor mRNA. AI024426 0.495 0.018 0.558 0.031
TYRO protein tyrosine kinase binding protein BC011175 0.473 0.019 0.591 0.068170
Table 5.8: Genes differently expressed between proliferative endometrium from
normally cycling women with PCOS (PS) and proliferative (PL) and hyperplasic (H)
endometrium from oligomenorrhoeic women with PCOS. .
A Spearman correlation (non-parametric data) was performed between hormones and
genes. There was a positive correlation between Insulin and Integral membrane protein 2A
(N=19, p<.000, 2-tailed).
There was a positive correlation between Insulin and Transforming growth factor, beta 3 (N=19,
p<.001, 2-tailed).
There was a negative correlation between LH and Insulin-like growth factor (N=20, p<.003, 2-
tailed).
After Bonferroni correction, the other correlations were non-significant.
Average cycle length
Average cycle length was positively correlated with Major Histocompatibilty Complex,
class II, DQ alpha (r=.511, n=20, p<.021, 2-tailed).
TGF beta 3 J03241 0.447 0.005 0.602 0.027
KIAA1210 protein AI024396 1.985 0.010 2.079 0.000
Ras homolog gene family, member U AI018035 1.997 0.002 2.080 0.021
Extracellular matrix protein 1 AI066584 2.076 0.009 2.368 0.011
Human prostaglandin D synthase precursor,
mRNA, complete cds. M61900 2.111 0.028 3.161 0.031
PL/PS; H/PL PL/PS ‘p’ H/PL ‘p’
ov90a05.x1 IMAGE:1644560 3' similar to
TR:Q61500 Integral membrane protein 2 mRNA. AI028165 0.34 0.024 1.77 0.043171
5.8 Data validation by Real-time reverse transcriptase
polymerase chain reaction (RT-PCR)
RT-PCR does not detect the size the size of the amplicon and thus does not allow
differentiation between DNA and cDNA. Real-time PCR quantification eliminates post-
PCR processing of PCR products. This helps to increase yield and reduce the chances of
carryover contamination. It also offers a wider dynamic range, which means that a wide
range of ratios of target and normaliser can be assayed with equal sensitivity and
specificity. (Dynamic range of an assay determines how much target concentration can
vary and still be quantified.)
Real-time PCR is based on the detection and quantitation of a fluorescent reporter which
is released from a primer only when that primer molecule is used to extend cDNA in
amplification cycle. This signal increases proportional to the amount of PCR products in
the reaction. The higher the starting copy of the nucleic acid target, the sooner a
significant increase in fluorescence is noted. (After ~3-15 cycles). A fixed fluorescence
threshold is set significantly above the baseline on the real-time cycler detector. The
parameter Ct (threshold cycle) is defined as the cycle number at which the fluorescence
emission exceeds the fixed threshold. Ct is related by a known mathematical formula to
the starting concentration of target templates.
Real-time PCR quantitation eliminates post-PCR processing of PCR products as signal is
only generated when an amplification cycle is initiated from a target specific primer. This172
helps to increase yield and reduce the chances of carryover contamination. Real-time
PCR also offers a wider dynamic range, i.e. a wider range of ratios of target and
normaliser can be assayed with equal sensitivity and specificity. (Dynamic range of an
assay determines how much target concentration can vary and still be quantified.)
There are three main fluorescence-monitoring systems for DNA amplification-1)
hydrolysis probes 2) hybridizing probes and 3) DNA-binding agents. Hydrolysis probes
include TaqMan probes as used in this study. TaqMan uses the fluorogenic 5’exonuclease
activity of Taq polymerase to release a fluorophore from a target specific primer during
amplification, to allow measurement of the amount of target sequences in cDNA
samples
198. TaqMan was chosen as it has a greater specificity to annealing to PCR
products. TaqMan probes are oligonucleotides longer than primers (20-30 bases long)
that contain a fluorescent dye usually at the 5’ end and a quenching dye at the 3’ end.
When irradiated, the excited fluorescent dye transfers energy to the nearby quenching dye
molecule rather than fluorescing. There is no fluorescence if the probe is intact; however
when the polymerase replicates a template to which the TaqMan probed is annealed, its
5’ exonuclease activity cleaves the fluorescent probe, which separated from the
quenching dye, fluoresces. Accumulation of PCR products is detected by monitoring the
increase in fluorescence as the fluorescent probes are released by Taq polymerase when it
extends from a primer. As cleavage occurs only if the probe hybridizes to the target and
is extended from the same target by Taq polymerase, the origin of the detected
fluorescence is measured in specific amplification.173
To evaluate the microarray data, 4 genes were selected which were differentially
expressed, these being OPN (osteopontin), DLG 7 (Disc-large homologue 7), APSRG-1
(asiologlycoprotein-1), CDK8 (cell division kinase). OPN and DLG 7 were selected
because of their high signal intensity in the microarray whilst APSRG-1 and CDK 8 had
signal intensity below the Cy5 signal intensity threshold applied. Thus only OPN and
DLG7 expression levels, as assessed by microarray, would be expected to be comparable
when assessed by real-time RT-PCR.
The real-time RT-PCR data replicates the findings obtained by microarray for the high
intensity genes OPN and DLG-7. OPN expression was approximately 3-fold greater in
the PS and H tissue compared to PL, when assessed by microarray. This pattern of
expression was replicated when assessed by real-time RT-PCR, as shown in figure y. For
DLG-7, the pattern of expression is not dissimilar in the three tissue type and although
the expression is higher in PL this is very marginally different.174
Figure 5.9 shows mean transcript expression levels in each tissue type, relative to the
internal control sample, as estimated by microarray analysis.
Figure 5.10 shows mean transcript expression levels in each tissue type, relative to a
standard endometrial cDNA sample, as estimated by real-time RT-PCR analysis.
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5.9 Discussion
In the normal menstrual cycle, endometrium stays in the proliferative state for the first 14
days, whereas in patients with cycles longer than 28 days, the endometrium remains
under the influence of oestrogen in the proliferative state for considerably longer than 14
days. Finally the hyperplastic endometrium is the result of the endometrium remaining
under the influence of oestrogen for a prolonged period and having morphological
changes indicative of a precancerous state. This discussion will focus on variant gene
expression when the three endometrial types are compared and attention will be paid to
genes that are known to play a role in carcinogenesis.
These specific tissue comparisons (H versus PL, H versus S, PL versus S), give us
important information on gene expression changes as the endometrium changes from a
normal proliferative type to a hyperplastic one, in women with PCOS. The short
proliferative tissue biopsies were from women who had normal 28-32 days menstrual
cycles and the long proliferative tissues were from women who had oligomenorrhoea.
The hyperplastic tissues were taken from women who were suffering both from
oligomenorrhoea and their endometrium had also started to undergo neoplastic
transformation.
As shown by the Venn diagram in page 172 when comparing H versus PL and PL versus
PS, there 26 variant genes expressed. The difference between these tissue type lies in the
fact that in the PL versus PS comparison (23 genes, see table xx where only qualified
genes have been tabulated), page175 , the gene expression may be altered because of the176
prolonged exposure to hormones such as oestrogen, insulin, and androgen whereas in the
H versus PL (5 genes) comparison the variation in gene expression may be accounted for
by the prolonged exposure to insulin and sex steroid in addition to neoplastic
transformation or altered growth. In the H versus S tissue comparison and PL versus PS
tissue comparison, the genes variably expressed only in the first tissue comparison (20
genes), may be a direct result of altered growth in the endometrium and may be
independent of hormonal exposure.
This discussion will concentrate mainly on the proteins that are known to have a role in
carcinogenesis and all the other various processes associated with it. One such protein is
Osteopontin. This protein was found to be variably expressed in all tissue comparison.
This raises the possibility that the alteration in the expression of osteopontin must be an
early occurrence as the endometrium starts to be affected by the altered hormonal
environment present in PCOS patients as they become oligo/amenorrhoeic. The
expression ratio was higher in the H versus PS (expression ratio: 3.531) than in the PL
versus PS (expression ratio: 0.285) comparison, raising the possibility that this may be
hormone independent. Osteopontin is a secreted non-collagenous, sialic-acid rich,
chemokine-like protein playing an important role in determining the oncogenic potential
of various cancers
199. Overexpression of OPN results in an increase in the malignant
potential. OPN is thought to exert its pro-metastatic effects by interacting with various
Integrins and CD44 receptors regulating the cell signalling events that ultimately lead to
tumour progression
200. OPN regulates the bioavailability of MMP‘s (matrix
metalloproteinases) and potentially provides the molecular link between degradation of177
extracellular matrix, tumour progression, and vascularisation. There is evidence to
indicate that OPN might be considered as a candidate target for the treatment of
cancer
201. It is being hail as a prognostic marker in various cancers such as breast,
prostate and melanoma. OPN is also thought to promote cancer progression by regulating
the tumour-surveillance mechanism and inhibiting apoptosis of neoplastic cells
202 and is
thought to do so via antiapoptotic protein Bcl-xl
203. One of the key steps involved in the
process of tumorigenesis and metastasis is the degradation of the basement membrane
and interstitial matrix which is dependent on the activity of MMPs and there has been
evidence to demonstrate that OPN can induce MMP activity in tumour cells
204. Finally
OPN is known to belong to a family of proteins collectively known as SIBLING. Their
mode of action is via the regulation of MMP activity and they are known to be over
expressed in several cancer cells and their abundance directly correlates with tumour
grade
202.
Matrix metalloproteinase-3 (MMP-3) is a member of a family of proteolytic enzymes
whose function include degrading constituents of the extra-cellular matrix surrounding
some carcinomas
205 and some regulatory genes such as cytokines, growth factors, cell-
surface receptors and adhesion molecules. They are classified in 4 groups: 1) interstitial
collageneases 2) gelatinases, 3) stromelysins (MMP-3, belonging to this group) and 4)
membrane type. Although MMP’s are expressed by tissue at various stage of
development, they are typically absent from cells of the adult organism. Furthermore
they have been implicated in the establishment growth, invasion and/or metastasis of
tumours owing to the high frequency with which they of are found in invasive178
tumours
206. MMP activity is regulated at least at 3 levels: transcription/translation,
proteolytic activation of the zymogen and inhibition of the active enzyme by up-
regulation of each of these associated with pathological events. MMP3 has broad
substrate specificity, degrading type IV collagen, laminin, fibronectin and proteoglycans.
MMP3 is expressed in areas of tissue growth
207, focally expressed around invasive cells
in the stromal component of breast tumours and expressed in both benign and malignant
breast cancer phenotypes
208.
MHC class-II- Tumour formation in immunocompetent hosts is believed to be
dependent on the ability of tumour cells to evade the immune system. This is reflected by
the alterations in the expression of the major histocompatibilty complex (MHC) and
related molecules in a number of cancers. Tumour cells are thought to exhibit reduced
surface expression of MHC class-II proteins thus reducing immunogenicity and favouring
tumour growth. MHC class-II proteins will associate with peptides, which are derived
from antigens, for presentation to T4 lymphocytes. CD4 molecules have been shown to
interact with MHC class-II molecules, leading to enhanced responses of T4 cells. This
balance seems to be affected in endometrial cancer, as in many other cancers. In
endometrial stromal cells (antigen presenting cells), high expressions of MHC class-II
molecules may be used as an as a lymphocyte activation marker in endometrial
carcinoma and this seems to be an early event in invasive cancers
209.
Disc-large homologue 7 (drosophila- dlg 7)- this is not a well-characterised gene but it
is known to be a novel-cell-cycle regulated gene and is a homologue of the drosophila179
melanogaster disc large -1.The latter is known to be a tumour suppressor gene
210. It has
also independently been shown to be over expressed in hepatocellular carcinoma
211 and
transitional cell carcinoma of the bladder
212. The function of dlg7 in mammalian cells is
currently unknown but in the mouse, its expression is tightly regulated during cell cycle
213. It is closely associated with Ubiquitin to which it binds and then becomes available
for proteolysis. It has recently been associated with Aurora-A which is expressed in many
human tumours. It is also postulated to have a function in cell-differentiation in
haemopoietic stem cells
214. It is also thought to be involved in cell differentiation
(especially haemopoietic stem cells).
Transforming growth factor beta 3- this cytokine is both a tumour suppressor (at early
stages) and a tumour promoter (at later stages) in carcinogenesis. TGF beta acts by
binding to intracellular type I and type II receptors, and these in turn cause the
phosphorylation of Smad receptors. This initiates a chain of reaction, involving gene
expression, with end results anti-proliferation and apoptosis. There is evidence that the
TGF beta/ smad pathway is responsible for early tumour suppression, however in late
stage tumours, this suppressive role is reversed into a promoting one where there is
stimulation of invasion and metastasis. Moreover it has also been shown that in tumours
like breast cancer, TGF beta, favours metastasis to bone and it has been suggested that
this protein should be targeted for therapy to reduce metastatic bone disease in breast
carcinoma.
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Integral membrane protein 2A (IMP2A) - This cell-membrane protein is known to be
involved in cell proliferation and cell destruction. In some tumours, e.g. Burkitt
Lymphoma, the absence of integral membrane protein 2A, will lead to tumour cells being
recognized and destroyed by natural killer and cytotoxic T-cells. In their presence or
over-expression of IMP2A the reverse is observed, i.e. a slowdown in apoptosis. IMP2A
has also been found to inhibit transforming growth factor B 1- induced apoptosis through
phosphatidylinositol 3-K/Akt pathway
216.
Insulin-like growth factor binding protein 3- Insulin growth factors (IGF) are known
to increase the risk for the development of certain tumours whilst the reverse is true for
insulin-like growth factor binding protein-3 (IGFB-3)
217,218. IGFB-3 is known to suppress
the mitogenic activity of IGF-1. IGFBP-3, like IGF-1, is a protease which is
manufactured in almost every cell of the body and is found mainly in extracellular fluid
or on the cell surface. IGFB-3 determines the bioavailability of IGF as it bounds 99% of
the latter
219. IGF expression is enhanced by oestrogen and they are known to increase cell
proliferation and apoptosis. A recent study by Oh et al ,looking at IGF-1, IGF-2 and
IGFBP-3 and their relationship with endometrial cancer risk, found that increased levels
of IGF-2 was associated with an increase risk of obesity and endometrial cancer whilst a
lower level of IGFBP-3 was directly associated with an increased risk of endometrial
cancer
220.
BCL2-related protein A1- Bcl2A1 is a member of the anti-apoptotic Bcl2 family whose
mechanism of action is through the inhibition of mitochondrial membrane release of181
cytochrome c. Bcl2 A1 was first identified as a tissue specific Bcl-2 related factor which
was induced during myeloid cell differentiation
221. It has later been found to inhibit
apoptosis triggered by various factors such as anti-cancer drugs or antigen receptor
ligation. Bcl2, more specifically, exerts an anti-apoptotic action by inhibiting
mitochondrial depolarization and release of cytochrome c by sequestering Bid (an
apoptotic protein) and preventing the latter’s association with Bax
222.
Human placental protein 14 (pp14) - This protein is also known as Glycodelin A,
which is secreted in by human endometrium in the late secretory phase of the menstrual
cycle and in the early phase of pregnancy under the regulation of progesterone
223. It is
known to induce immunosuppression
224 and has the ability to induce apoptosis via T-
cells
225. The role of pp14 is better characterised in the regulation of implantation however
it has also been implicated in endometrial carcinoma. Pp14 levels are higher in the
endometrial flushings of women with endometrial cancer. It was even proposed as a
potential marker of endometrial cancer.
As shown in table 5.3, there is a significant increase of FAI in patients who are
oligomenorrhoeic as compared to the regular cycle and hyperplasia patients. The altered
hormonal environment has been postulated to be the reason for a decreased endometrial
receptivity in women with PCOS. Could it also explain the switching on of important
oncogenes, such as osteopontin at a very early time in such patients? This study is small
but it is a known fact that PCOS patients have unopposed oestrogen as well as increased
androgen and insulin levels. Fugimoto et al
226 found that high oestrogen levels increase182
the number of androgen receptors in the endometrium. Apparao et al
98 later found that
there was an increased number of androgen receptors in the epithelial and stromal
compartment of the endometrium in the fertile window in women with PCOS. This is a
direct consequence of chronic hyperoestrogenism and hyperandrogenism was considered
responsible for the poor endometrial receptivity found in these patients. Often in the
reproductive world, women with PCOS are thought to have ‘poor quality’ endometrium.
This abnormal milieu acts on v3 integrin and modifying the endometrial implantation
window. The study raises a few similar issues and it is possible that this same chronic
altered milieu switches on oncogenes in the endometrium. For example, this study has
determined that one such oncogene is osteopontin.
Insulin was also found to be associated with altered expression of transforming growth
factor beta3, bcl2-A1, integral membrane protein 2A and major histocompatibilty
complex II and DQ aPLha1. Insulin is known to be a potent mitogen in the endometrium
227. It is possible that through binding to it receptors, insulin sets off a series of reactions
involving all these different protein which affect apoptosis, cell differentiation and re-
modelling.
Although the number of cases investigated in this study was small, a correlation was
found between cycle length and the expression of major histocompatibilty complex class
II. The longer the cycle length, the stronger the correlation. Clinicians, up to this date,
have been treating patients with PCOS with progestogens to induce a withdrawal bleed in
the presence of oligomenorrhoea. This study seems to support this view and more183
research is warranted to establish firm guidelines on when to offer therapy and what
seems to be the acceptable length of amenorrhoea.
Finally, the RT-PCR data confirms the microarray findings for OP and DLG-7. For OP
the expression is greater in PS and H compared to PL after microarray and this pattern of
expression is mirrored by the RT-PCR findings. DLG-7 expression was found to be
raised in PL tissue at both microarray and DLG-7. For the low signal intensity genes,
CDK 8 and APSRG-1, the expression after RT-PCR does not correlate well with that
found after microarray, raising doubts as to whether these two proteins were variably
expressed. It would have been preferable to confirm these findings with RT-PCR for
more than 4 proteins, but unfortunately due to time constraints and availability of
material, it was impossible to do so.
5.10 Conclusion
This is the first study of gene expression in the endometrium of women with PCOS. As
we have demonstrated even in the mildest form of morphological changes seen in simple
hyperplasia, there are gene alterations which are involved in carcinogenesis in other
studies. Furthermore, genes expression changes involved in carcinogenesis are seen in
seemingly normal endometrium in women who do not cycle regularly. Osteopontin, an
oncogene involved in carcinogenesis in other hormone sensitive cancers, is variably
expressed in the endometrium of the cohort of PCOS women studied. In addition other
oncogenes involved in cell growth, matrix remodelling and apoptosis, all processes
involved in carcinogenesis, were found to be variably expressed.184
To this date, there is no evidence to guide clinicians in manageing PCOS women with
oligomenorrhoea, to reduce the risk of developing endometrial hyperplasia. Some
medical practitioners firmly believe that these women are at high risk of endometrial
cancer and empirically prescribe progestogens every 3 months to induce withdrawal
bleed. In our study, some the women in the PL group had cycle length that were shorter
than 90 days and yet this subgroup of women were found to have genes expression
alterations in their endometrium which some studies have associated with carcinogenesis
(including endometrial carcinogenesis). The next step for this study is to treat women
with progestogens and then again study the endometrium for gene expression. This would
give valuable information to clinicians who would in turn be able to counsel and treat
women with PCOS accordingly. If these changes occur at such an early stage, these
oncogenes may be a target for screening. Osteopontin in prostate cancer can give
valuable information on prognosis. Similarly in the presence of endometrial cancer, these
genes could give information about prognosis.
It would also be of interest to do similar microarray studies on PCOS patients with high
insulin levels and then repeat the studies after they have been on a six months course of
insulin sensitizers such as metformin. Insulin is known to be mitogenic to the
endometrium. It is possible that the altered endometrial gene expression seen in the H and
PL groups maybe under higher hormonal influence such as insulin. There is still
reluctance for clinicians in the UK to prescribe metformin for PCOS patients for other
reason than impaired glucose metabolism. If insulin is also demonstrated to be the185
intrinsic stimuli for switching on oncogenes then undoubtedly there should be a greater
emphasis on metformin use.
This study helps shed more light on the once assumed association between PCOS and
endometrial cancer. However there is still more work to be done to target patients who
are more at risk as it is known that PCOS is a heterogeneous condition and patients can
present to clinicians with many phenotypes of the condition.186
Chapter 6
Conclusion187
6.1 Conclusion
In 1949, Speert reported that young patients with EC demonstrated ovaries which were
hypertrophied or cystic and subsequently Jackson et al published a study where they
found a strong association between women with Stein-Leventhal syndrome and
endometrial cancer. Though it has been demonstrated that the second study was
incorrect
228, many clinicians believe that there is a strong association between PCOS and
EC. In fact, this belief is so strong that across the world patients with PCOS are warned
about the risk of developing endometrial cancer. When a literature review on the subject
was performed, we found that most of the studies were poorly designed and inconclusive
and hence the evidence for such an association was lacking.
For a number of years, there also has been a theory that endometrial cancer has two
different aetiologies. The first is from a background of unopposed oestrogen stimulation
of the endometrium, as is the case in PCOS or in a background of atrophic endometrium.
In the former, EC was thought to develop mainly in relatively young obese women with
type 2 diabetes and carried a good prognosis, whilst the latter, EC was thought to be
found mainly in elderly women and carried a worst prognosis. However, endometrial
carcinogenesis is now known to involve more complex pathways where altered hormone
environments may play an active role. Oestrogen and insulin are known to be potent
stimulants of carcinogenesis
106,151 whilst and progesterone has been shown to have a
negative effect on the mitogenic potential of cells of the endometrium. Women with
PCOS are known to have high levels of oestrogen and insulin and as they tend to have
anovulatory menstrual cycles, they have less progestogenic effects on the endometrium.188
The aim of this study was to demonstrate whether the belief that has been held for more
than fifty years (and that has remained unquestioned), that PCOS women are more at risk
of developing endometrial cancer was true.
The hypothesis that -
1) PCOS is associated with EC
2) The type of endometrial carcinoma arising in women with PCOS carries a better
prognosis.
3) The risk of EC is confined to a subgroup of women with PCOS.
Hypothesis 1: PCOS is associated with endometrial cancer.
A retrospective study was undertaken on the ovaries of women diagnosed with
endometrial carcinoma and these were compared to the ovaries of age-matched controls
that had had oopherectomy for benign gynaecological conditions. This retrospective
study looked at the ovaries of a total of 211 women. 128 of these women were diagnosed
with endometrial cancer from 1987 to 2003, 83 age-matched controls were also selected.
Ovarian morphology was studied as a surrogate marker of PCOS. Semi-quantitative
criteria for the diagnosis of PCO morphology were devised in this study, these being the
presence of >8 peripherally arranged follicular cysts per section and <5 corpora albicantia
per section, the latter as evidence of reduced ovulation rate. In borderline cases (6 - 8
follicular cysts and 5 - 7 corpora albicantia), a diagnosis of PCO morphology was made if189
capsular thickening and/or stromal hyperplasia/hyperthecosis were also apparent.
Sections which failed to achieve these criteria were judged as normal.
The prevalence of PCO morphology in the women diagnosed with endometrial cancer
was found to not differ from those of women without EC. Thus, the first hypothesis was
proven to be incorrect.
Another point of interest that was revealed by this study was that on stratifying patients
according age, PCO morphology was significantly more prevalent in women aged less
than 50 years (51 years old being the average age of menopause). A criticism of the study
is that PCO was used as a marker of PCOS. It is known that 50- 70% of women with
PCOS will exhibit PCO morphology
169. However women with PCO only are also known
to exhibit metabolic and endocrine disorders similar to those exhibited in women with
PCOS, but to a lesser degree.
Hypothesis 2: The type of endometrial carcinoma arising in women with PCOS
carries a better prognosis.
Although evidence is limited, it is believed that the type of endometrial tumours arising
in the endometrium of women with PCOS tend to carry a better prognosis
155. Jafari et al
found that endometrial carcinoma in young PCOS patients tended to be well-
differentiated and carried a good prognosis. The assumption also stems from the fact that
endometrial cancers that originate from a background of unopposed oestrogen stimulation190
(as is the case in PCOS) tend to be well differentiated, responsive to treatment and
carrying a good prognosis.
To test the hypothesis, immunohistochemistry was performed on the endometrial tumours
of women with PCO morphology of the ovaries and compared to the endometrial cancers
of women without PCO morphology. p53, ki67, bcl2and cyclin d1 expression were used
as surrogate markers of prognosis. We found that there was no significant difference in
the expression of p53, ki67 and bcl2these proteins in both groups of tumours. The
prevalence of cyclin D1 was in increased in the tumours associated with PCO. This study
fails to prove the second hypothesis that endometrial cancer arising in women with PCOS
carries a better prognosis. This puts into question the previously held belief and adds
weight to our third hypothesis, since it would be expected that the expression of these
proteins would be significantly higher in the tumours not associated with PCO
morphology; the action and expression of p53 being well documented and it is usually
found in aggressive tumour types. The expression of cyclin D1 has been shown to be up-
regulated in endometrium subjected to oestrogen
229.
One would expect to see a vast difference in the expression of tumour markers such as
p53 or even Bcl2 in the two types of tumours if the prognosis of EC in women with
PCOS was different from that in women without PCOS. It thus appears that the second
hypothesis is correct, i.e., that the type of endometrial cancer arising in women with
PCOS not carries a better prognosis. Although cyclin D1 suggested a worse prognosis for
PCOS related tumours this was not supported by the bcl2 data. Bcl2, however, does not191
work in isolation but is opposed by bax and the ratio of bcl2: bax maybe more relevant.
Unfortunately, this was not investigated. It is possible that bcl2: bax expression may add
more weight to the findings with cyclin D1.
Hypothesis 3: The risk of EC is confined to a subgroup of women with PCOS.
A microarray study was undertaken which investigated the gene expression in the
proliferative endometrium of women with PCOS. Our subjects were classified into 3
groups: The H group which consisted of endometrial tissue obtained from women with
cycle length of greater than 40 days displaying simple endometrial hyperplasia, the PL
group consisted of endometrium from women who displayed proliferative endometrium
but were known to have cycle length greater than 40 days and the PS group consisted of
endometrium from women with cycle lengths less than 40 days. RNA was extracted and
Cy3 labelled c-DNA was generated which was hybridized onto microarray, along with
Cy5 labelled cDNA obtained from pooled RNA from the proliferative endometrium of
normal women with regular menstrual cycles.
This study revealed that a number of genes were differentially expressed across all 3
groups. One such example is the level of osteopontin, which was invariably altered in the
comparison between PS and PL, PL and H and finally H and PS. This indicates that gene
expression changes occur at an early stage when a PCOS patient starts becoming
oligo/amenorrhoeic. The results suggest say that, oligomenorrhoeic patients with PCOS
have altered expression of several genes which are linked to carcinogenesis, hence192
proving strong evidence in support of the third hypothesis that a subgroup of PCOS
patients are at risk of developing endometrial cancer.
As mentioned previously, the entire hyperplasia samples collected were of the simple
category. It was unfortunately not possible to obtain any atypical hyperplasia sample in
such a small sample group. It would have been very in formative to obtain samples with
histological subtype as well as it known that if left untreated, up to 40-45% of cases can
progress to endometrial cancer. On a molecular level, this tissue subtype has undergone
ore transformation towards becoming cancerous. It would be expected that gene
expression in atypical endometrial hyperplasia would be similar or overlap gene
expression in endometrial cancer. If the gene expression from the endometrium of
women with PCOS with atypical endometrial hyperplasia were compared to that in PCOS
with simple hyperplasia, more information would be obtained about oncogenes involved
in converting simple hyperplasia into atypical hyperplasia. If these genes are also
overexpressed in a subgroup of PCOS, then this may shed more evidence of a stronger
link between PCOS and cancer. Obviously this was outside the scope of this study and
can be a potential source for future work.
This thesis was first devised after it became clear that the evidence was lacking in support
of the assumption that endometrial cancer and PCOS are linked. I set out to prove this
assumption and in fact found that if there is a link between the two conditions, it seems to
be confined to younger women with long menstrual cycles, raised androgen levels and
increased insulin levels. These risk factors remain increased in the women whose193
endometrium demonstrated endometrial hyperplasia (even the mildest form of
endometrial hyperplasia - simple hyperplasia).
This study could be considered as a pilot study and larger numbers would be helpful in
confirming the findings.
6.2 Future work
As previously mentioned, this is the first time that endometrial gene expression has been
specifically investigated in women with PCOS. It would be interesting to confirm the
findings of Chapter 5 by performing immunohistochemical study to localize the sites of
gene expression differences. For example, hyperplasia may be focal and in chapter five
hyperplasia tissues on a background of proliferation was used. Immunohistochemistry
may show exactly the site at which the variable expressed genes were operating. It may
be when the whole tissue is considered, immunohistochemistry may not show a
difference in expression between the three tissue types. However, the changes may be
confined to the small hyperplasic section and this in itself poses certain dilemmas; The
small proportion of hyperplasia, in a sea of proliferative tissue, was found in the
microarray study to be driving gene expression changes 1.7 fold or more, for the whole
endometrium from which the sample was taken this difference must be greater as it is
very likely that there are several foci of hyperplasia.
The National Cervical Screening Programme has greatly improved the detection of pre-
cancerous conditions of the cervix and in fact the prevalence of cervical cancer in the194
western world has fallen as a result. A similar screening programme may help in reducing
the incidence of endometrial cancer as it is the most common gynaecological tumour in
the Western World. Women with PCOS may well constitute such an ‘at risk’ group and
more specifically those who are oligo/amenorrhoeic, may benefit from regular
endometrial biopsy to detect pre-malignant pathology. Those found to be suffering from
hyperplasia may be given progestogens therapy.
Prevention should also involve primary care where PCOS patients should actively be
encouraged to maintain a healthy lifestyle and be counselled about having regular
menstrual cycles. (As the various gene alterations note in this thesis seem to happen early
as a patient becomes oligomenorrhoeic, clinicians may have to be more aggressive in
inducing withdrawal bleeds with progestogens.) There is still little evidence about the
frequency of use of progestogens. Clinicians have arbitrarily chosen to give progestogens
on a 3-monthly period to reduce the risk of endometrial hyperplasia in PCOS women
with oligo/amenorrhoea. A future study could possibly utilize microarray as used in this
study to analyze gene expression in endometrium from patient before progestogens use
and then repeated after progestogens use to determine whether gene expressions is altered
by the withdrawal bleed.
Metformin is a drug now widely used in the management of PCOS. It has been shown to
act on insulin metabolism and has been known to restore ovulation in oligo/amenorrhoeic
PCOS patients. This is due to its effect on the peripheral action of insulin which in turn
acts on the ovarian stroma, hence androgen production. Another potential study could195
involve using microarray analysis to investigate gene expression in the endometrium of
women with PCOS before and after they have been on metformin for a specific period.
Risk factors for endometrial cancer include obesity, type II diabetes, hyperinsulineamia
and unopposed oestrogen stimulation of the endometrium. These are also features of
PCOS. It would be of value to find out whether there is a specific factor in PCOS alone
which increases the risk of endometrial cancer or whether it is the presence of the
confounding factors mentioned that increases that. One such factor such as obesity could
be investigated by microarray studies in the endometrium of oligomenorrhoeic PCOS
patients and that of oligomenorrhoeic obese non-PCOS patients.
This thesis sheds some light on the association between PCOS and endometrial
carcinoma. Currently it is advisable to counsel women about their risk of endometrial
hyperplasia when they are diagnosed with PCOS but it may be somehow felt premature
to counsel them about their risk of developing endometrial cancer. My study has shown
that there are significant oncogenic alterations even in simple hyperplasia, the mildest
form of neoplasia found in the endometrium. It is clear that it is important to treat PCOS
as a very serious condition with many health implications in later life, including a higher
risk of developing endometrial cancer. Women with PCOS and irregular cycles should be
tested for insulin resistance and hyperinsulineamia as my study shows that these women’s
endometrium are more at risk of switching on oncogenes which may play a role in
endometrial carcinogenesis. Every effort should be made by their general practitioner or
the gynaecologist to regularise their menstrual cycle. This could be in the form of196
lifestyle management with diet and regular exercise, progestogen (or the COCP) on a
regular basis if they are oligo or amenorrhoeic. In addition, if found to be insulin resistant
and/or hyperinsulinaemic, PCOS women with oligo/amenorrhoea, could be managed as
part of a multidisciplinary team, involving a gynaecologist, a dietician and an
endocrinologist. Insulin sensitizing agents may be started if they are found to be
hyperinsulinaemic and they should be carefully monitored with regular transvaginal scan
(endometrial screening) and glucose tolerance tests.197
APPENDIX
SCORING SHEET
Name: D.O.B:
Hospital no.
L R
Capsular thickness
Presence of peripheral cyst
Number
Stromal thickening
Number of corpora albicantia
Polycystic ovary:………………………………………………….198
IMMUNOHISTOCHEMISTRY: REAGENTS AND BUFFERS
1% (v/v) Acid-alcohol
1400 ml ethanol
580 ml distilled water
20 ml concentrated HCl
Acetone (BDH)
3-Aminopropyltriethoxysilane solution -APES (Sigma-Aldrich A3648)
294 ml of acetone with 6ml APES
Keep APES at 4°C and dilute in acetone just before use.
APES coating for slides
1. Wash in detergent for 20 minutes.
2. Rinse in distilled water and dehydrate in methanol.
3. Dry at room temperature.
4. Drop in APES solution in fume cupboard, rinse in distilled water.
5. Dry overnight at 37°C.
Blueing solution
1. Add 5g disodium tetraborate to 1 litre distilled water. 0.5% (w/v) final
concentration.
Bovine serum albumin (Fraction V, Sigma A-2153)
Citric acid monohydrate (Merck, ‘Analar’ 100813M)
DPX mountant (Merck 360294H)
Diaminobenzidine–DAB (Sigma-Aldrich, D-5637)
Disodium hydrogen phosphate anhydrous (Sigma-Aldrich, S0876)
Disodium tetraborate (Merck, 102674E)
Ethanol (Hayman ‘Absolute alcohol 100’)
Formaldehyde
Formol saline
40% formaldehyde 100ml
Sodium chloride 9g
Water 900ml
Neutral buffered formaldehyde
40% formaldehyde 100ml
Distilled water 900ml
Sodium dihydrogen phosphate monohydrate 4g
Disodium hydrogen phosphate anhydrous 6.5g
Haematoxylin and Eosin199
Hydrocholoric acid-concentrated (Merck, ‘Analar’ 101250D)
Hydrogen peroxide solution (Merck, ‘Analar’ 101284N)
1. Add 10ml 30% hydrogen peroxide to 90 ml distilled water.
Imidazole Solution (Merck, GPR 285466K)
1. Add 0.681g imidazole to 100ml distilled water.
2. Store at 4°C.
3. 0.1M imidazole solution.
Industrial methylated spirit
Mayers Haemalun ‘Gurr’ (BDH 350604T), (Merck, Lutterworth, Leics, UK)
Methanol (Merck, ‘Analar’ 101586B)
NaCl (Merck, ‘Analar’ 1913833X)
Normal Goat Serum (Dako X0907)
Normal Rabbit Serum (Dako, X0902)
Fresh Phosphate Buffered Saline (Sigma Aldrich, P4417)
1. Dissolve 1 tablet in 200ml distilled water.
Phosphate Buffered saline (ICN 17-604-20)
1. Dissolve 5 PBS powder sachets in 5l distilled water. pH 7.4
Protease XXIV (Sigma Aldrich P8038)
Protease solution for protease digestion:
1. Dissolve 37.5mg of protease XXIV in 200ml fresh PBS at 37°C.
2. Leave tissue sections for 7 minutes.
Sodium Citrate Buffer
1. Weigh out 2.1g citric acid monohydrate
2. Add 950 ml distilled water
3. Add 13ml 2M NaOH. Make up to 1l.
4. Adjust pH 6.0. Store at 4°C.
5. 0.01M Sodium citrate (pH 6.0 at 25°C).
Streptavidin-biotin complex duet kit (Dako K0492)
Tris [ Tris (hydroxymethy) methylamine] (Merck ‘Aristar’ 452054C)
Tris buffered saline (TBS)
1. Weigh out 43.83g NaCl and 30.6g Tris base.
2. Make up to 5l distilled water.
3. Add ~35ml of concentrated HCl, ensure pH is at 7.6.
4. Store at 4°C.
5. 0.05M Tris-HCl, 0.15M NaCl, pH 7.6.200
Xylene (Merck ‘Analar’102936H)
Composition of buffers used in RNA analysis
Buffer Composition
10X MOPS-acetate-EDTA
(MAE)
0.8 M sodium acetate, 0.05 M EDTA in 0.5 M 3-
(N-morpholino) propanesulphonic acid
RNA loading buffer 0.4% (w/v) bromophenol blue, 1 mM EDTA in
50% (v/v) glycerol
RNA sample buffer 8% (v/v) formaldehyde, 65% (v/v) formamide,
20 g/ml ethidium bromide in 0.6X MAE
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gynaecological disease (Controls), obtained retrospectively from patient records.
Table 4.1 shows the results obtained in each group, after immunohistochemistry.
Table 5.1 showing patient demographics and timing of biopsy.
Table 5.2- shows all the biochemical profiles and histological report of each patient in the
study
Table 5.3- shows the mean values of Progesterone, testosterone, free androgen index,
insulin and oestrogen in the three groups studied (short cycle proliferative - PS, long
cycle proliferative- PL and the hyperplasia- H).
Table 5.4: Genes differently expressed between proliferative endometrium from
normally cycling women with PCOS (PS) and proliferative (PL) and hyperplasic (H)
endometrium from oligomenorrhoeic women with PCOS.
Figure 5.5 shows mean transcript expression levels in each tissue type, relative to the
internal control sample, as estimated by microarray analysis.
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